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Abstract 
Histone deacetylases (HDACs) are a group of 18 enzymes that catalyze the deacetylation of 
acetyl lysine residues in proteins. Acetyl lysine residues are present within thousands of proteins, 
and acetylation/deacetylation has been shown to affect protein properties integral to cellular 
homeostasis and disease states. Determining which protein is deacetylated by which HDAC 
isozyme is central to understanding biological regulation.  To better identify HDAC substrates, I 
developed an assay to measure the acetate product formed by deacetylation catalyzed by metal-
dependent HDACs for the evaluation of peptide substrates.  Using this assay, I advanced a 
computational algorithm that predicts HDAC8 peptide substrates based on short range 
interactions.  This algorithm accurately predicts the catalytic efficiency of 7-mer peptide 
substrates based on the sequence of the peptide.  Using the deacetylation assay, I also 
demonstrated the reactivity of HDAC8 with peptide substrates derived from proteins with 
increased acetylation in vivo upon treatment with HDAC8 specific inhibitors.  These experiments 
suggest that a subset of in vivo HDAC8 substrates can be predicted based on the six amino acids 
flanking the acetyl lysine. I have also utilized singly acetylated histone tetramers to establish that 
HDAC8 has enhanced activity in comparison to corresponding peptide substrates. Combined 
with the peptide work, these results suggest that molecular recognition by HDAC8 is determined 
by a combination of short and long-range interactions and acetyl lysine accessibility of in vivo 
substrates.  Additionally, I have identified slow product dissociation as a novel regulatory 
method for HDAC activity.  In the future we will expand these methods to identify substrates for 
other HDACs. 
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Chapter 1  
HDAC8 substrates: Histones and beyond1,2,3 
  
Overview 
The lysine deacetylase family of enzymes (HDACs) was first demonstrated to catalyze 
deacetylation of acetyl lysine residues on histones. In subsequent years, HDACs have been 
shown to recognize a large pool of acetylated non-histone proteins as substrates. Recently, 
thousands of acetylated proteins have been discovered, yet in most cases, the HDAC that 
catalyzes deacetylation in vivo has not been identified. This gap has created the need for better in 
vivo, in vitro, and in silico approaches for determining HDAC substrates. While HDAC8 is the 
best kinetically and structurally characterized HDAC, few efficient substrates have yet been 
substantiated in vivo. In this review we delineate factors that may be important for determining 
HDAC8 substrate recognition and catalytic activity, including structure, complex formation, and 
post-translational modifications. This summary provides insight into the challenges of 
identifying in vivo substrates for HDAC8, and provides a good vantage point for understanding 
the variables important for predicting HDAC substrate recognition. 
 
                                                 
1 Reproduced in part from Wolfson, N.A. Pitcairn, C.A. Fierke, C.A. 2013. HDAC8 substrates: Histones and 
beyond. Biopolymers. 2013 Feb;99(2):112-26. doi: 10.1002/bip.22135. 
2 Chapter was updated to include material published through 5/10/14.  
3 Noah Wolfson wrote the entire chapter except for the post-translational modifications of HDAC8 section which 
was written by Carol Ann Pitcairn.  
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HDAC introduction 
Acetylation of lysine side chains in proteins is a reversible post-translational modification that 
occurs in a wide range of organisms[1]. This modification affects the properties of proteins, 
including protein-protein association, protein-DNA interactions, and protein stability[2]. 
Initially, acetylation gained recognition as a post-translational modification to histones. 
Acetylation of histones can regulate the accessibility of DNA to cellular machinery and thus 
change the protein expression profiles of cells[3]. Due to the effect of acetylation on the 
proteome, it is not surprising that many diseases have been associated with the aberrant 
acetylation of histones[4]. In the last twelve years the paradigm for protein acetylation has 
changed drastically, moving from a histone centric model to a proteome centric model. This 
change in mindset has resulted from the identification of acetylated lysine side chains that affect 
the function of numerous non-histone proteins[5, 6]. Currently, over 3,600 acetylation sites have 
been discovered in mammalian proteins[7] and these protein are important in many cellular 
processes, including gluconeogenesis and DNA damage repair[5, 6]. Regulation of the 
acetylation state of proteins is important as aberrant acetylation of both histone and non-histone 
proteins can contribute to the development of many disease states[8-10]. As proof of this, two 
broad spectrum HDAC inhibitors (suberoylanilide hydroxamic acid (SAHA) and Romidepsin) 
have been approved by the FDA and are currently on the market for the treatment of T-cell 
Lymphomas (Figure 1.1)[11].  
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Figure 1.1 Widely used HDAC inhibitors 
SAHA and Romidepsin have been approved by the FDA for use as second line treatments for T-
cell lymphomas. TSA is an inhibitor that has been used widely in in vitro and in vivo studies but 
is not being tested in drug trials[12]. All three inhibitors are competitive with substrates by 
occupying the substrate binding channel and coordinating the active site metal ion. The atoms 
colored red interact with to active site metal ion[13-19]. 
 
HDAC isozymes can be grouped into four classes based on their phylogenetic similarity[20]. 
Class I (HDAC1, 2, 3, and 8), class IIa (HDAC4, 5, 7, and 9), class IIb (HDAC6 and 10), and 
class IV (HDAC11) enzymes catalyze deacetylation using a metal dependent mechanism[20, 
21], while class III (Sirt1-7) enzymes use an NAD+ cofactor to perform deacetylation[22, 23]. 
Due to the abundance and importance of HDAC substrates, one of the foremost questions in the 
field is the determination of the substrate specificity of HDACs. This area of research seeks to 
identify which of the 18 deacetylases catalyzes deacetylation of each of the >3,600 mammalian 
acetylation sites. Adding to the complexity of this problem is the possibility that cellular 
regulation may alter both the catalytic activity and the substrate specificity of HDACs. 
Illuminating the substrate selectivity and regulation of HDACs should shed light on the 
mechanism and treatment of acetylation-related diseases.  
Mechanistically and structurally, HDAC8 is the best studied of the HDAC homologues. 
Furthermore, HDAC8 is proposed to recognize a number of non-histone substrates[24-26] and is 
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therefore a good model for developing techniques to unravel HDAC substrate specificity. In this 
chapter I discuss the current view of HDAC8 regulation, and compare HDAC8 to other 
promiscuous enzymes to identify factors that determine substrate specificity.  
 
Known HDAC8 substrates 
HDAC8 was initially discovered in 2000 and was shown to catalyze in vitro deacetylation of a 
number of acetylated histone variants[27-29]. These substrates include full-length H2A/H2B, 
H3, and H4 histones, acetylated at non-specific lysines[27, 28]. Concurrent studies showed that 
peptide sequences corresponding to the H3 and H4 histone tails with an acetylated lysine at 
position fourteen (Kac14) and sixteen (Kac16), respectively, were also in vitro substrates[28-30]. 
In subsequent years, several studies have used the H4 histone tail sequence as a peptide template 
to investigate the amino acid sequence preference of HDAC8 (discussed below)[31-33]. 
Recently, HDAC8 was demonstrated to catalyze in vitro deacetylation of a peptide 
corresponding to the Kac20 site on the H4 histone tail. However, HDAC8-catalyzed 
deacetylation of the Kac20 peptide is much slower than deacetylation of Kac16 peptides[34], 
suggesting that another HDAC isozyme may catalyze this reaction in vivo. Further studies have 
shown that HDAC8 also catalyzes deacetylation full length histones[27-29]. Using western blots 
analysis, Van den Wyngaert et al. showed that cell extracts from HEK293 cells which over 
express HDAC8 have significantly lower levels of acetylated H4 and modestly reduced levels of 
acetylated H3[29]. Similarly, Lee et al. showed that HDAC8 catalyzes the deacetylate acetylated 
histone H3 and H4 in vitro[35]. In contrast, Olson et al. show that treatment of HeLa cells with a 
cell permeable HDAC6/8 specific inhibitor (PCI-34051)[36] does not significantly alter the 
levels of H3 acetylation compared to treatment with the pan-HDAC inhibitor SAHA[37], yet 
TSA has been shown to have an effect on H4 acetylation levels[38]. Taken together, these data 
indicate that HDAC8 catalyzes the deacetylation the H3 and H4 histones in vitro, while HDAC8 
catalyzed deacetylation of in vivo substrates remains controversial. The discrepancies between 
the in vivo and in vitro data may be due to a number of factors including: the ability of other 
HDACs to catalyze the deacetylation of H3; cofactors and post translational modification alter 
the reactivity of HDAC8 with histone H3 in vivo; or that other factors, including cell cycle 
5 
 
progression, mask HDAC8’s effects on H3. Additionally, there are data suggesting that HDAC8 
may affect the acetylation of histone H3 in specific gene regions[39] and thus the HDAC8 
modulation of H3 acetylation (either directly or indirectly) may be masked by the noise of other 
regions on chromatin. As a result, the role of HDAC8 in catalyzing deacetylation of specific sites 
in histones in vivo remains unclear. 
Shortly after HDAC8 was identified, the first non-histone acetylated proteins were reported[40, 
41] which inspired researchers to hunt for other possible HDAC substrates. The search for new 
HDAC8 substrates was further spurred by the finding that this enzyme is present in the 
cytoplasm of smooth muscle cells[42, 43], causing evaluation of non-nuclear substrates. In fact, 
HDAC8 catalyzes deacetylation of a peptide corresponding to the C-terminal end of the p53 
transcription factor (Figure 1.2A) faster than the Kac16 H4 histone peptide[Biomol 
unpublished]. HDAC8 catalyzes deacetylation of coumarin derivatives of the acetylated p53 and 
H4 peptides with kcat/KM values of 7,500 M-1s-1[26] and 2,800 M-1s-1, respectively[44]. Since the 
kcat/KM parameter reflects the relative reactivity of an enzyme with different substrates[45], these 
values suggest that HDAC8 has a modest preference for catalyzing deacetylation of p53 over the 
H4 histone. It is important to note that these kcat/KM values for HDAC8 were measured using the 
commercially available Fluor-de-lys assay (Biomol) (Figure 1.2B). This assay uses peptide 
substrates containing a methylcoumarin fluorophore conjugated to the C-terminal side of the 
acetyl lysine residue. After deacetylation, digestion by trypsin cleaves the coumarin fluorophore, 
causing an increase in fluorescence at 460 nm and deacetylation is measured from this increase 
in the fluorescence signal[46] (Figure 1.2B). While this assay has been a valuable tool for 
studying histone deacetylases, the methylcoumarin fluorophore increases the reactivity with 
HDAC8[47]. Therefore, deacetylation of the nonlabeled acetylated p53 and H4 histone peptides 
catalyzed by HDAC8 may be slower than reported using this assay. Furthermore, the coumarin 
substrates may not reliably reflect HDAC substrate specificity in the context of full-length 
proteins.  
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Figure 1.2 The Fluor de Lys assay[Biomol][46]  
A) The sequence of two HDAC8 substrates used for the Fluor de Lys assay. B) Schematic of the 
Fluor de Lys assay, including the wavelengths used to measure the methylcoumarin 
fluorophores. 
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The steady state kinetic parameters for catalysis of the deacetylation of peptides can provide 
insight into both the kinetic mechanism and the in vivo reactivity of these substrates. HDAC8-
catalyzed deacetylation of the p53 and H4 coumarin peptides have a low value of kcat/KM (103 – 
104 M-1s-1) in comparison to enzymes that function near diffusion-controlled limits (106 – 108 M-
1s-1) and a high value for KM (320 µM, H4 peptide)[44] compared to other HDAC isozymes (~30 
µM)[48]. These data suggest a simple Michealis-Menten kinetic model whereby substrate 
binding and dissociation is rapid, and is followed by rate-limiting deacetylation. This conclusion 
is bolstered by the observed enhancement of the kcat value for deacetylation of peptides labeled 
with a more reactive trifluoroacetyl group[30, 49]. Therefore, substrate specificity is determined 
by both the affinity of HDAC8 for a peptide substrate and the reactivity of the enzyme-substrate 
complex.4 Assuming that the kinetic constants for deacetylation of these peptides mimic the full-
length proteins, the low kcat/KM and high KM values for the H4 and p53 peptides compared to 
reactivity with other isozymes[26, 44, 48] suggest that HDAC8 may not catalyze deacetylation 
of these sites in vivo. However, it is possible that natural, full length, substrates may be better 
optimized for efficient deacetylation to allow for regulation of these posttranstlational 
modifications. While knockdown data suggest that HDAC8 levels affects acetylation levels of 
K382 of p53 in vivo[50], other data implicating HDAC8-catalyzed deacetylation of H4 and p53 
in vivo is sparse. In addition to these proposed substrates, in vitro kinetic studies combined with 
cellular assays have yielded several promising candidates for in vivo HDAC8 substrates 
(discussed further below).  
There are a number of factors that must be taken into account when parsing whether substrates 
are acted upon by a given enzyme in vivo. HDAC selectivity is minimally described by the 
relative values of kcat/KM for deacetylation, the relative concentrations of the HDAC isozymes, 
and the concentrations of competing substrates. Relative kcat/KM values indicate the substrate 
preference of an enzyme when discriminating amongst multiple substrates[45]. The majority of 
enzymes have kcat/KM values of 105-106 M-1s-1[51]. These values are generally slower than the 
diffusion controlled rate constants for substrate binding, which can be as high as 107-108 M-1s-
1[45]. Consistent with this, the kcat/KM values for the HDAC8 homolog HDAC1 and, the 
                                                 
4 KM ad KD are roughly equivalent as data suggests that the rate limiting step for HDAC8 catalysis is chemistry (see 
Chapter 5 for a more through explination). 
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homologous enzyme, arginase I are on the order of 105 M-1s-1[48, 52], suggesting that similar 
values should be achievable for efficient HDAC8 substrates. One caveat to making conclusions 
from kinetic parameters measured in in vitro experiments is that some enzymes require an 
activator for optimal activity. Since many HDAC isozymes associate with large protein 
complexes in vivo, it is possible that other proteins in the complex could activate the catalytic 
activity or enhance the substrate affinity to increase the value of kcat/KM in the cell.  
 
Candidate non-histone HDAC8 Substrates 
One promising HDAC8 substrate is the Estrogen-Related Receptor α (ERRα). This orphan 
receptor is expressed in a number of organs, including the heart, kidney, and muscle, where it 
controls processes that are essential for maintaining energy homeostasis[53]. ERRα can be 
acetylated at four lysines, where these post-translational modifications inhibit DNA binding[25]. 
A role for HDAC8 in catalyzing the deacetylation of ERRα was suggested by the demonstration 
that the acetylation state of ERRα was altered by simultaneous incubation with HDAC8, the 
histone acetyltransferase PCAF, and 14C-acetyl-CoA[25]. Furthermore, incubation of purified 
acetylated-ERRα with HDAC8 enhances the affinity of ERRα for DNA, which is consistent with 
HDAC8-catalyzed deacetylation of ERRα. One caveat to these experiments is that this assay 
included metal chelators and low salt, conditions where HDAC8 has limited catalytic activity[26, 
54]. An alternative explanation of these data is that HDAC8 binds to ERRα to increase the DNA 
affinity and decrease acetylation catalyzed by PCAF. However, addition of the non-homologous 
deacetylase, Sirt1, to these in vitro assays also decreases acetylation of ERRα, suggesting that 
both enzymes recognize ERRα as a deacetylase substrate. Finally, RNAi-dependent decreases in 
cellular HDAC8 or Sirt1 levels are accompanied by increased ERRα acetylation in vivo[25]. 
Taken together, these results suggest that HDAC8 catalyzes deacetylation of ERRα in vivo. 
Consistent with this, the acetylation site (K129ac) in ERRα has Arg in the -1 position (the amino 
acid on the N-terminal side of the acetyl lysine), and RKac motifs have been demonstrated to be 
favorable for HDAC8 catalysis[47]. Additional analysis, such as directly measuring ERRα 
acetylation patterns using mass spectrometry in the presence and absence of HDAC inhibitors 
would further validate ERRα as an in vivo substrate of HDAC8. 
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Another proposed HDAC8 substrate is the aberrant inv(16) fusion protein found in a significant 
portion of patients with acute myeloid leukemia[55]. This fusion protein combines the N-
terminus of the transcription factor domain core binding factor β, with the C-terminus of the 
smooth muscle myosin heavy chain[56]. In COS7 cells, co-immunoprecipitation experiments 
demonstrated that overexpressed HDAC8 associates with inv(16)[24]. Furthermore, HDAC8 co-
localizes and immunoprecipitates with smooth muscle myosin heavy chain[57] suggesting that 
HDAC8 may interact with this domain within the inv(16) fusion protein. Other HDAC isozymes 
do not immunoprecipitate with inv(16) under similar conditions, which suggests that HDAC8 
may be the main HDAC that interacts with inv(16) in vivo. The addition of the HDAC inhibitor 
TSA inhibits the transcriptional repression activity of inv(16)[24], suggesting that HDAC8 
activity is important for inv(16) regulation. An alternative explanation of these data is that 
inv(16) is a binding partner with HDAC8 rather than a substrate, as HDAC inhibitors have been 
shown to disrupt the association of HDACs with non-substrate binding partners[58]. The 
sequence of the acetylation site in the core binding factor β is RSKacFE[5]. Peptide library 
studies have demonstrated that Phe in the +1 position is favorable for HDAC8 catalysis[32, 47] 
although Ser at the -1 position attenuates reactivity[47]. Furthermore a computational algorithm 
for determining HDAC8 substrates ranks this peptides as a substrate (Chapter 3). While the core 
binding factor β is acetylated in vivo[5], there is not yet direct evidence that inv(16) is 
acetylated[59]. Taken together, these data indicate that inv(16) is either an HDAC8 substrate or 
forms a functionally important complex with HDAC8. 
A third potential in vivo HDAC8 substrate is the transcription factor CREB. Acetylation at three 
CREB sites (Lys91, Lys96, and Lys136) helps to activate this protein[60]. HDAC8 and CREB 
overexpressed in HEK293 cells co-immunoprecipitate, demonstrating that these two proteins 
associate. When HDAC8 is overexpressed in cells, phosphorylation of CREB decreases, which 
in turn inhibits CREB transcriptional activation[61]. Likewise, treatment of cells with the HDAC 
inhibitor TSA increases CREB phosphorylation levels[62] suggesting that HDAC8 activity is 
important for CREB phosphorylation. However, the addition of a broad range HDAC inhibitor 
(such as TSA) decreases the activity of all metal-dependent HDACs. As HDAC overexpression 
can affect a number of targets within the cell, this inhibition may indirectly affect CREB 
phosphorylation. Furthermore, pulldown experiments demonstrate that CREB can interact with a 
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number of HDAC isozymes[61], complicating identification of CREB as an HDAC8 substrate in 
vivo. Due to the high amino acid identity between class I HDACs (>30%)[63], overexpression 
and pulldown experiments may not yield results that are representative of in vivo situations. 
Therefore, these experiments suggest, but do not confirm, a direct connection between HDAC8 
deacetylase activity, the phosphorylation status of CREB, and the regulation of CREB activation. 
Alternatively, HDACs may function as protein scaffolds to mediate the inhibitory interaction 
between CREB and PP1 phosphatase[61, 64-66], leading to a decrease in CREB phosphorylation 
and activity.  
The cohesin subunit SMC3 is a putative in vivo substrate that has gained acceptance by the 
HDAC field. The first evidence for this was the demonstration that 5-30% of Cornelia de Lange 
syndrome (CdLS) patients suffer from mutations in HDAC8[67, 68], while the vast majority of 
these patients suffer from mutations to the cohesin complex or associated proteins. As a result, 
the link between HDAC8 and cohesin was investigated. SMC3 acetylation levels were shown to 
rise upon HDAC8 siRNA knockout or inhibition by an HDAC8 specific inhibitor[69]. This 
suggests that HDAC8 either deacetylates SMC3 directly or regulates another acetyl transferase 
or deacetylase that acts on SMC3. siRNA knockout of HDAC8 effects cohesin localization 
within the chromosomes, showing that HDAC8 affects cohesin function. HDAC8 mutants found 
to cause CdLS phenotypes in humans were shown to reduce HDAC8 activity and cause gene 
expression phenotypes similar to those seen with other CdLS mutations. HDAC8 mutants which 
cause CdLS reduce HDAC8 activity by varying degrees; some mutations fully kill HDAC8 
activity while others lessen it by two fold[68, 69]. The location of the various mutants within the 
HDAC8 structure suggest variable effects on activity including: altering substrate specify; 
altering protein stability; and altering HDAC8 binding partner affinity. 
The current cellular methods for identifying substrates of HDAC isozymes in vivo have 
limitations. Since HDAC selectivity depends on the relative concentrations of the HDAC 
isozymes and the concentrations of all of the acetylated lysine substrates, overexpression of 
HDAC and/or HDAC substrates can alter the normal pattern of deacetylase activity. Therefore, 
experiments using overexpressed proteins can suggest that a particular interaction occurs in vivo, 
but does not prove that this contact occurs under physiological conditions. Native pulldown 
experiments, which should be more representative of physiological conditions, have thus far not 
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been successfully used to confirm the identity of HDAC8 substrates. It is possible that the 
HDAC-substrate interactions may be transient and/or weak and thus are not maintained through 
the multiple washes in pulldown experiments. Therefore alternate techniques, such as 
crosslinking, may be necessary to increase the lifetime of an HDAC-substrate complex to allow 
detection. Additionally, observation of enhanced acetylation after deletion or knockdown of a 
given isozyme does not prove that an HDAC isozyme directly catalyzes deacetylation of that 
site. Therefore alternative methodologies need to be explored to enhance the identification of 
additional HDAC8 substrates. One novel technique used for the identification of HDAC8 
substrates is mass spectrometry tracking acetylation with HDAC specific inhibitors (Chapter 4). 
This methodology compares the acetylation state of proteins after a cell has been treated with an 
HDAC specific inhibitor and a control. The differential acetylation state of identified proteins 
suggest that they are substrates, though this method does not differentiate between substrates and 
proteins affected downstream by HDAC deacetylation. 
 
HDAC8 complex formation  
Recombinantly purified HDAC8 catalyzes deacetylation and displays peptide substrate 
selectivity in the absence of additional protein cofactors[16, 17, 26-28, 30-33, 47, 48, 54, 70], 
suggesting that HDAC8 can catalyze deacetylation in vivo in the absence of a protein complex. 
In contrast, the other class I HDACs, HDAC1, 2, and 3, are observed in complexes in the cell 
and their substrate specificity largely depends on the combination of proteins incorporated into 
their complexes[71]. HDAC1 and 2 associate with Sin3 scaffolded complexes which serve a 
range of functions within the cell. The substrate specificity and function of these HDAC 
isozymes can change by altering the protein composition of the complex[72]. Although HDAC8 
is phylogenetically most similar to the other class I HDACs, divergent evolution[20] may have 
altered how HDAC8 interacts with cofactors, possibly allowing this isozyme to function 
independent of other proteins. However, HDAC8 does associate with other proteins, and these 
interactions may affect the biological function and selectivity of this enzyme.  
Distinguishing between HDAC8 substrates and binding partners in the cell is currently difficult, 
as discussed in the previous sections. For example, previous experiments have provided evidence 
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that the HDAC1/HDAC2 complex associates with both the PP1 phosphatase and CREB, leading 
to decreased CREB phosphorylation[66]. Because an inactive HDAC1 mutant still affects CREB 
activity, the function of the HDAC1/HDAC2 complex was proposed to co-localize PP1 
phosphatase and CREB. However, it is possible that HDAC2 catalyzes deacetylation of CREB 
under these conditions[66]. Similarly, both PP1 and CREB co-immunoprecipitate with HDAC8, 
and HDAC8 overexpression decreases CREB activity. These data are consistent with HDAC8 
either acting as a scaffold to enhance the interaction between PP1 phosphatase and CREB or 
catalyzing deacetylation of CREB.  
In addition to CREB, HDAC8 likely affects the activity of other transcription factors either 
through their deacetylation or through complex formation. Levels of the transcription factor 
DEC1, were shown by DNA-CHIP analysis to correlate with the co-localization of HDAC8 at 
specific promoter sites[73]. Co-immunoprecipitations of HDAC8 and DEC1 validate their 
association, though it is unclear whether HDCA8 catalyzes the deacetylation of DEC1. 
Furthermore, HDAC8 expression can change DEC1’s expression profile, where over-expression 
of or siRNA knockdown of HDAC8 correlates with the up- or down-regulation (respectively) of 
the DEC1 regulated expression levels of the TAp73 transcription factor. This result led to the 
suggestion that DEC1 recruits HDAC8 to the TAP73 promoter. Additionally, HDAC8 has been 
shown to affect the mRNA and expression levels of a number of other genes such as SOCs1, 
SOCS3[74, 75], and p53[76]. Based on these results, HDAC8 may act in a complex which is 
shuttled to DNA regions where it can act on nucleosomes and nucleosome-associated protein to 
alter gene expression. Alternatively, HDAC8 may stably associate with some substrates and 
affect their acetylation, thus changing their activity. Either way, it appears that HDAC8 has the 
ability to alter a subset gene expression. 
HDAC8 also co-localizes with α-actin, as indicated by immunofluorescence staining[42]. This 
interaction was confirmed by pulldown experiments using human smooth muscle cells, 
demonstrating an endogenous association between α-actin and HDAC8[43, 57]. The function of 
this interaction was partially elucidated by demonstrating that siRNA knockdown of HDAC8 in 
human smooth muscle cells decreased the ability of cells to contract, when exposed to a collagen 
lattice. Furthermore, the siRNA-treated smooth muscle culture cells were smaller and unable to 
spread. These changes in cell morphology occurred without detectable changes to α-actin 
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acetylation[43], suggesting that HDAC8 may act as part of a complex which modulates the cell 
cytoskeleton. Furthermore, pulldown experiments demonstrate that HDAC8 associates with the 
proteins Hsp20, myosin heavy chain, and cofilin[57] all of which can potentially affect actin 
dynamics[77, 78]. It is currently unclear whether Hsp20 or cofilin are acetylated and substrates 
for HDAC8. However, immunoprecipitation experiments suggest that HDAC8 associates better 
with the non-acetylated form of myosin heavy chain, suggesting that this protein is not an 
HDAC8 substrate[57]. Furthermore, α-tubulin (another cytoskeletal protein) acetylation levels 
are altered upon either addition of an HDAC8 specific inhibitor[38] or HDAC8 siRNA 
knockdown[79] which in turn destabilizes the microtubule system. Because HDAC8 enhances 
cell contractility and associates with many proteins important for actin function, it is likely that 
HDAC8 is a component of a complex that modulates actin and microtubule dynamics. The 
relationship between microtubule and cohesion activity[80-82] may provide an alternative 
explanation for HDAC8’s effects on microtubule dynamics. 
Additional potential HDAC8 interaction partners have been identified using a bacterial two-
hybrid system[83]. Two of the fifteen identified binding partners have been examined in detail: 
the human Ever-Shorter Telomeres 1B (hEST1B) protein that activates telomerase activity and 
HOP1, an adaptor protein linking Hsp70 and Hsp90. The two-hybrid results were confirmed 
using co-immunoprecipitation of overexpressed hEST1B and HDAC8 in Hela cells. HDAC8 
knockdowns led to decreased telomerase activity through diminished levels of hEST1B. As 
HDAC8 activity does not affect the promoter region regulating hEST1B, the hEST1B level is 
likely not regulated by alteration in transcription. However, hEST1B levels are increased by 
addition of a proteasome-dependent pathway inhibitor or decreased by overexpression of 
ubiquitin and rescued by phosphorylated HDAC8. These results argue that phosphorylated 
HDAC8 protects hEST1B from polyubiquitination and subsequent degradation by the 
proteosome. Since phosphorylation decreases HDAC8 activity this protective effect could be due 
to enhanced acetylation of hEST1b. The protective effects of phosphorylated HDAC8 on 
hEST1B levels are independent of deacetylase activity, remaining in the presence of the 
catalytically inactive His143Ala-HDAC8 mutant, or after exposure of cells to TSA. Therefore, 
HDAC8 interacts with hEST1B but deacetylation is not required for the functional effect. To 
further explore the interaction between HDAC8 and HOP1 indicated by the two-hybrid 
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experiment, the association of HDAC8 with known HOP1 binding partners was investigated. 
Pulldown experiments demonstrated that endogenous Hsp70 and Hsp90 co-immunoprecipitate 
with overexpressed HDAC8[83]. This result suggests that HDAC8, HOP1, Hsp70, and Hsp90 
form a complex. One proposed mechanism for the effect of HDAC8 on telomerase activity 
suggests that the Hsp70-HDAC8 complex protects hEST1B from ubiquitination catalyzed by the 
E3 ubiquitin ligase CHIP[83]. This in turn raises the levels of hEST1B and activates telomerase. 
Interestingly, interaction of HDAC8 with the Hsp proteins may help to elucidate the effect of 
HDAC8 on α-actin, since Hsp90 has been proposed to modulate α-actin dynamics[84, 85]. Thus 
it is possible that the HDAC8-HOP1-Hsp90 complex may regulate α-actin function.  
A similar study to the two-hybrid system (above) identified proteins that associate with an 
HDAC8-GFP fusion using mass spectrometry[86]. These data solidify several previously 
suggested HDAC8 interaction partners such as SMC1A and SMC3, while identifying a number 
of additional HDAC8 interaction partners/substrates. Some of these partners further elucidate 
proposed HDAC8 functions, while others hint at HDAC8 functions which have yet to be 
identified. Joshi et al. identified a number of cohesion associated proteins (STAG2, SMC1A, 
SMC3) and microtubule associated proteins (TPM3, TPM4, ADD3, SVIL) as well as 
transcription factors (ZSCAN2, MDM1, ZSCAN2). These proteins solidify HDAC8’s role in 
regulating cell motility and transcription. Other associated protein suggest a role for HDCA8 in 
additional cellular functions. For example associations of HDAC8 with mitochondrial protein 
CHCHD3 and the calcium dependent membrane protein CPNE3, suggest a role for HDAC8 in 
calcium mediated apoptosis[36] (as previously proposed). HDAC8 shares interaction partners 
with other HDACs. For example both HDCA8 and HDAC6 interact with microtubules and 
protein transport proteins, consistent with pervious data[42, 43, 87]. However Joshi et al.found 
limited interactions between the binding partners of HDAC8 and another isozymes. While this 
phenomenon could be an artifact, it could indicate that HDAC8 specializes in its functions and as 
a result may also have a relatively exclusive set of substrates. Finally, experimental variation of 
binding partners between trials could indicate that regulation affects HDAC8 activity and 
function. This phenomenon could explain why Joshi et al. failed to identify many of the HDAC8 
binding partners found in other studies. Alternatively, the GFP tag on HDAC8 may have 
prevented number of complexes from forming. 
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Enzyme structure affects substrate specificity  
The structure of HDAC8 yields clues about molecular recognition relevant to substrate 
selectivity. HDAC8 is the second smallest metal-dependent HDAC at ~42 kDa, containing little 
more than the catalytic domain[20, 27-29]. This HDAC folds as a single α/β domain with a core 
eight-stranded β-sheet surrounded by eleven α-helices (Figure 1.3A). The substrate binding 
surface, composed of nine loops and an 11 Å tunnel leading to the active site, is proposed to be 
conformationally flexible based on the poor occupancy and varying positions of the loop 
residues in crystal structures[13-19] (Figure 1.3B). Furthermore, one crystal structure illuminates 
a bound TSA molecule interacting with residues in the hydrophobic core of HDAC8[14] (Figure 
1.4). While this may simply be an artifact, the alternative binding mode suggests that the surface 
of the protein can change conformation enough to allow hydrophobic molecules to intercalate 
between these loops and interact with the interior of the protein. Loops are a common structure 
in promiscuous enzymes[88] and examples of proteins, such as chymotrypsin[89] and 
carboxypeptidase A[90], that use loops to bind a range of substrates are abundant in nature. 
These loops create a number of different conformations that bind ligands through a combination 
of induced fit and select fit mechanisms[45, 91]. The varied conformations and motifs provide a 
palette of binding sites to accommodate a multiplicity of substrates, and may account for the 
complex dynamics observed and simulated for HDAC8 inhibitors[92-94]. Furthermore, long 
range allosteric movements propagated through the loops may affect the active site and 
surrounding areas, potentially altering substrate preferences. 
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Figure 1.3 HDAC8 structures 
A) Side view of HDAC8 with bound peptide substrate PDBID: 2v5w[13]. Helices are purple, 
sheets are yellow, turns are white, the monovalent cations are orange, and the active site metal is 
colored green. The Fluor de Lys substrate representing the p53 sequence is colored cyan for 
carbon, red for oxygen, and blue for nitrogen. B) Front view of an overlay of the 21 HDAC8 
crystal structures in the PDB: PDBID: 2v5x, 2v5w, 1t69, 1t64, 1vkg, 1t67, 1w22, 3sfh, 3sff, 
3mz3, 3ezt, 3fo6, 3mz4, 3mz6, 3mz7, 3ew8, 3ezp, 3f07, 3f0r, 3ewf, and 3rqd[13-19]. Structural 
variations are especially apparent in the L1, L2, and C-terminal loops. C) A map of the crystal 
structure of HDAC8 outlining the loop regions. 
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Figure 1.4 HDAC8 with two bound TSA molecules 
PDBID: 1t64[14]. In this crystal structure, one molecule of TSA binds to the active site tunnel to 
coordinate the divalent metal ion (colored yellow) while a second TSA molecule binds nearby in 
between the L1, L2, and L3 loops. 
 
In fourteen of the twenty-one HDAC8 crystal structures, the enzyme crystallizes as a dimer 
along the substrate binding interface[13-18]. As HDAC8 is a monomer in solution[19], the dimer 
interface may provide insight into long range interactions between HDAC8 and its in vivo 
substrates. To date, substrate specificity has mainly been evaluated using peptide substrates, 
therefore only short range interactions have emerged as HDAC8 substrate binding motifs[31-33, 
47]. Based on the crystal structure of bound peptides[13, 16] and biochemical measurements, 
these interactions include ring stacking, hydrogen bonding, salt bridges, and electrostatic 
interactions. Ring stacking between Tyr100 and the methylcoumarin of the Fluor-de-lys peptides 
is observed in the crystal structure[13, 16]. Similarly, ring stacking between aromatic amino 
acids in the +1 position and Tyr100 may be important for substrate recognition[32, 47]. 
Additionally, hydrogen bonding between the backbone amides of the substrate and the Asp101 
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side chain oxygens are important for molecular recognition[16]. Salt bridges between positively 
charged arginines in the substrate and negatively charged carboxylate side chain oxygens, and 
general hydrophobic interactions can be seen in the peptide-enzyme interface[13, 16]. Because of 
the limited number of interactions, the binding affinity may be dominated by a few strong 
contacts, as observed for the interaction between Tyr100 of HDAC8 and the methylcoumarin 
moiety of short Fluor-de-lys peptides[47]. This pi-pi interaction (~2 kcal/mol)[95, 96] is of 
comparable energy with other HDAC8-peptide contacts. In contrast, binding a protein substrate 
could involve many more contacts, including multiple hydrogen bonds (0.5-1.5 kcal/mol), 
hydrophobic (~1 kcal/mol), electrostatic (<1 kcal/mol)[45], and solvent exposed salt bridge (~1-3 
kcal/mol)[97] interactions. Therefore, the binding affinity could depend on a large number of 
interactions that together create a promiscuous substrate binding profile. Determinants of 
substrate specificity are still being evaluated for HDACs and further identification of binding 
motifs will be beneficial for understanding the biology of these enzymes.  
When the structure of HDAC8 is compared to that of the homologous polyamine deacetylase, 
APAH[98], striking differences in loop size and structure can be observed. These differences in 
the loops may be important for substrate binding as APAH catalyzes deacetylation of small 
molecules, including acetylated spermidine, putrescine, and spermine, while HDAC8 
deacetylates macromolecules. In APAH, the L1 and L2 loops are much larger and contain many 
more hydrophobic residues than the corresponding HDAC8 loops (Figure 1.5A,B), while the C-
terminal loop and helix in HDAC8 are absent in APAH. Similarly, a comparison of the L1, L2, 
and C-terminal loops of different HDACs reveals interesting variations. The L1 and L2 loops of 
HDAC2[99], 4[100], 7[101], and 8[13] are more divergent in size, structure, and number of 
charged residues than other loops within these HDACs (Figure 1.5A,B). For instance, the size 
and number of charges within the L1 and L2 loops change two-fold between HDAC8 and 
HDAC4. Comparison of all of the HDAC8 crystal structures illustrates that the L1 and L2 loops 
have the most structural variability of the loops in the proposed substrate binding surface, 
suggestive of a role in ligand binding. Additionally, the L2 loop interacts with inhibitors, 
suggesting that it may be important for molecular recognition of substrates[16]. The L3 loop, 
which lies below the L2 loop and flanks the active site, also varies greatly in the number of 
charges in the loop among HDACs 2, 4, 7, and 8, consistent with a role in substrate or binding 
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partner selectivity. The C- and N- terminal portions of the HDACs, which lie on the outer edge 
of the substrate binding surface, may also interact with ligands. In the HDAC crystal structures, 
the C-terminal loops vary in position, charge, and size and may be responsible for long distance 
interactions between HDACs and their substrates, or used for recognition of binding partners.  
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Figure 1.5 Structural variation within the structurally characterized HDACs  
A) Aligned sequences of the published HDAC crystal structures[13, 98-101] using 
COBALT[102]. Highlighted in yellow are the residues that comprise the loop regions and amino 
acids that comprise the putative substrate binding region. The positively charged residues are red 
and the negatively charged residues are green. B) Surface visualizations of the crystal structures 
for HDAC2 (PDBID: 3max[99]), HDAC4 (PDBID: 2vqm[100]), HDAC7 (PDBID: 3c0y[101]), 
HDAC8 (PDBID: 2v5w[13]), and APAH (PDBID: 3q9b[98]). Superimposed into each structure 
is the Fluor de Lys substrate (green) from the HDAC8 structure. In red are the positively charged 
residues Arg and Lys, and in blue are the negatively charged residues Asp and Glu.  
 
Along with structural studies, peptide substrates have been useful for evaluating substrate motifs 
recognized by HDAC8. Reister and colleagues measured the reactivity of HDAC8 with a peptide 
library of the sequence Ac-X-Z-Kac-methylcoumarin, where X and Z were all amino acids 
except for cystine[31]. This work indicated that HDAC8 favors Pro, Met, Ala, Lys, Arg, Gln, 
Asp, Phe, and Ser at the -2 position and aromatic (Phe, Trp, and Tyr) and hydrophobic (Ile, Met, 
and Val) amino acids at the -1 position. However, the activity of HDAC8 in these assays was 
low, possibly due to the inclusion of the metal chelator EDTA in the assay. The Mrksich group 
developed a mass spectrometric assay to profile the local substrate specificities of HDACs[47]. 
The reactivity of HDAC8 with a peptide array of the sequence, Ac-G-X-Kac-Z-G-C-NH2 where 
X and Z were any amino acid other than cysteine, showed that the most efficient substrate 
contains Arg and Phe at the X and Z positions, respectively[47]. However, HDAC8 also 
catalyzes deacetylation of peptides containing the sequence X=Arg/Z= variable and X = 
variable/Z = Phe. HDAC8 selectivity was further screened using a peptide library with the 
following sequence: Ac-G-R-Kac-X-Z-C-NH2[32]. These data demonstrated a preference for 
Arg or Phe at the X position. Furthermore, when X is Phe the identity of the Z position has only 
a modest effect on activity. These results suggest that specific positions and combinations of 
amino acids contribute significantly to the substrate recognition of small peptides, while other 
positions fine tune recognition. The Mrksich group also demonstrated that an RHR motif added 
to the C-terminus of peptide substrates of varying lengths enhances reactivity, demonstrating that 
distal sequences can modulate HDAC8 substrate selectivity[33]. Interestingly, the sequences 
RHRK and RHKK are found in the H4 histone tail and in p53, respectively, and hint that distal 
sequences may enhance the reactivity of HDAC8 with these substrates in cells.  
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Finally, the structure of the active site may also play a role in HDAC substrate specificity. 
HDAC2 and 8 have well defined 11Å channels leading to their active sites that easily 
accommodate an acetyl lysine side chain, however, this tunnel is lacking in HDAC4 and 7[13, 
99-101] where only half of the channel is apparent. This modification in active site structure 
could suggest that HDAC4 and 7 catalyze deacetylation of alternate substrates, as proposed by 
Lombardi et. al.[98]. Alternatively, these isozymes might need substrates or binding partners that 
complement the active site to stabilize the binding of the acetyl lysine moiety.  
 
Catalytic Mechanism and Regulation of HDAC8 activity 
The active site of HDAC8 contains a divalent metal ion coordinated to two aspartate and one 
histidine side chain (Asp178, Asp267, and His180) and one or two water molecules. 
Additionally, a conserved tyrosine (Tyr306) and a pair of conserved histidine/aspartate hydrogen 
bond dyads (His142/Asp176 and His143/Asp183) are located near the bound acetyl lysine 
moiety (Figure 1.6). The enzyme is proposed to catalyze hydrolysis using a metal-coordinated 
water nucleophile and general acid-base catalysis (GABC) with either one or two side chains, 
similar to typical metallohydrolase mechanisms[16, 21, 103, 104] (Figure 1.6). The substrate 
binds to HDAC8 with the catalytic metal coordinating both the carbonyl oxygen of the acetyl 
lysine substrate and a water molecule. In the first step of the mechanism, His142 functions as a 
general base to abstract a proton from the metal-bound water that is reacting with the carbonyl 
carbon to form a high energy tetrahedral intermediate. The oxyanion intermediate is proposed to 
be stabilized by coordination with the metal ion, hydrogen bonding with Tyr306, and 
electrostatic interactions with positively charged groups in the active site. Proton donation from 
an active site general acid to the amine leaving group accompanies breakdown of the tetrahedral 
intermediate to form the acetate and the deacetylated lysine products[103]. In the GABC 
mechanism originally proposed from the crystal structure of the homologous HDLP 
enzyme[103], His142 and protonated His143 are proposed to function as the general base and 
general acid, respectively. In the one GABC mechanism, H143 functions as both the general acid 
and general base catalyst and H142 acts as an electrostatic catalyst[16, 104], similar to the 
23 
 
mechanism proposed for carboxypeptidase A[21]. Subsequent studies utilizing mutagenesis and 
molecular dynamics simulations suggest a preference for the one base mechanism[16, 44, 104].  
Figure 1.6 Schematic of the one base mechanism for HDAC8 
The acetyl lysine of the substrate is shown in blue while the nucleophilic water is green and red. 
For clarity, equilibration of exchangeable protons with solvent is not shown. 
 
The HDAC8 crystal structure also contains two monovalent cation sites[13-18], suggesting that 
the activity of HDAC8 may be modulated by both the concentration and type of ions in solution. 
One monovalent cation site is 7 Å from the divalent catalytic metal ion and is coordinated by the 
side chain oxygens of Asp176 and Ser199 and the backbone carbonyl oxygens of Asp176, 
Asp178, His180, and Leu200. The second site is 21 Å from the divalent catalytic metal ion, and 
is ligated by two water molecules and the backbone carbonyl oxygens of Phe189, Thr192, 
Val195, and Tyr225. Initial activity measurements demonstrated that the concentrations of K+ 
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and Na+ modulate HDAC8 catalysis[biolmol unpublished]. A detailed examination demonstrated 
that the value of kcat/KM for HDAC8-catalyzed deacetylation has a biphasic dependence on the 
concentration of K+ and Na+ ions[54]. In the absence of monovalent ions, the activity of HDAC8 
is very low; addition of monovalent cations to Zn-bound HDAC8 increases activity with K1/2,act = 
14 mM for K+. At higher K+ concentrations Zn-HDAC8 activity is inhibited with K1/2,inhib = 130 
mM. Mutagenesis studies indicate a significant decrease in potassium inhibition in the 
His142Ala and Asp176Ala/Asn mutants indicating that the monovalent ion site near the active 
site is inhibitory. Potassium binding next to His142 has been proposed to lower the pKa of this 
residue, decreasing the concentration of protonated His142, thereby lowering catalytic activity. 
Similar biphasic regulation has been measured for Na+, but activation and inhibition require a 
five-fold and ten-fold higher concentration of Na+ compared to K+, respectively[54]. At the 100 
mM K+ concentration within smooth muscle cells[105], HDAC8 activity is partially inhibited 
and sensitive to changes in the K+ concentration. 
 
HDAC8 catalytic activity is enhanced by a number of divalent metal ions, including Co2+, Zn2+, 
Ni2+, and Fe2+[26]. When HDAC8 is purified under aerobic conditions, the bound metal ion is 
Zn2+. However, recombinant HDAC8 purified anaerobically from E. coli contains 8-fold more 
iron than zinc, consistent with this, the recombinant HDAC8 activity in E. coli cell lysates is 
oxygen-sensitive[26]. Additionally, although HDAC8 binds Zn2+ nearly 106-fold more tightly 
than Fe2+[17], the affinities for both metal ions are comparable to the readily exchangeable metal 
concentrations estimated in living cells, suggesting that HDAC8 can bind either Fe2+ or Zn2+ in 
vivo. Furthermore, the identity of the bound metal ion alters the catalytic properties of HDAC8. 
When catalyzing deacetylation of the methylcoumarin-labeled p53 peptide, the kcat/KM value for 
Fe2+-bound HDAC8 is almost three times larger than that of Zn2+-HDAC8. Interestingly, 
substitution of Fe2+ for Zn2+ also decreases the KI for SAHA, suggesting that Fe2+ enhances 
ligand affinity[26]. However, a comparison of the crystal structures of the hydroxamate-bound 
Fe2+-HDAC8 and Zn2+-HDAC8 shows no significant differences in the active site or the rest of 
the protein[17]. These data suggest that either binding of the hydroxamic inhibitor stabilizes a 
common enzyme conformation, or that the bound metal ion affects protein dynamics that are not 
observable by crystallography. 
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Comparison of the Zn2+/Fe2+ metal affinities with the cellular concentrations of those metals 
suggests that HDAC8 likely binds a combination of iron and zinc cofactors in eukaryotic 
cells[17]. Furthermore, the cellular zinc concentration can change dramatically upon oxidative 
stress[106, 107] and metal toxicity[108] potentially altering the populations of Fe2+-HDAC8 and 
the Zn2+-HDAC8 based on cellular conditions. This provides a means by which the cell could 
couple HDAC8 activity to cellular stresses. 
A simple model for HDAC activation and inhibition assumes that compounds, cofactors, and 
binding partners equally affect the activity of HDAC8 with all substrates (Figure 1.7A). An 
alternative to this model proposes that substrate selectivity may be differentially regulated by 
stimuli. For example, scaffolding activators could preferentially enhance the binding of HDAC8 
to one set of substrates (Figure 1.7B). Similarly, alteration of the active site metal ion or bound 
monovalent ions could alter ligand specificity. For example, Fe2+-HDAC8 binds the inhibitor 
SAHA 2-fold more tightly than Zn2+-HDAC8[54] even though Zn2+ is a stronger Lewis 
acid[109]. This change in binding affinity suggests that the active site metal ion may contribute 
subtly to the structure, dynamics, and molecular recognition of HDACs.  
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Figure 1.7 Schematic of three potential models for describing the effect of an activating 
effector on HDAC activity 
A) In this model catalysis of deacetylation of each substrate is enhanced by an equivalent factor 
upon addition of the effector. B) In this model catalysis of deacetylation of each substrate is 
enhanced by a different factor upon addition of the effector. C) In this model catalysis of 
deacetylation of some substrates is activated while other substrates are inhibited by the effector. 
 
HDAC8 localization  
Most simply, protein localization may regulate HDAC8 substrate specificity by changing the 
effective substrate concentration. HDACs have been found to have a range of cellular locations. 
HDAC1 and 2 are exclusively nuclear, while HDAC6 is mostly cytoplasmic, and HDAC3, 4, 5, 
6, 7, 9, 10, and 11 appear to shuttle in and out of the nucleus[110]. Initially, HDAC8 was found 
to have a putative nuclear localization site and was observed in the nucleus of NIH3T3[27] and 
HEK293 cells[28]. Soon after, microscopy demonstrated that HDAC8 localizes to both the 
cytoplasm and nucleus of embryonic smooth muscle cells, skin fibroblasts, NIH3T3 cells, liver 
tissue[42, 50], and epithelial cells[79]. HDAC3, the closest HDAC8 human homologue[20], 
exists in both the cytoplasm and nucleus, and localization has been linked to the regulation and 
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cellular function of this enzyme. Whether cellular localization plays a role in HDAC8 activity is 
currently unknown, as no studies have yet broached this subject. 
 
Determining the cell type-dependent expression of HDAC8 may provide interesting insights 
about its substrate specificity and biological function. In general, class I HDACs are ubiquitously 
expressed amongst the various cells of an organism, while class II HDACs are more cell-type 
specific[110, 111]. Likewise, HDAC8 has been found in a number of different healthy and 
diseased cell types. 
 
HDAC8 knockouts after birth are non-lethal[112], consistent with the ability of humans to 
tolerate pan-HDAC inhibitors as an anti-cancer treatment[113]. However, protein expression 
profiles can vary significantly during development and several HDAC knockouts are lethal 
during mammalian embryonic development[8]. For example, cells lacking HDAC3 die before 
embryonic day 9.5; deletion of HDAC3 leads to hyperactivity of the nuclear receptor PPARα and 
problems with embryonic gastrulation[114]. Similarly, HDAC8 expression is crucial to 
development, as mice lacking this enzyme die soon after birth[112]. Death is due to brain 
hemorrhaging caused by defects in the development of the mouse skull resulting from problems 
with neural crest patterning. Skull defects in mice are similar to those that occur upon 
overexpression of the transcription factors Otx2 and Lhx1, suggesting that HDAC8 either 
directly regulates these proteins or affects regulators of these proteins[112]. The mechanism of 
HDAC8 regulation of Otx2 and Lhx1 has yet to be determined, though treatment with an 
HDAC8 inhibitor suggests that HDAC8 may alter histone H3 acetylation levels in the promoter 
region of Otx2 and Lhx1[39]. Furthermore, since HDAC8 knockouts in mice are not lethal after 
birth[112], it is unclear whether HDAC8 is not essential for regulation of proteins, whether this 
regulation still occurs but is not vital for viability, or whether another mechanism is utilized. In 
humans some HDAC8 mutations and truncations are non-lethal but cause facial abnormalities 
and intellectual disabilities[68, 69, 115]. Because some HDAC8 mutants are not lethal in humans 
while still able to cause facial abnormalities could in part reflect to HDAC8’s ability to act as a 
scaffold[61, 83]. Alternatively, HDAC8 could act by different mechanisms in mice and humans 
causing decreased lethality of these mutations. 
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Post-translational modification of HDAC8 
Post-translational modifications such as phosphorylation, may also regulate HDAC8 activity. A 
screen of three protein kinases, casein kinase II, protein kinase A (PKA) and protein kinase G 
(PKG) indicated that phosphorylation of HDAC8 could be catalyzed by both PKA and 
PKG[116]. Phosphorylation of HDAC8 by PKA appeared to be predominant means by which 
HDAC8 is phosphorylated. This function was authenticated in vivo by incubation of cells with 
the PKA inhibitor H-89, which lowered HDAC8 phosphorylation levels[117]. Based on 
consensus sequences, nineteen potential phosphorylation sites were identified in HDAC8. 
Phosphoamino acid analysis followed by two dimensional thin layer chromatography 
demonstrated modification of a serine residue[117] and, based on this information, Ser39 was 
identified as the only PKA phosphorylation site in the HDAC8 sequence[27, 117]. A Ser39Ala 
HDAC8 mutant, which cannot be phosphorylated, negates phosphorylation of HDAC8 catalyzed 
by PKA, confirming this location as the primary phosphorylation site on HDAC8. Furthermore, 
phosphorylation of this site modulates HDAC8 activity. The specific activity of HDAC8 purified 
from cells treated with forskolin, a PKA activator, decreased by five-fold in an in vitro assay 
using purified histones[117]. Furthermore, the specific activity of Ser39Glu HDAC8, a mutation 
that mimics phosphorylation, decreases to a level comparable to that of phosphorylated HDAC8, 
while the specific activity of the Ser39Ala mutant is similar to unmodified HDAC8. To examine 
whether in vivo effects of phosphorylation of HDAC8 correlate with the in vitro measurements, 
HDAC8-transfected HeLa cells were treated with forskolin. These cells showed increased levels 
of acetylated histones H3 and H4, suggesting that the decreased deacetylase activity of 
phosphorylated HDAC8 led to increased acetylation in vivo[117].  
 
Ser39 is located on the backside of the HDAC8 surface, 21Å from the catalytic metal ion[13-18] 
(Figure 1.8). Nonetheless, phosphorylation has the potential to affect the subcellular localization, 
protein-protein interactions, allosteric effects, and HDAC8 activity via conformational changes 
that propagate to the active site or enzyme-substrate interface. Ser39 lies near the junction with 
the L1 loop[13-18] that has been implicated in substrate recognition, and therefore 
phosphorylation at that position may alter enzyme-substrate interactions. The Ser39 residue is 
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located in a pocket on the enzyme surface surrounded by hydrophobic and acidic residues 
suggesting that phosphorylation of Ser39 could induce a drastic structural perturbation due to 
charge repulsion[14], where a Ser39Glu mutation decreases HDAC8 catalyzed deacetylation of 
core histones. Activity towards Ser39 also directly contacts the conserved Arg37 residue, which 
is proposed to be important for gating an acetate release channel in HDAC8[70] (Figure 1.8). 
The Arg37Ala mutation decreases the kcat/KM value for Co2+-HDAC8-catalyzed deacetylation of 
the Fluor-de-lys substrate (R-H-Kac-Kac-fluorophore) by 530-fold[70]. Based on the proximity 
of Ser39 to Arg37, phosphorylation at this position may similarly affect HDAC8 activity.  
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Figure 1.8 Phosphorylation of Ser39 may affect the active site structure and/or reactivity of 
HDAC8 
PDBID: 2v5w[13]. This structure shows that phosphorylation of Ser39 (red) may be able to 
perturb the position and/or electrostatic environment of Arg37 (orange) and in turn, affect the 
active site residues (yellow). Blue is the Fluor de Lys substrate and green is the active site metal. 
 
 
Phosphorylation may also regulate HDAC8 through the modulation of protein-protein 
interactions. In the bacterial two-hybrid assay that identified fifteen HDAC8-interacting 
proteins[83] expression of PKA was necessary for the pulldown of six of these identified 
proteins, and suggests that these proteins interact solely with phosphoHDAC8. Two of these 
interactions, those between HDAC8 and hEST1B and between HDAC8 and Hsp70, were further 
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observed by co-immunoprecipitation, showing that treatment of cells with forskolin, led to 
increased amounts of phosphorylated HDAC8 and increased interactions[83]. These data 
strongly suggest that HDAC8 phosphorylation regulates HDAC8 complex formation as well as 
catalytic activity. Similarly, phosphorylation of HDAC1 and HDAC2 regulates association of 
these proteins with complexes such as mSin3A, RbAp48, and CoREST[116, 118]. 
Phosphorylation-dependent complex formation may also regulate the cellular localization of 
HDAC8. Fluorescence microscopy of myometrial cells shows that HDAC8 and phosphoHDAC8 
both localize primarily to the cytosol, but cell fractionation data suggest that phosphoHDAC8 
has increased association with the cytoskeleton compared to HDAC8 in this cell type[57]. 
HDAC4, HDAC5, and HDAC7 have been proposed to utilize nuclear-cytoplasmic shuttling 
mechanisms involving phosphorylation-dependent binding to 14-3-3 proteins for regulating their 
subcellular localization, and a similar mechanism may regulate HDAC8 localization[119-122].  
 
The Ser39 site is an interesting location for phosphorylation amongst HDACs. Ser39 is not 
conserved among class I HDACs; the residue in the corresponding position of other class I 
HDACs is arginine in HDAC1 and 2, and alanine in HDAC3. Also, HDAC8 and HDAC5 
contain the only phosphorylation sites that are located within the HDAC catalytic domain[123-
125]. Additionally, HDAC8 is the only isozyme phosphorylated by PKA[125]. In general, the 
effect of phosphorylation on the activity of other class I isozymes, HDAC1 and 2, is ambiguous 
and/or contradictory[116, 118, 126, 127]. For example, phosphorylation of HDAC1 had little to 
no effect on deacetylase activity using a synthetic histone H4 peptide[126, 127] but activity on 
isolated histones decreased using mutants that could not be phosphorylated[118]. Therefore 
HDAC8 may be the best isozyme for examining the role of phosphorylation in regulating 
acetylation.  
 
Many HDACs undergo additional post-translational modification including acetylation, 
ubiquitination, and sumoylation[124], but additional modifications of HDAC8 have not yet been 
demonstrated. HDAC8 has a consensus motif for glycosylation at Asn136 that could be 
modified[27, 117]; however the NetNGlyc 1.0 server does not predict N-glycosylation of this 
site due to the lack of a signal peptide[128]. Acetylation has been observed for HDAC1 at 
multiple sites, and one of the acetylated residues is conserved in HDAC8. Two of the HDAC1 
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sites are located in the deacetylase domain and four sites are near the C-terminus; acetylation of 
these sites inhibits HDAC1 deacetylase activity toward histones in vitro and corepressor function 
in vivo[129]. The two sites in the deacetylase domain, Lys218 and Lys220, are located near the 
activating monovalent cation binding site, so decreased activity from acetylation of these 
residues may arise from alteration of monovalent cation binding[129]. Sequence alignment by 
Cobalt indicates that the Lys218 position in HDAC1 is conserved in the corresponding Lys221 
position in HDAC8[(http://www.ncbi.nlm.nih.gov/tools/cobalt/)]. This lysine is within the 
proximity of monovalent site. As this site hypothetically activates HDAC8 allosterically[54], it is 
feasible that HDAC8 activity could be regulated by modification at this location. However, no 
modifications at this site have yet been observed and post-translational modifications of HDAC8 
need to be further examined. 
 
Concluding remarks 
Due to the abundance and vital function of acetylation within the cell, enzymes that catalyze 
acetylation and deacetylation are regulated in a multitude of ways and on a number of time 
scales. One mechanism of regulating HDAC activity is changing the substrate preferences for 
these enzymes, which in turn affects cellular processes. These regulatory mechanisms may allow 
the cell to finely tune the substrate preference for many HDACs simultaneously by allowing the 
same stimuli to differentially alter the activity of each HDAC isozyme. Understanding the 
interplay between various stimuli and HDAC regulation will give us tremendous insight into the 
inner workings of cellular processes and the mechanisms of disease formation. Even though 
HDAC8 has been extensively studied, it is humbling to know the vast amounts of information 
that have yet to be determined regarding the cohort of HDAC8 substrates and binding partners, 
localization in the cell, and regulatory mechanisms. Therefore, even for the best-characterized 
HDAC, there are likely many factors that affect substrate recognition that have not yet been 
discovered. The dissection of these factors in the future will be tremendously important for 
understanding not only the cellular function of HDACs, but also cellular regulation by post-
translational modifications. 
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Chapter 2  
An enzyme-coupled assay measuring acetate production for profiling histone deacetylase 
specificity1,2 
 
Introduction 
Histone (or acetyl lysine) deacetylases (HDACs) are a family of 18 enzymes that catalyze the 
deacetylation of acetylated lysine side chains[1, 2]. Acetylation is a post-translational 
modification identified on over 3,100 lysines within the mammalian proteome[3] that alter the 
activities and properties of modified proteins[4]. As many of these proteins are essential to 
cellular processes[5, 6], aberrant acetylation and deacetylation may contribute to disease 
states[7]. Attesting to the role of HDACs in diseases are two HDAC inhibitors (Vorinostat and 
Romidepsin) that have been approved by the FDA for the treatment of T-cell Lymphoma[8], 
though the mechanism of action for these drugs is not well understood. One complicating factor 
to understanding the biological function and regulation of protein deacetylation is the lack of 
identified HDAC isozyme-substrate pairs. Determining the substrate specificity of HDACs 
would provide insight into cellular homeostasis and development of isozyme-specific inhibitors. 
                                                 
1 Reproduced in part from Wolfson, N.A. Pitcairn, C.A. Sullivan, E.D. Joseph, C.G. Fierke, C.A. 2014. Anal 
Biochem. 2014 Mar 24. pii: S0003-2697(14)00102-X. doi: 10.1016/j.ab.2014.03.012. 
2 Noah Wolfson developed the coupled acetate assay. Carol Ann Pitcairn developed the fluorescamine assay, 
acetylated tetramer and performed the assay on the tetramer. Eric Sullivan assayed HDAC3 and performed the 
continuous assay. Caleb Joseph developed the quench methodology. 
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There are four classes of HDAC enzymes. Classes I, II, and IV use an active site divalent metal 
ion cofactor to catalyze deacetylation, yielding lysine and acetate as products[9]. Class III 
HDACs use NAD+ as a cofactor and produce 2’-O’acetylribose, nicotinamide, and the 
deacetylated protein[10]. Current in vitro assays for the measurement of HDAC activity use 
environmentally sensitive fluorophores[9, 11-17], HPLC methods[18], free amine reactive 
reagents[11], radiolabeled acetate[19, 20], and mass spectrometry[21-23]. While these assays are 
useful, each has associated limitations. In particular, many of these techniques can only be used 
to measure deacetylation of short peptide substrates rather than the biologically-relevant 
acetylated proteins. Furthermore, in the most frequently used assay, the Fluor de Lys assay, the 
methylcoumarin substituent alters substrate recognition[23]. For assays that can be adapted to 
measure deacetylation of proteins, many cannot be adapted to high throughput formats, are hard 
to quantify, or require specialized equipment. 
 
Here we optimize an enzyme-coupled assay for the measurement of low micromolar acetate 
concentrations that can be used to evaluate the activity of class I, II, and IV HDACs. This assay 
couples the formation of acetate to the production of NADH that is monitored via an absorbance 
or fluorescence signal. This assay quantitatively measures deacetylation independent of the 
substrate size or structure, does not require specialized equipment, and can be adapted to real-
time and high throughput formats. Using this assay, we demonstrate that cobalt(II)-bound histone 
deacetylase 8 (Co(II)-HDAC8) catalyzes deacetylation of a peptide sequence from the H4 
histone tail containing a C-terminal methylcoumarin fluorophore with a kcat/KM value that is 50-
fold, 2.8-fold, and 2.3-fold greater than the kcat/KM value for deacetylation of the same peptide 
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containing a C-terminal carboxylate, amide, or tryptophan, respectively. The loss of catalytic 
efficiency for deacetylation of the C-terminal carboxylate peptide is a result of a 2.3-fold 
increase in the value of KM and a 22-fold decrease in the kcat value. These data demonstrate that 
interactions between HDAC8 and the C-terminal moiety are important for substrate recognition 
and efficient chemistry.  
 
Materials and Methods  
Reagents 
ATP, Coenzyme A, NAD+, L-malic acid, citrate synthase (CS), and malate dehydrogenase 
(MDH) were purchased from Sigma. The acetic acid detection kit was purchased from R-
biopharm. Fluor de Lys peptide and the developing reagent were purchased from Enzo Life 
Sciences. The unlabeled peptides (Ac-KGGAKac-COO-, Ac-KGGAKac-NH2, and Ac-
KGGAKacW-NH2) were purchased from Peptide2.0 (>85 % purity). Cobalt and magnesium 
were purchased as ICP standards from GFS Chemicals and the acetic acid standard was 
purchased from the Ricca Chemical Company. Chelex 100 resin was purchased from Bio-Rad. 
HDAC3/NCOR1 was purchased from Enzo Life Sciences. Ethylenediaminetetraacetic acid 
(EDTA) was purchased from Sigma-Aldrich at >99 % purity. All other materials were purchased 
from Fisher and were of a purity >95 % unless otherwise noted.  
 
Acetyl-CoA synthetase preparation 
The chitin tagged acetyl-CoA synthetase (ACS) plasmid (Acs/pTYB1)[24] was a generous gift 
from Professor Andrew Gulick (Hauptman-Woodward Institute). To increase the yield of 
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protein, the gene for ACS was subcloned from the chitin-tagged ACS plasmid into a pET vector 
containing a His6x affinity tag. The ACS gene from Acs/pTYB1was amplified using the 
polymerase chain reaction to add XhoI and XbaI restriction sites. The amplified DNA segment 
was digested using XhoI and XbaI and ligated into a pHD4 vector[25] containing a T7 RNA 
polymerase promoter and a C-terminal TEV (Tobacco Etch Virus) protease sequence followed 
by a His6x motif to form the pHD4-ACS-TEV-His6x expression vector. The plasmid sequence 
was confirmed by sequencing at the University of Michigan DNA Sequencing Core. 
 
The pHD4-ACS-TEV-His6x vector was transformed into BL21(DE3) cells. An overnight culture 
(12.5 mL/L) was used to inoculate autoinduction TB medium (12 g/L tryptone, 24 g/L yeast 
extract, 4.6 g/L KH2PO4, 20.6 g/L K2HPO4, 4 g/L lactose, 1 g/L glucose, 10 mL/L glycerol) that 
was supplemented with 100 μg/mL ampicillin and grown at 30˚C for 20 hours prior to harvest. 
The cells were pelleted by centrifugation (9,000 x g, 10 min) and then resuspended and lysed in 
low imidazole buffer (30 mM HEPES, 150 mM NaCl, 20 mM imidazole, 1 mM TCEP, pH 8) 
using an M110L microfluidizer (Microfluidics). The lysate was cleared by centrifugation (39,000 
x g, 45 min) and the supernatant was loaded onto a 12 mL GE Chelating Sepharose column 
charged with NiCl2. The ACS was eluted with a gradient of low (20 mM) to high (200 mM) 
imidazole buffer. Fractions containing ACS were identified using SDS-PAGE chromatography 
and were concentrated to <1 mL using 30,000 MWCO Amicon Ultra-15 centrifugal units and 
loaded onto a GE HiPrep 16/60 Sephacryl S200 HR size exclusion column equilibrated with size 
exclusion buffer (30 mM HEPES, 150 mM NaCl, 1 mM TCEP, pH 8). The fractions containing 
ACS were collected, combined with his-tagged TEV(S219V) protease (0.5 mg per liter of 
culture) purified in our lab using the method of Tropea et al.[26] and dialyzed against >500 fold 
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excess of low imidazole buffer at 4˚C overnight. The dialyzed ACS was run over a second Ni2+-
charged Sepharose column, and the flow-through containing ACS was collected and 
concentrated to ~2 mM. The protein was then flash frozen in liquid nitrogen and stored at -80˚C. 
Frozen ACS can be used for at least 12 months with little to no effect on the assay. 
 
HDAC8 expression and purification 
HDAC8 was expressed and purified as previously described[9] with the exception that a 20 mL 
DEAE Sepharose column was used after the second Chelating Sepharose column to remove 
excess metal from HDAC8. This column utilized a gradient from low to high salt buffer (50 mM 
HEPES, 10 μM ZnSO4, 1 mM TCEP, 50 mM NaCl, 5 mM KCl, pH 7.8 and buffer with 50 mM 
HEPES with 1 M NaCl).  
 
Fluor de Lys assay 
All assays were performed in metal free tubes using metal free tips before being quenched into 
96 well black plates (Corning plate# 3638). The Fluor de Lys assay was performed as previously 
described[9]. Briefly, HDAC8 was reconstituted with stoichiometric cobalt(II) at a final 
concentration of 10 μM and incubated on ice for 1 hour. Fluor de Lys HDAC8 deacetylase 
substrate (Ac-KGGAKac-methylcoumarin) (0 to 100 μM) was resuspended in HDAC8 assay 
buffer (50 mM HEPES, 137 mM NaCl, 2.7 mM KCl, pH 8) and incubated at 30˚C for 5 minutes. 
Reactions were initiated by adding 0.5 µM Co(II)-HDAC8 and the reaction was quenched by a 
10-fold dilution into 0.05x Enzo developer II and 1.2 μM Trichostatin A (TSA) in HDAC8 assay 
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buffer (above) at 0, 30, and 60 seconds. Samples were incubated at room temperature for 15 
minutes and the fluorescence was measured using a Polarstar Galaxy fluorometer (ex. = 340 nm; 
em. = 450 nm and 380 nm). The initial rate of deacetylation was determined from the time-
dependent increase in the fluorescence ratio (450 nm/380 nm) and the concentration of product 
was calculated using a standard curve. 
 
Acetate assay kit 
Acetate standard curves were made by diluting the Ricca acetic acid standard with HDAC8 assay 
buffer (above). The acetic acid detection kit (R-biopharm) was used according to the instructions 
except that the reaction volume and coupled solution volume were decreased 10-fold and no 
additional water was added to dilute the reaction. Solutions 1, 2, 3 and 4 in the kit were 
preincubated at room temperature for 20 minutes before being mixed with acetate. The reaction 
was incubated at room temperature for 40 minutes and then NADH fluorescence (ex. = 340 nm, 
em. = 460 nm) was measured using a Polarstar Galaxy fluorometer in a 96 well plate. 
 
Optimized stopped coupled acetate assay 
To remove contaminating metals from peptide substrates, ~6 % (v/v) hydrated Chelex 100 was 
added to the Ac-KGGAKac-NH2 and Ac-KGGAKacW-NH2 peptides and incubated at room 
temperature for three hours. The Ac-KGGAKacW-NH2 peptide concentration was determined 
from the absorbance measurement (OD280) using an ND-1000 Spectrophotometer (Nanodrop) 
with a calculated extinction coefficient of 5500 M-1 cm-1[27]. Additionally, the concentration of 
peptides containing a free amine (lysine) was measured using the fluorescamine assay described 
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below. Peptide substrates without a fluorophore (0 – 1600 µM) were preincubated in HDAC8 
assay buffer (above) at 30˚C for 10 min. The reactions were initiated by adding 0.5 µM (final 
concentration) Co(II)-HDAC8 or HDAC3/NCOR1, and quenched by addition of 0.37 % (v/v, 
final concentration) HCl after 0, 30, 60, and 90 minutes of incubation. The reactions were flash 
frozen within 20 minutes of quenching and stored at -80˚C. Upon thawing, the reactions were 
neutralized by addition of 0.6% (w/v, final concentration) NaHCO3. The coupler mixture (50 
mM HEPES, 400 μM ATP, 10 μM NAD+, 30 μM CoA, 0.07 U/μL CS, 0.04 U/μL MDH, 50 μM 
ACS, 100 mM NaCl, 3 mM KCl, 50 mM MgCl, 2.5 mM L-malic acid, pH 8) were incubated for 
20 minutes at room temperature and added to each quenched reaction (at a ratio of 10 µL coupler 
mix/65 µL reaction) in a 96 well black plate. The reactions were incubated at room temperature 
for 40 minutes and the NADH fluorescence (ex. = 340 nm, em. = 460 nm) was measured. 
Variation in data between experiments was <10 %. The steady state kinetic parameters for the 
Ac-KGGAKac-COO- peptide were determined from fitting the Michaelis-Menten equation to the 
concentration dependence of HDAC-catalyzed deacetylation. Substrate inhibition is observed for 
the peptides Ac-KGGAKac-NH2 and Ac-KGGAKacW-NH2, therefore the kinetic parameters for 
these substrates were determined by fitting Equation 1 to the dependence of the initial velocities 
on peptide concentration. Equation 1 was derived from rearrangement of the Michaelis–Menten 
incorporating a hill constant (n) to report the value of kcat/KM and the standard error directly from 
the output.  
 Equation 1:  
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Optimized continuous coupled acetate assay 
The 96 well plates were soaked (>3 hours) in 100 mM divalent metal-free EDTA to strip the 
plate of contaminating metal. The continuous assay buffer (50 mM HEPES, 400 μM ATP, 10 
μM NAD+, 30 μM CoA, 0.07 U/μL CS, 0.04 U/μL MDH, 50 μM ACS, 127 mM NaCl, 2.7 mM 
KCl, 2.5 mM L-malic acid, pH 8) was incubated with Chelex resin for 1 hour at room 
temperature. The mixture was clarified by centrifugation at 16,800 x g for 2 minutes and the 
supernatant was collected. Then 6 mM magnesium was added to the buffer and the mixture was 
incubated for 20 minutes to allow NAD+/malate and NADH/OAA to equilibrate. The peptide 
(100 μM final concentration Ac-KGGAKac-NH2) in HDAC8 assay buffer was added to this 
assay mixture at a ratio of 2:1, respectively. The reaction was initiated with the addition of 
Co(II)-HDAC8 (0.5 – 1 μM final concentration) and deacetylation was measured from the time-
dependent increase in NADH fluorescence (ex. = 340 nm, em. = 460 nm). 
 
Fluorescamine assay 
The peptide substrate Ac-KGGAKac-COO- (0 - 1600 µM) was preincubated in HDAC8 assay 
buffer (above) at 30˚C for 10 minutes. The reactions were initiated by adding 0.5 µM HDAC8, 
and quenched by addition of 1 µM TSA after 0, 30, 60, and 90 minutes of incubation. The 
reactions were used immediately or flash frozen and stored at -20˚C. Upon thawing, solutions 
were filtered through Pall 10K mwco NanosepMF Centrifugal devices to remove HDAC8. The 
flow-through (80 µL) was mixed with 50 μL of 1 M boric acid (pH 9) and the mixture was added 
to a Corning 96 well black plate. 33 μL of 4.3 mM fluorescamine (dissolved in acetone) was then 
added to the sample, incubated at room temperature for 10 minutes, and fluorescence (ex. = 340 
53 
 
nm, em. = 460 nm) was measured[28]. A standard curve was created using N-α-acetyl lysine 
methyl ester (0 – 5 µM). To measure the peptide concentration, peptides were diluted into 1 M 
borate, pH 9, and 0.56 mM fluorescamine was added. The mixture was incubated at room 
temperature for 10 min and the fluorescence (ex. = 340 nm, em. = 460 nm) was measured. The 
peptide concentration was determined from the standard curve. 
 
Results  
Assay 
An acetate detection assay was initially described in the Official Collection of Assays according 
to § 35 of German food law[29] and a kit containing the assay components is distributed by the 
R-biopharm company (Figure 2.1). This assay system couples enzymatic reactions that produce 
one molecule of citrate, CoA, and NADH per molecule of acetate. The NADH concentration is 
monitored using fluorescence and/or absorbance, allowing determination of the acetate 
concentration from a spectroscopic signal. This assay is optimized to measure millimolar 
concentrations of acetate with a detection limit of ~100 µM (Figure 2.2 and 2.3), which is not 
sufficiently sensitive to measure the steady state kinetic parameters of many enzymes, including 
HDACs. 
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Figure 2.1 HDAC Assay scheme 
Acetate is a product of deacetylation catalyzed by HDAC8. Acetate, ATP, and CoA are 
converted into acetyl-CoA, AMP, and inorganic pyrophosphate by acetyl-CoA synthetase. 
Acetyl-CoA and oxaloacetate are converted into citrate and CoA catalyzed by citrate synthase. 
Simultaneously, malate dehydrogenase catalyzes equilibration of NAD+ and malate with NADH 
and oxaloacetate. When a molecule of oxaloacetate is removed from solution by formation of 
citrate, a molecule of NADH is formed. NADH concentrations are quantified using absorbance 
or fluorescence. 
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Figure 2.2 Comparison of R-biopharm kit and optimized assay for detection of acetate 
The fluorescence change as a function of acetate concentration is measured using the R-
biopharm kit ( ) and the optimized acetate assay ( ). The fluorescent signal is normalized to 0 
μM acetate using the optimized assay. The signal from the optimized assay is much larger in the 
µM range, which is required to measure steady state turnover catalyzed by HDAC8. This signal 
is accurate to ~1 μM with a coefficient of variance equal to 2.2. The R-biopharm kit standard 
curve is linear at higher concentrations of acetate (250 – 1250 μM acetate) (Figure 2.3).  Data 
from a single reaction is shown, the variation between experiments is <10 %. 
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Figure 2.3 Extended acetate standard curve 
An acetate standard curve using the optimized coupled assay ( ) and the kit ( ) shows that the 
optimized coupled assay is linear from 0 – 50 μM. The kit assay has a limit of detection of ~200 
μM and is linear at higher concentrations. A 130:20 ratio of reaction to couplers was used for the 
optimized coupled assay while a ratio of 10:123 was used for the kit according to the 
instructions. Data from a single reaction is shown, the variation between experiments is <10 %. 
 
Optimization of Assay for Measuring HDAC Activity 
The KM values for HDAC-catalyzed hydrolysis of acetyl lysine residues in peptides are typically 
in the low to mid micromolar range. Therefore, to measure the initial rate (≤10 %) of the 
reaction, the detection limit should be in the low micromolar range. To optimize the detection 
limit for the acetate-coupled assay, the signal to noise ratio was improved by: (1) using highly 
purified recombinant ACS, which decreased the background signal; (2) lowering the 
concentration of L-malic acid and NAD+ to decrease the background signal due to the 
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equilibrium formation of OAA and NADH; and (3) increasing the ratio of the sample to the 
coupling solution volume to improve the signal intensity. With these alterations, a linear standard 
curve from 0 to 50 µM acetate with a limit of detection of ~1 μM (coefficient of variance 2.2; 
Figure 2.2) was produced using this assay. This assay can be altered to measure larger 
concentrations of acetate (>50 µM) by adding higher concentrations of the limiting reagents CoA 
and NAD+. This standard curve indicates that the optimized coupled assay is sensitive enough to 
measure the steady state kinetic parameters for HDACs and other enzymes. 
 
Based on the assay design, each molecule of acetate should yield one molecule of NADH. To 
test this, the fluorescence change from the addition of acetate to the coupled assay was compared 
with the fluorescence of a comparable concentration of NADH (Figure 2.4). The slopes of the 
standard curves for NADH and acetate were 770 ± 61 and 790 ± 50 fluorescence units per μM, 
respectively. The equivalence of these slopes indicates that there is a one to one relationship 
between the concentration of acetate and the signal created by the production of NADH, 
allowing calculation of the acetate concentration from the fluorescence change. 
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Figure 2.4 Standard curve for the acetate assay compared to NADH fluorescence 
The fluorescence change observed upon addition of acetate to the coupled assay ( ) is compared 
to the NADH fluorescence under comparable conditions (50 mM HEPES, 100 mM NaCl, 3 mM 
KCl, 50 mM MgCl, pH 8) ( ). The two slopes are equal, indicating that in the coupled assay one 
mole of NADH is formed per mole of acetate. The higher background observed in the acetate 
standard curve is a result of NADH formed before addition of acetate due to the equilibrium of 
the malate dehydrogenase-catalyzed reaction. Representative data is shown, the variation 
between experiments is <10 %. 
 
Stopped Assay 
We first optimized the acetate assay in a stopped format to measure HDAC8 activity. After 
reacting HDAC8 with the substrate of interest, the reaction was quenched by the addition of HCl 
and flash frozen in liquid nitrogen. Upon thawing, the pH was neutralized by addition of 
NaHCO3. Using the Fluor de Lys assay to measure activity, the HCl solution quenches HDAC8 
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activity immediately (<10 sec), and HDAC8 activity is not restored upon neutralization (data not 
shown). The acetate concentration in this sample is then measured using the coupled assay. 
Under these optimized conditions, formation of NADH from the addition of acetate occurs 
within minutes. Upon mixing the coupling enzymes with the assay substrates, NAD+ and L-
malic acid equilibrate to form NADH and oxaloacetate. This equilibration is complete in 20 
minutes (Figure 2.5), forming ~4 µM NADH, consistent with the equilibrium constant for the 
reaction catalyzed by malate dehydrogenase[30]. The reaction of up to 20 μM acetate is complete 
within 30 minutes and the signal remains stable for over an hour. The limiting step in this assay 
is the formation of citrate and CoA catalyzed by citrate synthase (CS). Therefore, the rate of 
acetate production can be increased by the addition of higher concentrations of CS, if needed. 
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Figure 2.5 Time course for the formation of acetate 
At -25 minutes the assay reagents are mixed and incubated at room temperature (~25°C). 
Equilibration is complete in <20 minutes, forming ~4 μM NADH. The reaction is initiated (t = 0 
min) by addition of 20 μM acetate. The reaction reaches equilibrium at ~30 min and the signal is 
stable for at least one hour. 
 
 
To demonstrate the effectiveness of the acetate assay in measuring deacetylation, we compared 
the rate of HDAC8-catalyzed deacetylation determined using the coupled assay with the 
fluorescamine assay. Fluorescamine is a reagent that increases in fluorescence intensity upon 
reaction with primary amines[31] and therefore a fluorescent signal is coupled to the formation 
of lysine generated by HDAC-catalyzed deacetylation. We measured the reactivity of Co(II)-
HDAC8 with an unlabeled peptide (Ac-KGGAKac-COO-) mimicking the H4 histone K16 
acetylation site (H4 K16ac). HDAC8-catalyzed deacetylation of this peptide (200 µM peptide, 
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0.5 µM HDAC8) measured by the coupled acetate assay and the fluorescamine assay yielded 
comparable rates within experimental error of 0.0021 ± 0.0003 μM s-1 and 0.0027 ± 0.0008 μM 
s-1, respectively. Therefore, both assays measure the deacetylation rate and are viable for 
measuring HDAC8 activity, though the fluorescamine assay is less accurate for substrates 
containing multiple lysine side chains due to a higher signal to noise ratio. 
 
To demonstrate that this optimized stopped assay can serve as a general acetate assay, we 
measured the initial rate of deacetylation of 100 μM Ac-KGGAKac-NH2 catalyzed by another 
HDAC isozyme, 0.5 μM HDAC3/NCOR1 (Figure 2.6). The initial rate for this reaction was 
0.015 ± 0.0016 μM s-1, comparable to the value measured for HDAC8.  
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Figure 2.6 HDAC3/NCOR1 stopped assay time course 
A time course measuring 0.5 μM HDAC3/NCOR1 deacetylation of 100 μM Ac-KGGAKac-
NH2. An initial rate of 0.022 ± .0016 μM s-1 is measured. Data is linear within error over the 15 
minute time course. Data from a single time course is shown and standard error was calculated 
from the fit to the three points. 
 
Continuous Assay 
We next evaluated whether the coupled acetate assay could be carried out as a continuous, real-
time assay to measure HDAC8 activity. Since HDAC8 is sensitive to inhibition by metals[9], and 
monovalent cations[15], the acetate coupling solutions were reformulated with concentrations of 
NaCl and KCl typically used to assay HDAC8 activity (127 mM and 2.7 mM respectively)[15] 
and treated with Chelex resin prior to addition of magnesium. The concentration of magnesium 
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was decreased to 2 mM to minimize inhibition of HDAC8 activity (~2-fold inhibition under 
these conditions) (Figure 2.7). To counteract the loss in activity of the coupling enzymes due to 
the lower concentration of magnesium, the concentration of these enzymes was increased by 2.3-
fold to yield a final rate for the coupling reactions of 0.046 μM s-1. These assay conditions were 
used to measure HDAC8-catalyzed deacetylation of 100 μM Ac-KGGAKac-NH2 peptide 
yielding rates of 0.018 ± 0.00013 μM s-1 and 0.028 ± 0.00024 μM s-1 at 0.5 μM and 1 μM 
HDAC8, respectively (Figure 2.8). The linear dependence on the HDAC8 concentration 
demonstrates that the assay rate is not limited by the coupling reactions. Furthermore, the 
HDAC8 activity measured using the stopped assay (0.5 µM HDAC8 and 100 µM Ac-
KGGAKac-NH2) is 0.033 ± 0.0034 μM s-1 which is within the two-fold of the continuous assay 
measured rate, and represents the difference expected due to magnesium inhibition of Co(II)-
HDAC8.  
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Figure 2.7 Mg2+ dependence of HDAC8 and acetate assay 
The value of kcat/KM for HDAC8 is decreased up to two-fold by millimolar concentrations of 
magnesium ( ) (0.5 μM Co(II)-HDAC8, 50 μM Fluor de Lys substrate). The coupled assay 
reactions are increased up to 5-fold by similar concentrations of magnesium ( ).  A single 
representative curve is shown for each experiment. 
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Figure 2.8 Continuous assay to measure HDAC8 activity 
The initial rates for deacetylation of the Ac-KGGAKAc-NH2 peptide (100 μM) measured using 
the acetate assay in a continuous formate are 0.018 ± 0.00013 μM s-1 and 0.028 ± 0.00024 μM s-1 
for 0.5 μM ( ) and 1 μM ( ) Co(II)-HDAC8, respectively. A side-by-side acetate assay using 
the stopped formate (0.5 μM Co(II)-HDAC8, 100 μM Ac-KGGAKac-NH2) has an initial rate of 
0.033 ± 0.0021 μM s-1 ( ).  Error was calculated on the descrepancies between the data a line fit 
to that data from a single data set.  The doubling of rate upon doubling of HDAC8 concentration 
shows that the coupling reactions are not rate limiting.  Furthermore, as the continuous and 
stopped reaction rates are within error it suggests that both methods are feasible for the 
measurement of HDAC deacetylation. 
 
 
Additionally, we measured the HDAC8-catalyzed deacetylation of H3/H4 tetramer acetylated 
using acetic anhydride, where ~100% of the lysines were acetylated as indicated by mass 
spectrometry (data not shown). The initial rate for deacetylation of ~0.076 µM acetylated H3/H4 
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tetramer catalyzed by 0.5 µM Co(II)-HDAC8 is 0.0021 ± 0.0001 μM s-1 (Figure 2.9), 
demonstrating that this assay can measure deacetylation of both peptide and protein substrates. 
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Figure 2.9 HDAC8-catalyzed deacetylation of pan-acetylated H3/H4 histone tetramer  
Histone tetramer was assembled from recombinantly expressed and purified histones H3 and H4 
as in [32]. Tetramer was chemically acetylated using a method adapted from [33, 34]. In brief, 
tetramer was dialyzed in 2L of acetylation buffer (65.5 mM sodium bicarbonate pH 8.0, 2 M 
sodium chloride, 1 mM EDTA, 0.5 mM DTT). Dialyzed tetramer incubated on ice and 10 µL of 
acetic anhydride was added to pan-acetylate the histones. 0.1 N NaOH was added dropwise, with 
stirring, to maintain pH 8. The reaction was incubated on ice for 40 minutes. The reaction was 
subsequently dialyzed in 2L acetylation buffer. Following dialysis, the tetramer was concentrated 
and exchanged into 50 mM HEPES pH 7.8, 300 mM NaCl, then incubated with Chelex resin at 
4°C. The concentration of tetramer was measured using the BCA protein assay kit (Pierce). 
Tetramer was assayed using the continuous assay with 0.5 µM Co(II)-HDAC8 and 0.076 µM 
pan acetylated H3/H4 tetramer.  
 
Reactivity of HDAC8 with peptides 
Using a mass spectrometric assay, Gurard-Levin et al.[23] previously demonstrated that HDAC8 
catalyzes deacetylation of a peptide representing the local sequence of p53 containing a C-
terminal methylcoumarin fluorophore significantly faster than a comparable peptide with a C-
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terminal cysteine followed by an amide terminus. To further analyze the recognition of the 
peptide C-terminus by HDAC8, we measured Co(II)-HDAC8-catalyzed deacetylation using the 
stopped coupled assay of an H4 peptide mimic containing varied C-termini, including: a 
carboxylate (Ac-KGGAKac-COO-); an amide (Ac-KGGAKac-NH2); and a tryptophan capped 
by an amide (Ac-KGGAKacW-NH2) (Figure 2.10 and Table 2.1). The steady state kinetic 
parameters for Ac-KGGAKac-COO- were determined from fitting the Michaelis-Menten 
equation to the concentration dependence of activity, yielding values of kcat/KM, kcat and KM of 56 
M-1 s-1, 0.041 s-1 and 730 μM, respectively (Table 2.1). For the Ac-KGGAKac-NH2 and Ac-
KGGAKacW-NH2 peptides, modest to substantial inhibition was observed at higher peptide 
concentrations. This inhibition is not due to metal contamination of the peptide[9] as pre-
incubation of the peptide with Chelex 100 resin had no effect on the observed activity (Table 
2.1). Furthermore, the pH of the peptides was measured (pH ~5) as a result, it is likely buffered 
Hepes used in the reactions and is also unlikely to affect the HDAC8 deacetylation rate. 
Therefore, these data indicate that the activity is inhibited by high substrate concentrations. As 
many HDAC isozymes form multi-protein complexes[35, 36], the peptides may inhibit HDAC8 
activity by binding to non-active site protein-protein interaction sites. For these peptides the 
kinetic parameters were determined by fitting an equation including terms for substrate inhibition 
(Equation 1) to the data; the values of kcat/KM for deacetylation of Ac-KGGAKacW-NH2 and Ac-
KGGAKac-NH2 are 1200 ± 250 M-1s-1 and 980 ± 47 M-1s-1, respectively (Table 2.1). However, 
since the KM and KI parameters are coupled, independent values for these parameters could not 
be accurately determined. Substrate inhibition by the Ac-KGGAKac-NH2 peptide appears to be 
cooperative with a Hill coefficient (n) that is larger than 1. In general, substrate inhibition 
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significantly complicates the analysis of the reactivity of HDAC8 with peptide libraries, 
especially if activity is measured at a single peptide concentration. 
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Table 2.1 Structure and kinetic constants for HDAC8-catalyzed deacetylationa 
aThe steady-state kinetic parameters and standard errors for HDAC8-catalyzed are measured as 
described in the legend of Figure 2.10.  
bValues reported in ref [25]. 
cKinetic parameters determined using Equation 1, including substrate inhibition. 
dN.D. indicates values that were not determined as a result of substrate inhibition. 
The four peptides differ in their C-terminus; the Fluor de Lys peptide contains a methylcoumarin 
fluorophore while the non-fluorophore conjugated H4 K16ac peptides contain a C-terminal 
carboxylate, carbamide, or tryptophan followed by a carbamide. The kinetic constants of these 
peptides suggest that the differences in the peptides affect both substrate binding and chemistry. 
Standard error is reported.  
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Figure 2.10 Dependence of HDAC8-catalyzed deacetylation on the concentration of H4 
K16ac peptide mimics 
The steady state kinetics of deacetylation catalyzed by HDAC8 were measured at 30˚C in 50 
mM HEPES, 137 mM NaCl, 2.7 mM KCl, pH 8, 0.85 μM HDAC8. The solid line is a fit of the 
Michaelis-Menten to the initial rates for deacetylation of a peptide ending in A) carboxylic acid 
(Ac-KGGAKac-COO-). B) The peptide ending in an amide (Ac-KGGAKac-NH2). C) The 
peptide ending in a tryptophan and capped with an amide (Ac-KGGAKacW-NH2). Equation 1 
was fit to the data for the Ac-KGGAKac-NH2 and Ac-KGGAKacW-NH2. The solid lines shown 
are the best fits with the following values: Ac-KGGAKac-NH2, kcat/KM, KM, KI, and n values of 
980 ± 47 M-1 s-1, 90 ± 21 μM, 190 ± 15 μM, and 3.9 ± 0.6, respectively and Ac-KGGAKacW-
NH2, kcat/KM, KM, and KI values of 1250 ± 250 M-1 s-1, 890 ± 2100 µM, and 440 ± 1600 µM 
respectively. As the KM and KI values are highly correlated, these values are not accurate.  
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These data demonstrate that the structure of the C-terminal moiety significantly affects the 
reactivity of Co(II)-HDAC8 with peptide substrates. Furthermore, a comparison of these data to 
the kcat/KM value of 2800 M-1s-1[25] for HDAC8-catalyzed deacetylation of the Ac-KGGAKac-
methylcoumarin peptide demonstrates that the methylcoumarin fluorophore enhances (up to 50-
fold) the catalytic efficiency of HDAC8-catalyzed deacetylation (Table 2.1). 
 
Discussion 
The current HDAC assays have limitations that do not allow in-depth and/or high throughput 
analysis of HDAC substrate specificity. The first kinetic measurements of HDAC activity 
employed radioactively labeled peptides and proteins and detected the formation of radiolabeled 
acetate[19, 20]. While this assay is effective and sensitive, radioactive peptide substrates are 
expensive to produce, and many radiolabeled protein substrates are acetylated non-specifically, 
preventing the determination of detailed kinetics at specific sites. Recently, the Fluor de Lys 
assay (Biomol) has become popular for measuring HDAC kinetics[9, 11-17]. This assay uses a 
methylcoumarin fluorophore-conjugated peptide, which upon deacetylation becomes a substrate 
for the serine protease trypsin, cleaving the fluorophore and altering the fluorescence spectrum of 
the methylcoumarin. The rate of deacetylation is measured by the change in the fluorescence 
signal[12]. However, the methylcoumarin fluorophore can interact with HDACs and alter the 
kinetics of deacetylation[23] (as discussed later). Thus, the results obtained using this method 
may not accurately report the selectivity of HDACs for native peptides and proteins. 
Additionally, because the fluorophore is located immediately on the C-terminal side of the acetyl 
lysine moiety, this method cannot be used to determine the preference for sequences downstream 
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of the acetylated lysine. Many of these limitations were solved by a mass spectrometric assay 
developed by the Mrksich group; this assay uses MALDI mass spectrometry of peptides attached 
to a gold surface to observe the mass difference caused by deacetylation[23]. This assay is 
effective for peptide substrates and can be carried out in a high throughput manner, however a 
MALDI mass spectrometer is required. Additionally, this method requires the inclusion of a 
cysteine in the peptide sequence to conjugate the peptide to the plate via a maleimide linkage. 
HPLC separation of acetylated and deacetylated peptides on a C18 column is another method 
employed to determine deacetylation kinetics[18]. This assay quantifies product formation by 
absorbance (230 or 280 nm) and can measure the deacetylation of any peptide, yet it suffers from 
labor intensive techniques such as the determination of peak elution times making it not ideal for 
a high throughput format. Furthermore, it is not easily transitioned to assaying the deacetylation 
of proteins due to the difficulty of separating full length proteins differing by a single acetylated 
lysine. The assay presented in this paper provides an alternative that overcomes many of the 
limitations of the previous assays. This acetate assay is versatile; either fluorescence or 
absorbance can be measured using a cuvette or 96-well plate and in a stopped or continuous 
format. The continuous method is well-suited for high-throughput screening. Peptide substrates 
for the assay are inexpensive to purchase as they do not require conjugated fluorophores, and 
results can be quantified using an acetic acid standard curve. Furthermore, the assay can measure 
deacetylation of proteins (Figure 2.9). However, the acetate assay cannot be used with 
fluorescent peptides (i.e. methylcoumarin-conjugated peptides) that absorb and emit at 
wavelengths similar to NADH, nor can it be used on cell lysate extracts containing NADH, other 
metabolites, or various other enzymes. Overall, this assay provides a stable and sensitive 
platform for the measurement of deacetylation with few limitations. Finally, as this assay has 
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been optimized to measure micromolar acetate concentrations, it can be used to assay other 
enzymes that produce acetate as a product and have KM values in the micromolar range, 
including other HDAC isozymes (Figure 2.6).  
While most kinetic measurements of HDAC8 have been performed using the Fluor de Lys 
assay[9, 11, 13-15], the Mrksich group used a mass spectrometric assay to demonstrate that a 
peptide mimicking the p53 transcription factor was deacetylated significantly slower than the 
same peptide containing a methyl-coumarin fluorophore[23]. However, the steady state kinetic 
parameters were not determined for these substrates. Using the optimized coupled assay that 
measures the formation of acetate, we demonstrated that substitution of the coumarin 
fluorophore with a carboxylate lowered the value of kcat/KM for Co(II)-HDAC8 by 50-fold, 
resulting from a 22-fold reduction in the value of kcat and a 2.3-fold increase in the KM value 
(Table 2.1). As the value of KM is relatively high (730 μM) and the value of kcat is relatively low 
(0.041 s-1) compared to other enzymes acting under diffusion control[37], it is likely that 
substrate dissociation is faster than deacetylation, indicative of a rapid equilibrium substrate 
binding model. This assumption is further validated by the increase in kcat measured for trifluoro-
acetyl lysine substrates[18, 38], suggesting that deacetylation is the rate-limiting step for kcat. 
This conclusion is further bolstered by the low kcat/KM values for HDAC8 deacetylation of 
peptide substrates (<104) further suggesting that chemistry is rate limiting. Based on this 
assumption, KM reflects KD for the peptide. Therefore, ΔΔGbinding, calculated from the alteration 
in the KM values3, indicative of the additional binding affinity conferred by the methylcoumarin 
fluorophore relative to a carboxylate at the C-terminus, is equal to ~0.45 kcal/mol. This 
alteration in binding energy is modest but within the range of energy due to the addition of a 
                                                 
3 ΔΔGbinding = RT ln(KM Fluor de Lys peptide) - RT ln(KM non-fluorophore conjugated peptide) 
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single pi-pi interaction[39, 40] or hydrogen bond[37]. Crystal structures of a methylcoumarin-
conjugated peptide bound to HDAC8 visualize interactions between the methylcoumarin and the 
side chain of Tyr100[13, 41]. These structures suggest that the enhanced binding energy for the 
methylcoumarin peptide results from a combination of interactions between the C-terminus of 
the peptide and the hydrophobic cavity formed by the L1, L7, and L8 loops, and interactions 
between the aromatic C-terminal residue of the peptide and Tyr100 on the L2 loop of HDAC8.  
 
The steady state kinetic parameters for deacetylation catalyzed by HDAC8 demonstrate that the 
significant (50-fold) enhancement in Co(II)-HDAC8 kcat/KM for the Ac-KGGAKac-
methylcoumarin peptide compared to the Ac-KGGAK-COO- peptides is largely due to an 
increase in the kcat value. The change in the stabilization of the transition state relative to the 
unbound ground state (ΔΔG‡)4 of 2.3 kcal/mol likely results from a combination of altered 
electrostatic and pi-pi interactions between the peptide and HDAC8 that enhance optimal 
positioning of the peptide and side chains in the active site to efficiently catalyze deacetylation. 
The effects of the C-terminal interactions of the peptide with Co(II)-HDAC8 on kcat and KM are 
consistent with data demonstrating that L2 loop residues are important for both binding and 
catalysis; mutations at Asp101 in HDAC8 lead to both higher KM and lower kcat values[13], 
compared to the wildtype enzyme. However, these mutations do not lead to observable 
alterations in the crystal structure of inhibitor-bound HDAC8[13, 41], suggesting that the activity 
decrease may be due to an alteration in the HDAC8 dynamics. The catalytic efficiency (kcat/KM) 
of Co(II)-HDAC8 with the Ac-KGGAKac-NH2 peptide is enhanced 9-fold (ΔΔG‡ = 1.6 
                                                 
4 ΔΔG‡ (kcat/KM) = RT ln(kcat/KM peptide1) - RT ln(kcat/KM peptide2) 
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kcal/mol)5 compared to the Ac-KGGAKac-COO- peptide indicating that electrostatic interactions 
between the C-terminus and HDAC8 impair peptide binding and/or reactivity. Addition of a 
tryptophan (Ac-KGGAKacW-NH2) or methylcoumarin moiety to the peptide increases net 
transition state stabilization by 0.1 – 0.5 kcal/mol, providing an estimate of the enhancement of 
the catalytic efficiency by base stacking with Tyr100. Previous studies performed by the Mrksich 
lab show that HDAC8 catalyzes deacetylation of peptides containing a phenylalanine on the C-
terminal side of the acetyl lysine faster than substrates containing any other amino acid, 
including tryptophan, at that position[21, 23]. These data suggest that both amino acid 
hydrophobicity and volume play a role in substrate preference. However, a direct comparison of 
the reactivity of peptides in this paper compared to those in Gurard-Levin et al.[21, 23] is 
complicated by differences in peptide length, the sequence at other positions of the peptide, and 
method of kinetic measurement. Further kinetic experiments utilizing the Ac-KGGAKacW-NH2 
peptide will be necessary to determine exactly how the studies correlate to each other. 
 
Interestingly, Co(II)-HDAC8-catalyzed deacetylation of acetyl lysine peptides have low values 
for kcat/KM (56 – 2800 M-1 s-1) compared to enzymes that are limited by diffusion[37], suggesting 
either that these peptides are poor substrates for this enzyme or that the low activity is 
biologically relevant for control of enzyme activity[42]. The in vivo catalytic efficiency could be 
enhanced either by additional interactions with the protein substrates or by additional cofactors 
or binding partners. Furthermore, the measured rate constants for Co(II)-HDAC8-catalyzed 
deacetylation of Ac-KGGAKac-COO- and high concentrations of Ac-KGGAKac-NH2 peptides 
are similar to the rates measured for deacetylation catalyzed by various class II HDAC isozymes 
                                                 
5 ΔΔGbinding = RT ln(KM Fluor de Lys peptide) - RT ln(KM non-fluorophore conjugated peptide) 
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(HDAC7, 10)[17, 43] suggesting that the low activity of these isozymes in the Fluor de Lys 
assay may reflect decreased enhancement of reactivity by aromatic C-terminal moieties.  
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Chapter 3  
Profiling small peptide substrates to identify HDAC8 recognition motif(s)10 
 
Introduction 
Multiple studies have utilized short peptides to determine HDAC substrate specificity[1-5]. 
These studies measure HDAC catalyzed deacetylation of short peptides with one or two amino 
acid changes. While these studies have been effective in identifying amino acid preferences in 
peptide substrates, they have been unable to identify in vivo HDAC substrates. One possibility 
for the lack of biological relevance is that combinations of three or more amino acids may be 
necessary for HDAC protein recognition. Alternatively, distal interactions not represented in the 
short peptides, may be necessary for protein recognition. 
Of the metal dependent HDAC isozymes, HDAC8 has been historically regarded as the HDAC 
least likely to form a large protein complex that specifies substrate preference[6]. As a result, 
identifying HDAC8 specificity may be more straight forwards than for other HDAC isozymes. 
To determine the substrate preference of HDAC8, we utilized a computational approach which 
was informed by, and verified using experimental measurement of HDAC8 activity kinetics. In 
this chapter we developed an algorithm utilizing data from systematically altered peptide arrays 
and identified 26 corresponding to acetyl lysines in proteins which were grouped 
computationally into “good,” “bad,” and “mediocre” peptides. These peptides were subsequently 
synthesized and assayed, and based on the data, the algorithm was adjusted, and a new set of 
                                                 
10 I performed all of the experimental studies with the peptide substrates (Figure 3.4, 3.7 and Table 3.4, 3.5) and I 
wrote all of the text pertaining to these experiments. Development of the computational algorithm was performed by 
Nawsad Alam and Lior Zimmerman. 
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peptides was predicted. One of the peptides in this second set is the most efficient peptide 
substrate for Zn(II)-HDAC8 measured to date. Overall, these results suggest that kinetic data of 
how one or two amino acid positions affect specificity is not sufficient to determine the substrate 
specificity of HDAC8, but a statistical compilation of ~6 amino acids surrounding the acetyl 
lysine provides a more accurate model for identifying efficient HDAC8 peptide substrates.  
 
Materials and Methods 
Reagents 
ATP, Coenzyme A, NAD+, L-malic acid, citrate synthase, and malate dehydrogenase were 
purchased from Sigma. The initial peptide set was purchased from Sigma-Aldrich (~70 % pure). 
The second round of peptides was purchased from Peptide2.0 (~70 % pure). Cobalt and zinc 
were purchased as ICP standards from GFS Chemicals and the acetic acid standard was 
purchased from Ricca Chemical Company. Chelex 100 resin was purchased from Bio-Rad. All 
other materials were purchased from Fisher and were of a purity >95 % unless otherwise noted.  
 
HDAC8 expression and assay 
HDAC8 was expressed and purified as previously described [7]. The peptides purchased from 
Sigma-Aldrich were solubilized in 50 % acetonitrile. The peptides purchased from Peptide 2.0 
were initially solubilized in water, 50 % acetonitrile, or 10 % DMSO as needed. Once 
solubilized, the metals were removed from the peptides from Peptide 2.0 by incubation with ~30 
μL of Chelex resin per <5 mg peptide at 4ºC for at least 16 hours. Peptides were quantified as 
previously described in Chapter 2. HDAC8 assays were performed as stopped assays as 
described in Chapter 2. Briefly, 1 μM metal Zn(II)- or Co(II)-HDAC8 was added to peptides 
(concentrations specificities in the text) under standard assay conditions (2.7 mM KCl, 137 mM 
NaCl, 50 mM HEPES, pH 7.8) at 30˚C. It should be noted that under the assay conditions (150 
μM substrate, 1 μM HDAC8) the zinc concentration was 2.5 µM sufficient to inhibit HDAC8[7]. 
As a result, the peptides were screened using Co(II)-HDAC8, which should only be partially 
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inhibited (~20%) by the presence of 1.5:1 zinc:HDAC8, instead of the Zn(II) enzyme which 
would be closer to ~70% inhibited. At various time points, the reaction was quenched by 
addition of 0.37% HCl. The reactions were neutralized by addition of 0.6% NaHCO3, were 
added to a coupling solution, and incubated at room temperature for 45 minutes. The increase in 
NADH reflected acetate production and was determined by fluorescence (ex. = 340 nm, em. = 
460 nm). Linear portions of the time versus fluorescence curves were fit to a line were graphed 
versus HDAC8 concentration.  The Michaelis-Menten equation was fit to these data.  
 
Improving the assay conditions 
Prior to validation of the second model, we improved the assay conditions. In order to make the 
results more biologically relevant, changes were made to the assay. First, a method for chelating 
peptides was developed whereby Chelex 100 was added to each peptide and incubated overnight.  
Inhibitory concentrations of contaminating Zn2+ were likely a result of the synthesis and 
solubilization process.  Chelation allows for the use of Zn(II)-HDAC8, as inhibitory 
concentrations of zinc are no longer present in the assay. Zn(II)-HDAC8 is a more biologically 
relevant form of the HDAC8 enzyme when compared to the cobalt form. This allows us to better 
probe biologically relevant reactions than previously.  
The first validation set of peptides contained a C-terminal carboxylate. Previous results have 
shown HDAC8 catalyzes the deacetylation of a peptide with a C-terminal carboxylate 
(immediately C-terminal of the acetyl lysine) 17.5-fold slower than the same peptide with a 
carboxylamine in the same position (Chapter 2). To determine if this is also the case when the C-
terminal carboxylic acid is contained 3 amino acids C-terminal of the acetyl lysine, two peptides 
representing the Lys350 position of KAT6A were assayed. HDAC8 was incubated with two 
peptides (0 – 100 μM), one containing a C-terminal carbamide and the other a C-terminal 
carboxylic acid. HDAC8 showed a preference for the carboxylamine peptide by ~2.2-fold. While 
this difference is relatively insignificant, the next set of peptides were purchased with a 
carbamide at the C-terminus. 
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FlexPepBind protocol 
We have adapted the Rosetta FlexPepBind protocol[8, 9] to predict the substrate specificity of 
histone deacetylase 8 (HDAC8). The core strategy of the protocol is to model a peptide-HDAC8 
complex structure for each of the investigated peptide sequences, and then to distinguish binders 
from non-binders based on these structural models. This involves calibration of different 
parameters such as the template structure used to represent the receptor (HDAC8), the peptide, 
the amount of sampling, and the adaption of the scoring function. Conformational sampling is 
biased towards relevant conformations by implementation of constraints that reproduce 
conserved structural features identified from known structures of the interaction, or from 
experiment.  
The underlying assumption of this approach is that chemistry is the kinetic mechanism for steady 
state turnover is in rapid equilibration with substrate to form the ES complex followed by 
equilibration with substrate followed by rate-limiting chemistry (see chapter 5 for an 
explanation). This is a reasonable assumption given the large KM and low kcat values for peptides. 
As a result, utilizing binding data to model the catalytically activated complex (kcat/KM) would 
inform HDAC8 substrate preference. Our goal was therefore to obtain maximal separation 
between peptides that are HDAC8 substrates (i.e., binders) and those that are not (i.e., cannot 
bind).  We also sought to define an algorithm which produces a good correlation between 
predicted relative binding affinities and corresponding experimental values. We first optimized 
the protocol on a training set of peptides that have been tested for deacetylation catalyzed by 
HDAC8. Subsequently, we validated our protocol on a corresponding test set, and a number of 
further validation sets of peptides that were analyzed as we proceeded with the protocol 
development. Finally, the calibrated protocol was applied to identify new substrates. In the 
following, we describe the different steps of this strategy in detail. 
 
Modeling the structures of peptide-protein complexes  
A major component of our protocol is the generation of a peptide-receptor complex structure for 
each of the investigated peptides. The first step involves the generation of a coarse starting 
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structure of the peptide-receptor complex. In the second step, this starting structure is then 
optimized, by either (a) extensive optimization with Rosetta FlexPepDock[10], or (b) simple 
minimization of the peptide-receptor interface. In the third step the optimized structure is scored, 
and peptides are ranked for their ability to bind the HDAC8 activated complex.  
 
Step 1: Preparation of a coarse starting model of a peptide-HDAC8 complex 
For each of the peptides, a coarse model of the complex was generated, based on a template 
crystal structure of HDAC8 bound to a peptide substrate, and the sequence of the given peptide. 
PDB ID 2v5w[11] was used as a template: it includes the catalytically dead mutant Tyr306Phe 
HDAC8 in complex with a p53-derived acetylated peptide Ac-RHKacKac-methylcoumarin, and 
is expected to represent efficient peptide binding.  
We tested 3 approaches to create the starting complex: (1) Initially, we created an extended 
peptide starting from the acetylated Lysine in the peptide of the solved crystal structure (all Φ 
angles were set to -135.0 degrees, all Ψ angles to +135.0 degrees). Subsequently, we created a 
better starting structure, by (2) using the peptide backbone in the solved structures where 
available, (and complementing the missing part with an extended conformation), and finally (3) 
using extensive optimization of the peptide backbone conformation for an efficient HDAC8 
peptide substrate (using Rosetta FlexPepDock[10], see below). The latter assumes that most 
peptides will adapt a similar conformation in the HDAC8 binding site, and that this conformation 
will be easiest to model for a high affinity substrate onto HDAC8.  
We threaded different peptide sequences, to create starting structures for further optimization 
(below). Rosetta fixed-backbone design[12] was used to thread the peptide sequence onto the 
template peptide backbone conformation.  
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Step 2: Optimization of the peptide-HDAC8 complex structure 
In our previous studies on peptide substrate specificities using FlexPepBind[8, 9], we have used 
two main approaches for the optimization of a peptide-receptor structure from the coarse starting 
model, namely: (a) Extensive optimization using Rosetta FlexPepDock[10, 13] and (b) Short 
minimization of the starting structure. Minimization was only shown in previous studies of 
FlexPepBind to provide results of similar quality as the extensive FlexPepDock optimization 
protocol for calibration for FTase peptide substrate specificity[8], while for BCL specificity, full 
optimization was critical for good performance[9]. 
 
Step 2(a) Extensive optimization using Rosetta FlexPepDock 
This protocol has been developed previously in our lab to robustly refine coarse models of 
peptide–protein complexes into high resolution models. Optimization includes all internal 
degrees of freedom of the peptide (backbone and side chain torsion angles), as well as its rigid 
body orientation relative to the receptor (translation and rotation), and the side chains of the 
receptor. The receptor backbone is fixed. To allow significant perturbations within the binding 
pocket, while preventing the peptide and protein from separating during energy minimization, 
the simulation initially begins with strongly reduced (2 %)/increased (225 %) weights of the 
repulsive/attractive Van der Waals terms, which are gradually ramped back towards their 
original weights during the optimization. This non-deterministic protocol is applied repeatedly to 
generate a set of models (typically 200; 1000 models were generated for optimization of the 
starting structure, see above), and the best-scoring model is selected (according to a scoring 
function detailed below).  
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Step 2(b) Short minimization of starting structure 
We also investigated a shorter protocol that simply minimizes all internal degrees of freedom of 
the peptide, the receptor side chains, and the rigid body orientations (as implemented for FTase 
specificity prediction[8]).  
 
Parameters optimized for HDAC8 FlexPepBind 
Biasing conformations with constraints 
Conformational sampling was biased towards relevant conformations by implementation of 
constraints that reproduce conserved structural features identified from known structures of the 
interaction or experimental data. HDAC8 catalyzes deacetylation of a wide range of different 
substrates, which all must bind to the catalytic active site. Maintaining the structural features that 
are important for binding is critical to structure-based substrate specificity prediction. Inspection 
of HDAC8 bound to a methylcoumarin conjugated peptide representing p53 (PDB ID 2v5w), 
identified potential critical interactions that we implemented as constraints. These constraints, 
and how they are implemented into the Rosetta scoring function, are listed in Table 3.1 and 
shown in Figure 3.1. 
 
 
 Constraint 
type 
Function type Atoms involved 
 
Constraint 
1 Atom Paira  BOUNDEDb D101 Oδ2 : Kac N 2.2 - 3.2Å
2 Atom Pair BOUNDED D101 Oδ1 : Coumarin N 2.5 - 3.5Å
3 Dihedralc CIRCULAR 
HARMONICd
Kac N : Kac Cα : Kac C : 
Coumarine N
5.46 
radians
4 Atom Pair HARMONICe D267 Oδ2 / D267 Oδ2 : Kac 
Oη
2.8Å  
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5 Atom Pair HARMONIC H180 Nδ1 : Kac Oη 3.3Å
6 Atom Pair HARMONIC G151 O : Kac Nζ 3.0Å
7 Atom Pair HARMONIC F152 Cε1 / F152 Cε2 : Kac 
Cδ
3.8Å 
8 Atom Pair HARMONIC F208 Cδ1 / F208 Cδ2 : Kac 
Cγ
3.7Å 
Table 3.1 Different constraints derived from the solved structure ( 2v5w ) 
a Distance constraint between two atoms 
b Bounded function:  
, where lb, ub 
represents the boundaries within which zero scoring penalty is applied. rswitch is set to 0.5  
c Dihedral constraint between four atoms 
d Circular harmonic function: , where x0 and sd 
represent the radian in the starting structure and a standard deviation (set to 0.2), 
respectively. 
e Harmonic function:  
 
 
The first three constraints tether the peptide backbone of the acetylated lysine to the receptor via 
two hydrogen bonds to the side chain of receptor residue Asp101. This enforces a cis dihedral 
angle conformation between the two adjacent backbone nitrogen atoms. The importance of  
89 
 
 
Figure 3.1 Key interactions within the HDAC8-substrate interface 
Receptor in green, peptide in cyan, peptide residues and interacting residues in the receptor are 
shown as sticks. 
 
Asp101 is evident from the fact that the Asp101Ala mutation leads to complete loss of 
deacetylation activity with both peptides and purified histones substrates[11]. The next two 
constraints tether the acetyl group of the lysine to the zinc ion (using zinc-binding residues 
His180, Asp267; the zinc atom itself is not included in the simulations). The remaining 
constraints, interaction of the Gly151 oxygen atom with the lysine nitrogen atom, and the 
stacking interactions of the side-chain rings of Phe152 and Phe208 residues with the acetylated 
lysine side-chain, tightly lock the acetylated lysine side-chain within the binding pocket. 
Definition of axes for rigid body movements 
The rigid body orientation between the HDAC8 receptor and the peptide substrate is defined by 
two anchors that connect the receptor to the peptide. In the FlexPepDock framework, these 
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anchors are by default defined as the peptide α carbon atom nearest to the peptide center of mass, 
and the receptor α carbon atom nearest to the peptide anchor. In order to optimize rigid body 
sampling to relevant conformations, we explicitly defined the α carbon atom of the acetyl lysine 
as the peptide anchor. 
 
Addition of an electrostatic term to default scoring function score12  
Initially, we used the Rosetta default scoring function in all simulations (score12). Subsequently 
we added a weak, short range Coulombic electrostatic energy term to the scoring function 
(fa_elec), which consists of a simple, linearly increasing and distance dependent dielectric term 
to model solvent screening effects, with all interactions truncated at 5.5 Å. This preserves the 
short-ranged nature of the all-atom potential. In addition, the penalty for burial of a carboxyl 
group oxygen atom was increased to prevent formation of too many buried polar interactions (the 
∆Gfree parameter of the Lazaridis-Karplus solvation potential was modified from -10.0 to -13.5 
for this atom type). In a previous study, we found these parameters improve our prediction of 
BCL binding specificity[9]. Moreover, an independent study on DNA binding specificity 
demonstrated that the incorporation of this explicit electrostatics term, together with the 
modification of one of the parameters in the Lazaridis-Karplus solvation potential, in addition to 
Rosetta’s orientation-dependent hydrogen bonding potential[14], helped to prevent unfavorable 
short-range electrostatic interactions, modulated the interaction strength of charged and polar 
hydrogen bonds, and generally improved the performance of their DNA-protein interaction 
specificity predictions[15]. 
 
Step 3: Ranking of the peptide substrates based on the optimized peptide-receptor complex 
structures 
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In the last step of the FlexPepBind protocol, different peptide-HDAC8 activated complexes are 
ranked to model the relative binding ability of different peptides to HDAC8 (and thus, their 
ability to undergo deacetylation cartelized by HDAC8). In order to focus on the peptide-HDAC8 
interface, different subsets of the total score were investigated: 
(1) Peptide score - includes only energy terms that involve the peptide, i.e. the internal energy of 
the peptide, and interactions across the interface. A similar term, Peptide score (noref) was used 
in the FlexPepBind FTase specificity protocol[8]. This term does not contain the reference 
energy term, (Eref), originally introduced to allow comparison of structures of different 
sequence, and to bias for native protein sequences during fixed backbone design. 
(2) Interface score - includes the sum of interactions across the interface. 
(3) Reweighted score - sum of peptide score, interface score and total score. This score gives 
more weight to the contribution of peptide to the overall energy. 
 
Dataset 1: Training and test set: 361 GXKacZGC peptides 
The Fierke group has tested the ability of HDAC8 to deacetylate 361 6-mer peptides with the 
sequence Ac-GXKacZGC-NH2 (where X,Z can be any amino acid, except cysteine), under two 
different conditions: for zinc and iron bound HDAC8 (Joseph and Fierke unpublished results). 
For each of these peptides, the level of deacetylation by HDAC8 was measured by reacting the 
substrate for 30 minutes at 30˚C, for both Zn- and Fe-bound HDAC8 and measuring the fraction 
product with a SAMDI mass spectrometric assay in collaboration with the Mrksich group. In this 
study, we focus only on Zn bound (0.5 μM Zn(II)-HDAC8) as a first step in deciphering the 
entire co-factor dependent specificity profile of the enzyme. We divided this dataset of 361 
peptides into a training and a test set, by sorting the peptides according to their experimental 
activity with Zn(II)- HDAC8, and assigning all even/odd-numbered rows to be the test/training 
set, respectively. This division assured an even distribution of peptides with respect to their 
activity levels (avoiding a situation where one set holds a large number of high/low activity 
substrates).  
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Initial calibration set: 5 substrates & 5 non-substrates 
As a first step, we evaluated how well a protocol can distinguish between 5 active substrates and 
5 peptides that are not HDAC8 substrates (Table 3.2). 
Substrates Non-substrates
GYKacFGC (93%) 
GYKacWGC (80%)
GLKacFGC (66%) 
GFKacFGC (64%) 
GIKacFGC (62%) 
GDKacRGC 
GYKacEGC 
GNKacHGC 
GTKacKGC 
GMKacPGC 
Table 3.2 Initial calibration set 
Dataset 2: Validation set: 361 GRKacXZC peptides 
Mrksich et al. evaluated the reactivity of HDAC8 with a library of peptides (Ac-GRKacXZC-
NH2) peptides with many possible amino acid combinations of the X and Z positions[2]. The 
arrays were prepared by immobilizing the peptides to a self-assembled monolayer of 
alkanethiolates on gold and then analyzed by a mass spectrometry technique termed SAMDI 
(self-assembled monolayers for matrix assisted laser desorption/ionization time-of-flight mass 
spectrometry).  
 
Statistical tests 
In this study, we used two measurements to evaluate the performance of HDAC8 FlexPepBind 
substrate prediction: (1) Binary distinction between substrates and non-substrates, and (2) Linear 
correlation between predicted relative binding affinity and experimentally determined kcat/KM 
values for each substrate. An optimal protocol should be able to reliably identify (at least the 
strongest) peptide substrates, and preferably to rank peptide substrates according to their relative 
reactivity with HDAC8.  
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Binary distinction between substrates and non-substrates  
For binary distinction, we determined a deacetylation level, beyond/below which a peptide is 
defined as a substrate/non-substrate, respectively (below). The non-parametric Kolmogorov-
Smirnov test was applied to determine whether substrates and non-substrates are derived from 
two distinct populations (e.g., they can be distinguished). 
 
Prediction of relative substrate activity 
In order to assess the ability of FlexPepBind to rank substrate peptides according to their 
reactivity with HDAC8, we calculated correlations and the associated statistical significance, 
using the non-parametric spearman correlation test. 
False Discovery Rate (FDR) corrections were applied to evaluate the statistical significance 
taking into account the number of hypotheses tested for each data set. 
 
Results 
First round of calibration 
After development of an initial algorithm based on the library data, we decided to perform a 
quick calibration on a small set of peptides (5 peptide substrates proposed to have high HDAC8 
activity and 5 peptides proposed to have low HDAC8 activity) (Table 3.2). A satisfactory 
distinction between substrates and non-substrates could be obtained in the computational model 
using: (1) Optimization of structure with minimization only, rather than the more time 
consuming FlexPepDock optimization; (2) Default scoring using score12; (3) The acetylated 
lysine substrate constrained to its present location using a set of distance and dihedral constraints 
(Table 3.3; standard deviation of constraints: 0.2); (4) The structural template HDAC8-peptide: 
2v5w with an extended peptide conformation (see Methods); and (5) Defined peptide anchor 
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residue of α carbon of the acetylated lysine (residue 366 in HDAC8 structure). These initial 
parameters were chosen based on experience in previous studies[8, 9], and/or from inspection of 
the solved HDAC8-peptide complex structure (PDBID 2v5w). Table 3.3 shows that substrates 
could well be distinguished from non-substrates, using any of the scores for ranking. 
Scoring scheme 
 
Interface score Peptide score Peptide score 
noref 
Reweighted score 
KS p-values 0.036 0.036 0.036 0.036 
Table 3.3 Distinction between substrates and non-substrates in the initial calibration run 
For the next phase, we ran our peptide modeling protocol on the whole training set, mainly using 
the set of parameters that exhibited superior performance in this short calibration phase. 
 
Analysis of performance in Training and Test sets 
The original dataset measured by Caleb Joseph contains sequences of acetyl lysine peptides that 
are ranked by their activity level as substrates, we needed to develop a protocol for binary 
classification into substrates and non-substrates with a cutoff value that can be used as a lower 
limit to define peptides as substrates. We derived that cut off by applying a 2 sample 
Kolmogorov-Smirnov (KS) test on all possible activity levels ([0,1], in resolution of 0.01). The 
activity level that was chosen as a cutoff is the one that obtained the lowest p-value in the KS 
test, thus, the one that could best differentiate between the 2 distributions of scores for substrates 
vs. non substrates (Figure 3.2). Our best distinction between substrates and non-substrates is 
obtained for a cutoff of 34 % deacetylation under defined assay conditions. This value did not 
change significantly upon variation of parameters (data not shown). 
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Figure 3.2 Log(p-value) of KS test vs. activity level plot shows that the best cutoff 
for binary classification is around 0.34 
Searching for novel, non-histone substrates 
The Phosphosite database[16] (http://www.phosphosite.org/) contains a compilation of all 
experimentally observed acetylation sites in proteins. We extracted from this database 3184 
acetylated sites in 1603 proteins. These present a pool of potential targets for catylysis of 
deacetylation by HDAC8. In order to use our algorithm to predict their ability to be deacetylated 
by HDAC8, we shortened the sequences around the acetylated lysine to the same size of the 
sequences in our experimental dataset - XXKacXXX, and used these as input. Figure 3.3 shows 
the distribution of peptide scores for the 3184 acetylation sites. From the previous training and 
test runs, we defined a threshold value of peptide score -5 units, above which our confidence in a 
true prediction is very high. While most sequences in the Phosphosite database are probably not 
highly efficient HDAC8 substrates, we predict that some peptides with scores lower than -5 units 
will nevertheless be substrates. This finding could suggest that there are quite a number of 
potential substrates of HDAC8 or other deacetylases that are yet to be discovered. 
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Figure 3.3 Distribution of peptide scores in the 3184 acetylated lysine sequences 
The rightmost bar concentrates all the peptides that have a minimization score below 7 (a high 
score that suggests that our approach was not able to model successfully these peptides into the 
binding site). 
 
Experimental validation of de-novo predictions 
To test our prediction algorithm, we selected a set of 26 acetylated peptide sequences for 
experimental validation. This set includes: 
 (1) A positive set (“Good” peptide) - the 10 top-ranking peptides in phosphosite (peptide score ≤ 
-6). In addition to this positive set, we selected acetylated peptides that occur in the same 
proteins: (2) A negative set (“bad” peptides) - 10 peptides predicted not to undergo deacetylation 
by HDAC8 (high peptide scores 0 to 7), and (3) Additional potential substrates that ranked in the 
middle (-6 to 0) (“Mediocre” peptides). 20 out of 26 peptides were successfully characterized by 
experiments. This set of 20 peptides is named Pep20 set throughout the rest of the paper.  
In order to assess the accuracy of the algorithm, the predicted peptides were purchased and 
assayed. These peptides were dissolved in 50% acetonitrile, and 20 of the 26 peptides were 
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soluble. The zinc content of one of the peptides (Ac-VSKacGPF-COO-) was determined, using 
ICP-MS, to be one-one hundredth of the peptide concentration. All soluble peptides were 
assayed using a coupled assay developed to measure the acetate release from a deacetylation 
reaction (Table 3.4) and varied three orders of magnitude in their initial velocities. Of these 
peptides, the peptide representing the Lys350 of the histone acetyl transferase KAT6A (Ac-
VSKacGPF-COO-), was deacetylated four-fold faster than the next fastest peptide (61 M-1s-1 
versus 12 M-1s-1). Two peptides representing other acetylation sites on KAT6A (Lys604 and Lys 
815) were also assayed. These peptides were deacetylated by HDAC8 slower than the Lys350 
peptide (7.5 M-1s-1 and > 0.6 M-1s-1, respectively). Finally, to determine the accuracy of the 
Score12, the log(kcat/KM peptide) was graphed versus the Score12 score (Figure 3.4). This 
comparison yielded a direct linear correlation with an R2 value of 0.15. 
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Figure 3.4 Experimental validation of the Pep20 set 
Experimental values (X-axis) plotted against the predicted score (Peptide score, Y-axis, all 
positive scoring peptides have been assigned zero score for better representation) indicate that 
while strong substrates are favorably scored, this prediction scheme also identifies many false 
positive hits (points in the lower left of the figure).  
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Peptide Sequence Uniprot 
Accession
Protein Kac 
position
Peptide 
score 
log(kcat/KM)
Predicted strong substrates 
SGKacKGQ Q92922 SWI/SNF complex 
subunit 
SMARCC1 
345 -7.5 0.66 
IIKacDGE O95831 Apoptosis-
inducing factor 1 
593 -7.55 1.5 
DIKacYPL P00387 NADH-
cytochrome b5 
reductase 3 
42 -7.6 7.9 
PGKacGVK Q01094 Transcription 
factor E2F1 
117 -7.6 3.7 
DDKacYTL Q15005 Signal peptidase 
complex subunit 2 
169 -7.6 0.67 
TQKacQEQ P12270 Nucleoprotein TPR 755 -7.6 1.5 
VSKacGTL P16401 Histone H1.5 93 -7.69 8.5 
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SFKacSDQ Q9UPN9 E3 ubiquitin-
protein ligase 
TRIM33 
769 -7.74 12 
ESKacFQQ P06400 Retinoblastoma- 
associated protein 
896 -8.79  
VSKacGPF Q92794 Histone 
acetyltransferase 
KAT6A 
350 -9.61 61 
Predicted non-substrates in same proteins 
FSKacVRT Q92794 KAT6A 355 1792  
VGKacSVS Q92794 KAT6A 815 1751 <0.6 
DHKacTLY Q92794 KAT6A 604 174 7.5 
MIKacHLE P06400 Retinoblastoma- 
associated 
protein 
548 186  
FTKacDHL Q9UPN9 TRIM33 252 965 3.2 
KGKacTAQ Q9UPN9 TRIM33 953 2.61 3.1 
GVKacKVA P16401 Histone H1.5 168 624 1 
KPKacAAK P16401 Histone H1.5 209 145 4.1 
SFKacLNK P16401 Histone H1.5 109 16.17 0.061 
IVKacEVE P12270 Nucleoprotein 
TPR 
428 1430  
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NQKacLTA P12270 Nucleoprotein 
TPR 
748 975 <0.6 
Additional predicted substrates 
VSKacAVE P06733 Alpha-enolase 64 -5.07  
MGKacGVS P06733 Alpha-enolase 60 -5.16  
SGKacYDL P06733 Alpha-enolase 256 -7.15 6.6
DSKacNAK Q92793 CREB Binding 
Protein CBP 
1583 -4.4 5.2
KKKacNNK Q92793 CBP 1588 -5.24 1.7
 
Table 3.4 Experimental measurement of potential substrates and a corresponding 
predicted negative set 
 
These experimental results show that while our initial protocol (namely minimization only, using 
the default scoring function (score 12), and starting from an extended peptide) performs well on 
training and test sets the ability to predict HDAC8 substrates as indicated by the Pep20 results: 
While strong substrates are recognized very well, the overall correlation between the predicted 
score and experimental activity is low, largely due to false positives (Figure 3.4 and Table 3.4). 
 
Second round of calibration 
The reduced performance on the Pep20 set compared to training and test sets indicates that the 
training set was too restricted in sequence variability and that a more general protocol might be 
developed by including more diverse substrates. This motivated us to perform a second round of 
calibration, starting from Pep20. Our aims were to improve performance on the Pep20 set, while 
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maintaining similar performance on the previous training and test sets. Furthermore, we were 
interested in maintaining good performance with a more extended, fully optimization protocol, to 
ensure robustness, and to enable the modeling of very different peptide substrates in the future. 
For the second round of calibration, we investigated three main parameters of our model, each 
relating to a different step of the protocol. In step 1, preparation of starting structure, we 
attempted to create a better starting structure, assuming that this would result in better 
predictions. In step 2, optimization of peptide-HDAC8 complex structure, we investigated 
inclusion of an electrostatic term into the default scoring function, motivated by improved 
performance observed in previous studies on prediction of BCL peptide binding specificity[9] 
and DNA binding specificity[15]. In step 3, in which different peptide substrates are ranked, we 
further evaluated different scoring terms, in particular Interface score vs. peptide score, which 
were both shown to perform similarly in the first optimization round, but produced different top-
ranking substrate lists.  
 
Improved starting structure and score function 
While the template in the initial protocol contained an extended peptide conformation anchored 
on the acetylated lysine substrate residue, we investigated how to include more information 
about peptide backbone conformations preferred by HDAC8. Since the only peptide substrate 
(Ac-RHKacKac-methylcoumarin) solved with HDAC8 (PDB ID 2v5w; see Methods) does not 
cover the full peptide backbone of the hexamer peptides used to calibrate the protocol 
(XXKacZZZ), atoms beyond the nitrogen atom of the methylcoumarin need to be modeled.  
We investigated two possible approaches: (1) partial threading of the peptide residues combined 
with an extended conformation (XXKacZZZ, X,Kac=threaded, Z extended; see Methods), and 
(2) an optimized template. The latter was obtained starting from a partially threaded peptide (the 
first option above), onto which the sequence of an active substrate, Ac-GYKacFGC-NH2 was 
threaded. This structure was then optimized using the full optimization protocol (see Methods). 
The underlying assumption is that a backbone conformation optimized for a sequence known to 
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be a good substrate is a better starting structure for modeling peptide sequences into the HDAC8 
substrate binding site. These two starting structures are shown in Figure 3.5. 
Figure 3.5 Improved starting structures for optimization 
In green: HDAC8 crystal structure (2v5w); in yellow: partially threaded template; cyan: 
optimized template). Note that while the acetyl lysine is not changed, the position of the N- and 
C-terminal peptide tails vary. 
 
We also increased the number of design runs (ndrun = 100), to obtain better starting structures 
(see Methods). The optimized template significantly improved the prediction of substrate 
efficiency in the Pep20 set. We therefore chose this template as a starting structure for the further 
optimization steps below. 
To further improve our protocol, we investigated modifications of the scoring function. We 
improved prediction of HDAC8 substrates by inclusion of electrostatic energy term. 
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Second round of Phosphosite screen  
With this improved protocol in hand, we proceeded to a second screen of the Phosphosite 
database. For this, we used the improved protocol after trimming sequences around the 
acetylated lysine to hexamers, as in our experimental datasets. The goal was to screen for 
putative novel HDAC8 targets by top-ranking peptides. Peptides were again chosen as “good” 
(interface score < -17), “bad (interface score > -12) and “mediocre” (-12 > interface score > -17) 
substrates (Figure 3.6). We therefore compiled Pep19, a set of 19 peptides (Table 3.5) that could 
help us to validate the new protocol along with choosing the best scoring term for ranking and 
discrimination between substrates and non-substrates.  
 
 
 
Figure 3.6 Distribution of interface score in the acetylated peptides 
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Assessing the second set of peptides 
A second set of 19 peptides (17 of which were soluble) were purchased and rendered metal free 
using Chelex 100 resin. Zn(II)-HDAC8 and two peptide concentrations (≥100 μM) were 
incubated and measured using the coupled assay system (Chapter 2). The initial slopes were fit to 
a line yielding kcat/KM values. The catalytic efficiencies of these peptides range over 1000-fold 
(<2 M-1s-1 to 4,400 M-1s-1). Peptides corresponding to a DNA mismatch repair protein Msh6, E3 
sumo ligase CBX4, and Elongation factor 1-alpha 1are the fastest measured peptides (to date) for 
HDAC8 catalyzed deacetylation with rates of 880 M-1s-1, 1,200 M-1s-1, and 4,400 M-1s-1 
respectively. In this case, there is a rough linear correlation between log(kcat/KM) and the 
Interface score (Figure 3.7). This graph also resulted in a linear correlation with an R2 value = 
0.4 which is better than double R2 the value for the pep20 set.  
For better insight into the recognition of efficient peptide substrates by HDAC8, Michaelis-
Menten kinetics were determined for the three fastest peptides. 1 μM Zn(II)-HDAC8 and 0 - 400 
μM peptides where incubated under standard assay conditions (Table 3.5). For these peptides, 
low kcat values (<0.05 s-1) consistent with non-fluorophore conjugated peptides were measured 
(Appendix A). KM (<50 μM) were measured and appear to be the deterring factor in the high 
kcat/KM values. The peptide concentration dependence (0-400 µM) for the initial rate for 
deacetylation catalyzed by HDAC8 was determined (Table 3.5). The catalytic efficiency 
(kcat/KM) is mainly due to a decrease in KM, likely reflecting enhanced binding interactions. This 
is consistent with the algorithm which mainly measures enhanced HDAC8-peptide affinity.  
 
Peptide Uniprot 
ID 
Protein Kac 
position
Interface 
score 
peptide 
score 
kcat/KM 
SLKacEFY P30838 Aldehyde 
dehydrogenase, 
dimeric, NADP-
preferring 
K269 -17.9 -7.8 78 
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LSKacFLR P27708 CAD protein K747 -21.6 -7.3 880 
ISKacYDR P52701 DNA mismatch 
repair protein 
Msh6 
K504 -28.6 -8.2 85 
RKKacGEP P04637 Cellular tumor 
antigen p53 
K292 -11.9 -4.9 13 
KIKacRLR P18124 60S ribosomal 
protein L7 
K31 -18.5 -5 7.7 
LGKacFRR Q6PKG0 La-related 
protein 1 
K1017 -19.1 -6.1 50 
RLKacYSQ Q14683 SMC1A K713 -16.8 -7.2 83 
SGKacYFA Q01433 AMP deaminase 
2 
K517 -16.2 -9.2 20 
TWKacANF P14316 Interferon 
regulatory factor 
2 
K78 -19.6 -7.9 77 
TFKacGVD Q9UK76 Hematological 
and neurological 
expressed 1 
protein 
K8 -15.4 -8.2 14 
GGKacAFG P55008 Allograft 
inflammatory 
factor 1 
K11 -14.5 -7.4 21 
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FVKacAFA P51649 Succinate-
semialdehyde 
dehydrogenase, 
mitochondrial 
K358 -14.7 -8.9 2.8 
GIKacPFL Q9NQW6 Actin-binding 
protein anillin 
K371 -7 -7.1 <2 
FGKacFSW Q5VUA4 Zinc finger 
protein 318 
K1275 -19.9 -9.5 4400 
SFKacYAW P68104 Elongation factor 
1-alpha 1 
K55 -20.8 -10.2 1200 
SGKacYYY O00257 E3 SUMO-
protein ligase 
CBX4 
K149 -16.7 -9.7 21 
SEKacPEK P78527 DNA-dependent 
protein kinase 
catalytic subunit 
K1970 -8 -2.8 21 
KGKacDAE Q9Y618 Nuclear receptor 
corepressor 2 
K878 -14.5 -5 2.6 
 
Table 3.5 The second experimental validation: Pep19 set 
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Figure 3.7 Performance of new protocol on the second validation set, Pep19 
Data was fit to a linear equation yielding an R2 value of 0.7. 
 
 
Discussion 
Determining HDAC substrate preference is integral to determining the role of HDAC8 in cellular 
homeostasis and HDAC related diseases. As a result, identification of in vivo HDAC substrates is 
currently one of the important challenges of the HDAC field. One of the most successful high 
throughput methods utilizes systematic changes to peptide substrates and relates those changes to 
full length protein substrates[1-4]. In this method, peptide arrays made of a 3- to 7-mer peptides 
are altered systematically in one or two amino acid positions. These studies have proposed 
HDAC preferences for various amino acids in specific peptide positions. For instance, these 
studies have indicated that HDAC8 prefers an aromatic amino acid in the +1 position in the 
context of a specific sequence. Similarly, these studies do not describe reactivity with peptides in 
other contexts indicating “context dependence” recognition: where multiple amino acid 
interactions contribute to specificity. While these experiments have been somewhat successful in 
identifying HDAC8 preference for peptides, they have thus far failed to identify in vivo full 
length protein substrates for HDAC8. We therefore innitiated this study to determine whether 
HDAC peptide preference could be improved by utilizing a computational approach to aid in 
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evaluating specificity. If a computational model is able to identify better peptide substrates, this 
would provide evidence for multiple interactions contributing to selectivity.  
In this chapter, we used an initial training set followed by two rounds of optimization to 
determine a general substrate binding algorithm to predict “good” peptide substrates for HDAC8. 
Initial experiments were based on a training set of peptides for which kinetics were 
experimentally determined (Joseph, Mrksich, and Fierke unpublished)[1]. These experiments 
utilized a mass spectrometry based assay to determine the deacetylation rates for a set of peptides 
with systematic amino acid changes in the -1 and +1 positions, and in the +1, +2 positions. This 
study showed that HDAC8 displays a preference for aromatic amino acids (specifically 
phenylalanine) in the +1 position.  
The set of substrates identified using the first algorithm had low values of kcat/KM for 
deacetylation catalyzed by HDAC8 (≤61 M-1s-1). The low catalytic activity, especially when 
compared to the second set of peptides, likely suggest that none of the corresponding proteins are 
in vivo substrates for HDAC8. The activity of this peptide may also be decreased by the 
inclusion of a –COO- at the C-terminus which likely lowered activity ~2-fold (data not shown) 
and by inhibition by Zn(II) contamination of the peptides that could decease activity by 70%[7].  
After multiple rounds of optimization of the computational method, a roughly linear correlation 
between the algorithm score and the experimental log(kcat/KM) value was observed providing 
confidence that this method evaluates HDAC8-peptide affinity. In fact the second validation set 
yielded peptides with the fastest known catalytic efficiencies (4400 M-1s-1 and 1200 M-1s-1) for 
Zn(II)-HDAC8 peptide substrates corresponding to the elongation factor 1-alpha 1 and the E3 
SUMO-protein ligase CBX4 respectively. These sequences contain aromatic amino acids in both 
the +1 and +3 positions (Ac-FGKacFSW-NH2 and Ac-SFKacYAW-NH2). Aromatic motifs in 
the +1 position of peptides has been previously observed to increase HDAC8 catalytic efficiency 
towards peptide substrates[1, 2]. Pi-pi interactions between Tyr100 within HDAC8 and a 
methylcoumarin moiety at the +1 position have been observed in high resolution HDCA8-
peptide structures and are theorized to increase the HDAC8 catalytic efficiency. It is not yet clear 
what interactions the aromatic amino acid in the +3 position are making with the HDAC8 
peptide binding grove. Interestingly, another peptide containing three aromatics (Ac-
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SGKacYYY-NH2) was deacetylated with a catalytic efficiency of only 20 M-1s-1, indicating that 
multiple aromatic amino acid side chains are not sufficient for activity. Thereby suggesting the 
formation of specific peptide-protein interactions. 
The prediction of faster substrates by the second algorithm suggests that more than 2 amino acids 
are required to define HDAC8 catalysis of peptide substrates. This is due to the fact that the 
initial algorithm had difficulty identifying fast substrates in the first peptide set, as it only 
contained data from two amino acid residues. Once consideration of all 6 amino acids was taken 
into account, the algorithm was able to better predict faster substrates.  
Previously, this algorithm was used to determine the substrate preference of another promiscuous 
post translational enzyme, farnesyltransferase. In the case of farnesyltransferase, this algorithm 
was less effective as it could only yield yes or no answers[8] as opposed to the gradient of rates 
that it predicts in this chapter. One possible explanation for this is that kcat/KM includes multiple 
steps for FTase activity and does not correlate with the peptide affinity[17]. HDAC8, which 
utilizes a rapid equilibrium substrate binding model, reflects both chemistry and binding affinity 
in the value of kcat/KM. As the algorithm mainly reflects binding affinity, this is a better 
correlation with HDAC8 substrate specificity.  
We are hopeful that these substrates will improve the in vivo identification of HDAC proteins 
substrates. We are currently in the process of working with the Holson group to determine 
whether the acetylation state of proteins corresponding to the efficient peptide substrates increase 
after addition of an HDAC8 specific inhibitor (for method see Chapter 4), which would suggest 
that deacetylation in vivo is catalyzed by HDAC8. 
In this chapter, we have determined how short range interactions affect HDAC8 substrate 
recognition, but how and whether long range interactions affect substrate specificity needs to be 
investigated.  As the HDAC8 putative substrate recognition motif extends tens of angstroms 
beyond the binding site of short peptide substrates, it appears likely that interactions within distal 
regions of the peptide binding region may also foster HDAC8 substrate recognition.  The work in 
the chapter provides a framework by which we can use to begin to ask this question.  In the 
future, experiments utilizing the combinations of “good,” “bad,” and “mediocre” peptides and 
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singly acetylated full length substrates (Chapter 5) can be performed to understand how the 
contributions of the short and long range interactions affect substrate recognition.   
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Chapter 4  
Mining the Acetylome: An Unbiased Approach to Identify the Endogenous Substrates of 
Histone Deacetylase 8 (HDAC8)11,12,13 
 
Introduction 
Despite being extensively characterized structurally and biochemically, the functional role of 
histone deacetylase 8 (HDAC8) has remained largely obscure due in part to a lack of known 
cellular substrates. Herein, we describe an unbiased approach using chemical tools in 
conjunction with sophisticated proteomic methods to identify novel non-histone substrates of 
HDAC8. These proteins are involved in diverse biological processes such as mitosis, 
transcription, chromatin remodeling, and RNA splicing. 
Results and discussion 
Posttranslational acetylation of lysine residues is a highly conserved modification[1-3] which 
alters protein functions ranging from stability to activity and results in effects ranging from 
cytoskeletal reorganization[4] to changes in gene expression[5]. Histone deacetylases (HDACs) 
play a key role in maintaining the balance of acetylation states by catalyzing the removal of 
acetate groups from the ε-amino position of acetyl lysine residues. As a result, these enzymes 
                                                 
11 Reproduced in part from Olson, D.E. Udeshi, N. Wolfson, N.A. Pitcairn, C.A. Sullican, E.D. Jaffe, J. Scinkina, T. 
Natoli, T. Liu, X. Paulk, J. McCarren, P. Barker, D. Howe, E. Lazzaro, F. Zhang, Y. Gale, J. Subramanian, A. 
Fierke, C.A. Holson, E.B. 2014. Mining the Acetylome: An Unbiased Approach to Identify the Endogenous 
Substrates of “Histone” Deacetylase 8 (HDAC8). in preparation. 
12 Chapter was edited and includes a longer discussion of my in vitro peptide experiments. 
13 I performed all of the experimental studies with the peptide substrates (Figure 4.3 and 4.4) and I wrote all of the 
text pertaining to these experiments. 
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have become important therapeutic targets for a number of disease states including cancer[6, 7] 
and psychiatric illnesses[8]. HDACs deacetylate a large number of non-histone proteins[2, 9], 
and identification of the endogenous substrates of HDAC enzymes is a fundamental area of 
HDAC research. Of all the HDACs, HDAC8 is the best characterized structurally and 
kinetically[10-23]. As a result, HDAC8 can be used as a platform to develop methods for the 
identification of substrate specificity determinants in HDAC isozymes. Despite extensive studies, 
only two cellular HDAC8 substrates have been identified[24], namely, the estrogen-related 
receptor-α[25] (ERR-α) and the structural maintenance of chromosome 3[26] (SMC3) protein. 
The complete HDAC8 substrate set remains undetermined, which is largely due to difficulties in 
distinguishing binding partners from substrates (Chapter 1). 
To elucidate the cellular substrates and better define the biology of HDAC8, we undertook an 
unbiased, chemical biology approach that involves monitoring global acetylation and gene 
expression changes in a representative cell line following treatment with a known, potent, and 
highly selective HDAC8 small molecule inhibitor. Small molecule modulation coupled with 
mass spectrometry can offer distinct advantages for the identification of acetylation substrates 
and specific acetyl lysine sites responsive to HDAC8 in comparison to protein knockdown, 
knockout, or pulldown approaches, including: 1) de-convolution of catalytic vs. scaffolding 
functions associated with HDACs[27], 2) temporal control, 3) increased resolution and 
sensitivity, and 4) the avoidance of complications associated with transient and/or metastable 
interactions and complexes. Therefore, we focused on using the highly selective and potent 
HDAC8 inhibitor, PCI-34051[28] as well as a suitably designed negative control compound to 
account for potential compound driven off-target effects (Figure 4.1a,b). The inclusion of a 
negative control compound was particularly important, as PCI-34051 contains a metal-chelating 
hydroxamic acid group known to bind a variety of metalloenzymes[29]. As such, we designed 
and synthesized BRD3811 (Figure 4.1a), a compound that retains the hydroxamic acid 
functionality but contains a minor structural modification to PCI-34051 (i.e., a single methyl 
group introduced ortho to the hydroxamic acid group) resulting in over 1,000-fold reduction in 
potency for HDAC8 inhibition (Figure 4.1b). Consistent with this finding, molecular docking of 
PCI-34051 and BRD3811 into the active site of the HDAC8 crystal structure 2v5w reveals that 
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the methyl group of BRD3811 cannot be accommodated in the catalytic binding domain of 
HDAC8 while maintaining an optimal zinc chelation geometry (Figure 4.1c). 
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Figure 4.1 Chemical tools for studying HDAC8 
 (a) Chemical structures of the HDAC8 inhibitor PCI-34051 and the structurally related negative 
control compound BRD3811. (b) HDAC inhibitor potencies for PCI-34051, BRD3811, and the 
pan-inhibitor SAHA. (c) PCI-34051 docked into the 2V5W crystal structure of HDAC8. (d) 
Replacement of the ortho-hydrogen in the docked structure of PCI-34051 (c) with a methyl 
group. The methyl group protrudes from the enzyme pocket. (e) BRD3811 docked into the 
2V5W crystal structure of HDAC8. Again, the methyl group protrudes from the enzyme pocket. 
 
Using these chemical tools, we compared the changes in global acetylation in a representative 
cell line known to express HDAC8[30] (i.e. MCF7) after treatment with each compound using 
Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC)-based quantitative mass 
spectrometry (MS). Briefly, cells were grown in the presence of light, medium, or heavy arginine 
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and lysine then treated with either PCI-34051 (10 M), BRD3811 (10 M), or vehicle (DMSO) 
for 24 hours (Figure 4.2a). Global acetylation profiling was completed by digesting cellular 
proteins with trypsin and enriching acetylated peptides by immunoprecipitation using an 
antibody specific for acetylated lysine residues. Over two replicates, 1,361 acetylation sites were 
quantified using high-resolution MS. 
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Figure 4.2 Scheme and results of mass spectrometry identification of HDAC8 substrates 
(a) Schematic of experimental design. (b) Acetylated proteins regulated by treatment with PCI-
34051 as compared to DMSO or (c) BRD3811 as the control. Each axis represents a single 
replicate and denotes log2-fold changes in acetylation with dashed lines indicating a 1.5-fold 
change in acetylation. Proteins that passed a p-value cutoff of  0.05 in both replicates and were 
not regulated by the negative control compound BRD3811 are highlighted in red. Insets show 
log2-fold changes in acetylation for select examples of replicate 1 and emphasize the relative 
lack of histone acetylation by comparison to SMC3 for each experiment. (d) Tables depicting 
acetylation sites regulated by more than 1.5-fold and passing p-value cutoffs of  0.05 in both 
replicates when PCI-34051 treatment was compared to DMSO or to (e) BRD3811 treatment as 
the control. These proteins are the same as those highlighted in red above, their subcellular 
localization is predominantly nuclear, and they are involved in a variety of cellular processes 
including gene transcription and RNA splicing.  
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This approach enabled us to identify numerous sites in proteins where acetylation increased by 
more than 1.5-fold in each of two replicates upon treatment with PCI-34051 relative to DMSO 
(Figure 4.2b). Of these, 7 passed a p-value cutoff of  0.05 (Figure 4.2b, red; Figure 4.2d) and 
were not regulated upon treatment with negative control compound BRD3811 relative to DMSO 
(Figure 4.2b,c). Alternatively, a direct comparison of PCI-34051 treatment to BRD3811 
treatment (Figure 4.2c) revealed 20 proteins whose acetylation increased by more than 1.5-fold 
with 7 passing a p-value cutoff of  0.05 in two replicates (Figure 4.2c, red; Figure 4.2e). From 
these two data sets, we deemed 5 proteins (i.e., SMC3, RAI1, ZRANB2, NCOA3, and THRAP3) 
to be high-confidence substrates for HDAC8 as they were identified by comparing PCI-34051 
treatment to both DMSO as well as to the negative control compound. Furthermore, ARID1A 
and SRSF5 were also considered candidate substrates for HDAC8 as they narrowly fell outside 
the bounds of our arbitrary cutoffs (i.e., 1.5-fold change and p-value  0.05) in only one of four 
replicates. 
Importantly this unbiased approach successfully identified SMC3, a known substrate of 
HDAC8[26], as being significantly regulated by treatment with the HDAC8-selective inhibitor 
and not BRD3811. Furthermore, we were able to demonstrate for the first time that this 
acetylation occurs specifically on K106 of SMC3. Our coverage of acetylated proteins did not 
include ERR-α; and therefore, we cannot verify its regulation by HDAC8 in MCF7 cells. Our 
coverage did include several histone loci (Figure 4.3), and we did not observe any significant 
changes in histone acetylation status upon treatment with PCI-34051 when compared to DMSO 
or BRD3811.  
To further validate the acetylated proteins identified by our proteomics experiments as HDAC8 
substrates, we assayed peptides with sequences corresponding to the identified acetylation sites. 
Short peptides (8 to 10 amino acids) (Figure 4.3) containing an acetylated lysine with an 
acetylated N-terminus and C-terminal amine were purchased. The steady state kinetic parameters 
were determined from a fit of the Michaelis-Menten equation to the dependence of HDAC 
catalyzed deacetylation on the peptide concentration. Zn(II)-HDAC8 catalyzed deacetylation of 
all of these peptides in vitro (Figure 4.3) with catalytic efficiencies varying from 4.6 ± 0.10 to 
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740 ± 36. The peptide corresponding to ARID1A is one of the fastest peptides representing an in 
vivo protein sequence assayed thus far (Appendix A) with a kcat/KM value of 740 M-1s-1 [31] 
(Figure 4.3). Consistent with previous work, peptides containing an aromatic residue at the +1 
position (ARID1A and CSRP2BP) are the most efficient HDAC8 substrates[23]. These amino 
acids likely form a pi-pi bond with Tyr100 of HDAC8 to increase catalytic efficiency[24]. 
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Figure 4.3 Deacetylation of peptides identified by mass spectrometry 
(a) Acetylated peptides of 8-10 residues in length corresponding to the sequences surrounding 
the acetylation sites of a subset of identified HDAC8 substrates were subjected to an in vitro 
deacetylation assay using Zn-bound HDAC8 enzyme (see methods). Michaelis-Menten 
parameters for the deacetylation of each peptide are reported with the synthetic peptide 
corresponding to ARID1A exhibiting the largest kcat/KM reported to date for the HDAC8-
catalyzed deacetylation of a non-fluorophore conjugated synthetic peptide. (b) Plot for the 
determination of Michaelis-Menten parameters for the ARID1A peptide. 
a 
b 
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To examine the specificity of HDAC8 reactivity with these peptides, we measured kcat/KM values 
for deacetylation catalyzed by the metal dependent deacetylases HDAC1-4, 6-9 (Figure 4.4). 
These data suggest that HDAC3 is a promiscuous enzyme, consistent with previous library 
studies[17, 18]. This isozyme has an aspartic acid substituted for the tyrosine in HDAC8 that 
interacts with the aromatic amino acid at the +1 position suggesting a change in the molecular 
recognition determinants. All of the acetylated peptides are substrates for HDAC8 with varying 
efficiencies and also substrates for other isozymes. It is currently unclear what the value of 
kcat/KM must be to identify the corresponding protein as a biological substrates. Additionally 
identification of known substrates and peptides are needed to address this question. 
Changes between the reconstituted Zn(II)-HDAC8 and commercial HDAC8 were observed. 
These changes may be the result of the utilization of BSA and Triton-100 which increases 
reaction rate by 2- to 3-fold (Lopez and Fierke unpublished). 
 
 
Figure 4.4 In vitro peptide deacetylation using commercially available HDACs 
kcat/KM (M-1s-1) values for commercially available HDAC enzymes are reported as the mean of 
one experiment ± the standard error of the fit for 3 points. Dashes indicate particular 
combinations of peptides and enzyme isoforms that were not measured. Values for the metal 
reconstituted Zn(II)-HDAC8 enzyme (average of 3 experiments) are listed in grey for 
comparison.  
 
The vast majority of the substrates identified in our study are localized in the nucleus (Figure 
4.2d, e) and include transcription factors as well as proteins intimately involved in epigenetic 
regulation, chromatin remodeling, or RNA splicing. Interestingly, histone proteins were not 
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identified as substrates in our acetylome profiling experiments, and this fact was later confirmed 
in separate targeted SILAC experiments designed to specifically monitor histone acetylation 
changes. Intrigued by the non-histone but primarily nuclear nature of the candidate substrates, 
we tested if HDAC8 inhibition could lead to changes in gene expression independent of changes 
in histone acetylation. To this end, we measured the expression changes in MCF7 cells of 
approximately 1,000 landmark genes (L1000) as a representative measure of genome-wide 
effects upon treatment with PCI-34051 or BRD3811 across the dose range of 0.04 – 10 M (see 
methods). We then selected the dose-responsive genes using the IsoGene package 
(http://CRAN.R-project.org/package=IsoGene). As expected, PCI-34051 altered the expression 
of significantly more genes (70 genes) than did BRD3811 (6 genes). 
In order to identify what non-histone proteins might be involved in PCI-34051-mediated changes 
in gene expression, we performed pathway analysis using Ingenuity® 
(http://www.ingenuity.com/) (Figure 4.5a) with our high confidence HDAC8 substrates (Figure 
4.2d,e) and the 70 genes dose-responsive to PCI-34051 treatment (Figure 4.5) serving as our 
inputs. Not surprisingly, Ingenuity® did not report any direct associations between HDAC8 and 
the newly identified substrates; however, several of these proteins were directly linked to genes 
upregulated upon PCI-34051 treatment. Furthermore, we were intrigued to find that 3 of the 
newly identified substrates (i.e., ARID1A, RAI1, and MLL2) were directly linked to the cell 
cycle regulator p21 (CDKN1A). This led us to speculate that the well-known ability of ARID1A 
to regulate p21[32, 33] might be linked to HDAC8 inhibition, or alternatively, that RAI1 and/or 
MLL2 are involved. Many HDAC inhibitors are known to cause the upregulation of p21, but 
until now, the exact substrates responsible for mediating that effect have remained obscure[34]. 
When MCF7 cells are treated with PCI-34051 over the dose range 0.04 – 10 M, a robust dose-
dependent increase in the level of p21 transcript is observed (Figure 4.5). Conversely, BRD3811 
does not elicit as robust a dose-response, even though it does seem to increase the level of p21 
transcript at the highest dose (i.e., 10 M) (Figure 4.5b). However, when assayed at the protein 
level, PCI-34051 treatment increased p21 (visualized via western blot) while BRD3811 
treatment did not (Figure 4.5c,d). 
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Figure 4.5 The tumor suppressor p21 is linked to HDAC8 inhibition 
(a) Map of the proteins identified by mass spec approach and interactions of those proteins. (b) 
Treatment with PCI-34051 for 24 hours results in a dose-dependent increase in p21 expression. 
(c) Representative western blot after treatment of MCF7 cells with either PCI-34051 or 
BRD3811 at 10 M for 48 hours shows that PCI-34051, but not the negative control, induces an 
increase in p21 protein levels. (d) Quantitation of western blot data from 4 independent 
experiments. The star denotes p  0.05, relative to DMSO, as determined by a one-way analysis 
of variance (ANOVA) utilizing a post-hoc Dunnett’s multiple comparison’s test. 
 
To further validate our findings beyond the context of a single cell type and incorporate into our 
analysis orthogonal biological perturbations, we expanded our gene expression studies using 
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L1000 into several cell lines representative of distinct tissue types: PC3 (prostate), HEPG2 
(liver), HCC515 (lung), HA1E (kidney), A375 (skin), A549 (lung), HT29 (colon). We then 
created a gene expression signature using the 1,000 landmark genes, and compared PCI-34051 
and BRD3811 treatments to the signatures of other bioactive perturbing agents using the 
connectivity map (cmap) database (www.broadinstitute.org/cmap/) as previously described (see 
methods). We integrated the results of multiple independent cmap queries using the cell lines 
highlighted above, and we observed that PCI-34051 treatment was highly correlated with the 
overexpression of p21 across multiple cell lines while BRD3811 treatment was not. In fact, p21 
overexpression was the most highly correlated overexpression perturbation with PCI-34051 
treatment, with an average rank in the 96th percentile (BRD3811 treatment did not correlate well 
with p21 overexpression, 66th percentile rank). It is quite attractive to speculate that the anti-
cancer effects of the HDAC8 inhibitor PCI-34051[35] might be mediated by increasing p21 
levels through these newly discovered substrates.  
 In conclusion, we have identified several novel substrates of HDAC8 by taking an unbiased 
approach coupling chemical tools with acetylome profiling. The proteins identified include the 
known HDAC8 substrate SMC3, but do not include histones. Furthermore, these candidate 
substrates were predominantly nuclear and involved in a diverse range of cellular functions 
including transcription and RNA splicing. We demonstrated through in vitro enzymatic assays as 
well as gene and protein expression studies that inhibition of HDAC8 can affect acetylation 
status and influence the levels of downstream proteins. Our experimental design relied on using 
BRD3811, a negative control compound based on the structure of the potent and selective 
HDAC8 inhibitor PCI-34051. Our approach represents a general strategy that should prove 
useful in future studies aimed at the identification of bona fide HDAC substrates or in 
elucidating the off-target effects of HDAC inhibitors. 
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Methods 
Reagents 
ATP, Coenzyme A, NAD+, L-malic acid, citrate synthase (CS), and malate dehydrogenase 
(MDH) were purchased from Sigma. Fluor de Lys peptide and the developing reagent were 
purchased from Enzo Life Sciences. The peptides were purchased from Peptide2.0. Cobalt(II) 
was purchased as an ICP standard from GFS Chemicals and the acetic acid standard was 
purchased from Ricca Chemical Company. Chelex 100 resin was purchased from Bio-Rad. All 
HDACs (with the exception of HDAC8 expressed and purified in our lab) were purchased from 
BP Biosciences and given to us as a generous gift from Edward Holson. All other materials were 
purchased from Fisher and were of a purity >95 % unless otherwise noted.  
 
HDAC8 expression and purification  
A freshly transformed plate of BL21(DE3)pHD4-HDAC8-TEV-His6x or BL21(DE3)pHD4-
HDAC8(codon optimized)-TEV-His6x was used to inoculate 5 mL of 2xYT supplemented with 
50 µg/mL ampicillin and grown at 37˚C. Upon reaching an OD600 ~1 the cells were transferred to 
a flask containing 12.5 mL of 2xYT (per liter of expression media) containing 50 µg/mL 
ampicillin. These cells were grown to OD600 > 0.6 and the 12.5 mL 2xYT was used to inoculate 
1 L of modified-autoinduction TB medium (12 g/L tryptone, 24 g/L yeast extract, 8.3g/L Tris-
HCl, 4 g/L lactose, 1 g/L glucose, 10 mL/L glycerol, pH 7.4) supplemented with 50 µg/mL 
amipcillin and 200 μM ZnSO4. The cells were grown overnight at 30˚C with shaking at ~170 
rpm and harvested 20-24 hours post inoculation by centrifugation (9,000 x g, 10 min, 4˚C) and 
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then either lysed immediately or frozen as a dry cell pellet at -80˚C. Before lysing, cells were 
resuspended in low salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 50 mM 
NaCl, 5 mM KCl, 1 µg/mL TAME, 10 µg/mL PMSF, pH 7.8) and passed through a 
microfluidizer (Microfluidics) twice. The lysate was incubated with 0.1% PEI 
(polyethylenimine) (pH 7.9) for 10-15 minutes stirring on ice. The lysate was pelleted by 
centrifugation (16,800 x g, 45 min, 4˚C) and the supernatant was run through a 100 mL DEAE 
Sepharose column pre-equilibrated with low salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 
1 mM TCEP, 100 mM NaCl, 5 mM KCl, pH 7.8). The column was washed with 300 mL low salt 
DEAE buffer and eluted with 200 mL high salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 
mM TCEP, 500 mM NaCl, 5 mM KCl, pH 7.8). The elusion was dialyzed (Spectra/Por 8K 
MWCO) against 50 mM HEPES, 50 mM NaCl, pH 7.8 for 1 hour at 4˚C to remove the salt and 
ZnSO4. The eluate was then mixed with 20 mL of chelating sepharose resin charged with NiSO4 
in low imidazole buffer (50 mM HEPES, 100 mM NaCl, 25 mM imidazole, pH 7.8) and was 
incubated for 20-30 minutes stirring on ice. The slurry was poured into a column. The column 
was washed with 25 mM and 50 mM imidazole and HDAC8 was eluted with 250 mM imidazole. 
0.5 mg of TEV protease per 3 mg HDAC8 was added to the eluate, and the mixture was dialyzed 
(Spectra/Por 8K MWCO) overnight against low imidazole buffer at 4˚C. The next day, the eluate 
was applied to a 5 mL column of clean chelating sepharose resin charged with NiSO4 and 
equilibrated with low imidazole buffer. The column was washed with low imidazole buffer with 
50 mM. The flow through and wash were concentrated to <3 mL using 30,000 MWCO Amicon 
Ultra-15 centrifugal units and loaded onto a GE HiPrep 16/60 Sephacryl S200 HR size exclusion 
column equilibrated with size exclusion buffer (30 mM HEPES, 150 mM NaCl, 1 mM TCEP, 
pH 8). The fractions of >95 % pure HDAC8 (confirmed by SDS page) were combined and 
concentrated to <0.7 mL in 30,000 MWCO Amicon Ultra-15 centrifugal units. The HDAC8 was 
dialyzed against 4 L of metal free chelation buffer (30 mM MOPS, 3 mM KCl, 1 mM EDTA, 1 
mM TCEP) overnight at 4˚C followed by metal free dialysis buffer (30 mM MOPS, 3 mM KCl, 
1 mM EDTA, 1 mM TCEP). Finally, HDAC8 was applied to a PD-10 column in metal free 
dialysis buffer on a PD-10 column. All the fractions containing HDAC8 were concentrated >500 
μM, flash frozen in 10 µL aliquots, and stored at -80˚C. HDAC8 activity was confirmed using 
the Fluor de Lys assay as described previously[21]. This protocol utilizing pHD4-HDAC8-TEV-
His6x yielded ~1.5 mg/L HDAC8 whereas BL21(DE3)pHD4-HDAC8(codon optimized)-TEV-
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His6x yielded ~3mg/L. 
 
Peptides 
The lengths of these peptides were chosen to include an aromatic amino acid or lysine for the 
measurement of peptide concentration while maintaining a length of 8 to 10 amino acids that is 
equivalent for all peptides. The peptides solubilized in water, 50 % acetonitrile, or 10 % DMSO 
as needed. Once solubilized the pep20 set of peptides were chelated with Chelex resin. Peptide 
concentrations were measured using the fluorescamine assay when possible, or ND-1000 
(NanoDrop), or just assumed based on the molecular weight and mass of the dried peptide. 
Peptide (0 – 800 µM) were incubated in HDAC8 assay buffer (50 mM HEPES, 137 mM NaCl, 
3.7 mM KCl, pH 7.8) and the reactions were initiated by adding 1 µM (final concentration) 
Zn(II)-HDAC8 and incubated at 30˚C for 0 to 120 minutes.  
 
Peptide deacetylation assay 
Peptides were assayed using coupled assay system which enzymatically links the formation of 
acetate to the fluorogenic molecule NADH[23]. The reactions quenched by addition of 0.37 % 
(v/v, final concentration), flash frozen, and stored at -80˚C. Upon thawing, the reactions were 
neutralized by addition of 0.6% (w/v, final concentration) NaHCO3 and a coupler mixture (50 
mM HEPES, 400 μM ATP, 10 μM NAD+, 30 μM CoA, 0.07 U/μL citrate synthase, 0.04 U/μL 
malate dehydrogenase, 50 μM acetyl CoA synthetase, 100 mM NaCl, 3 mM KCl, 50 mM MgCl, 
2.5 mM L-malic acid, pH 8) was added at a ratio of 10 µL/65 µL and incubated for 40 minutes at 
room temperature in a 96 well black plate. Then NADH fluorescence (ex. = 340 nm, em. = 460 
nm) was measured. Linear portions of the assay data were fit to a line yielding an initial reaction 
velocity.  
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Fluorescamine assay 
Standard curves using the peptide Ac-KGGAKacW-NH2 (50 – 200 µM in water) and the 
fluorescamine reagent were prepared. The absorbance at 280 nm of these standards were 
measured using the NanoDrop spectrophotometer (Thermo Fisher Scientific) and the 
concentrations were calculated using the extinction coefficient 5690 μM-1 cm-1[36]. For the 
fluorescamine standard curve the Ac-KGGAKacW-NH2 peptide mixed with 0.75 M borate (final 
concentration, pH 9) and then 0.13 mM fluorescamine (final concentration) in a 96 well plate, 
(corning #3686) incubated at room temperature for 10 minutes, and the fluorescence (ex. 340 nm 
em. 460 nm) was measured. The peptide concentrations were calculated utilizing the Ac-
KGGAKacW-NH2 standard curve. 
 
Compound Synthesis 
PCI-34051 is commercially available. BRD3811 was synthesized according to the following 
procedure: A solution of methyl 5-methyl-1H-indole-6-carboxylate (100 mg, 0.529 mmol, 1.0 
equiv), potassium iodide (8.8 mg, 0.053 mmol, 0.1 equiv), and sodium hydride (60 % dispersion, 
23.3 mg, 0.581 mmol, 1.1 equivalents) in DMF (1.6 mL) was stirred at 0 ºC for 1 hour. Next, a 
solution of 1-(chloromethyl)-4-methoxybenzene (124 mg, 0.793 mmol, 1.5 equivalents) in DMF 
(1 mL) was added, and the reaction mixture was heated to 65ºC for 2 hours. The reaction was 
diluted in saturated with Na2CO3(aq) (50 mL) and extracted with EtOAc (3 x 25 mL). The 
combined organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated 
under reduced pressure. The resulting residue was purified by flash chromatography 
(hexanes/EtOAc) to yield methyl 1-(4-methoxybenzyl)-5-methyl-1H-indole-6-carboxylate (99.0 
mg, 0.320 mmol, 61 %). To a solution of methyl 1-(4-methoxybenzyl)-5-methyl-1H-indole-6-
carboxylate (99.0 mg, 0.320 mmol, 1.0 equivalents) and sodium hydroxide (64.0 mg, 1.60 mmol, 
5.0 equivalents) in 1:1 MeOH:THF (1.3 mL) was added 50 % aqueous hydroxylamine (0.628 
mL, 10.2 mmol, 32 equivalents), and the resulting solution was stirred for 7 hours. Upon reaction 
completion, 5 mL of water was added followed by removal of organic solvents under reduced 
pressure. Neutralization of the remaining aqueous solution with 1 M HCl(aq) resulted in the 
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precipitation of product, which was filtered, washed with cold water, and dried under reduced 
pressure to yield BRD3811 (45.0 mg, 0.145 mmol, 45 %) as a white powder in >95 % purity (as 
determined by LCMS). 1H NMR (300 MHz, DMSO-d6): δ 10.72 (br s, 1H), 8.97 (br s, 1H), 7.51 
(d, J = 2.8 Hz, 1H), 7.41 (s, 1H), 7.37 (s, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 
6.40 (d, J = 2.8 Hz, 1H), 5.31 (s, 2H), 3.70 (s, 3H), 2.36 (s, 3H) ppm.  
 
Caliper Assay 
The biochemical determination of HDAC IC50s for compounds was performed as described 
previously.(US Patent Application WO 2013067391) All HDACs were purchased from BPS 
Bioscience. The substrates Broad Substrate A and Broad Substrate B were synthesized in house, 
but can be purchased from PerkinElmer (Product number CLS960006 and CLS960007, 
respectively). All other reagents were purchased from Sigma. Caliper EZ reader II system was 
used to collect all data. Compounds were tested in duplicate in a 12-point dose curve with 3-fold 
serial dilution starting from 33.33 μM. Purified HDACs were incubated with 2 μM 
carboxyfluorescein (FAM)-labeled acetylated or trifluoroacetylated peptide substrate (Broad 
Substrate A and B, respectively) and test compound for 60 min at room temperature, in HDAC 
assay buffer that contained 50 mM HEPES (pH 7.4), 100 mM KCl, 0.01% BSA and 0.001% 
Tween-20. Reactions were terminated by the addition of the known pan HDAC inhibitor LBH-
589 (panobinostat) with a final concentration of 1.5 μM. Substrate and product were separated 
electrophoretically and fluorescence intensity in the substrate and product peaks was determined 
and analyzed by Labchip EZ Reader. The percent inhibition was plotted against the compound 
concentration, and the IC50 values were automatically fitted by Genedata Screener software using 
4-parameter logistic dose response model. 
 
Molecular Docking 
The best pose of compound PCI-34051 in the HDAC8 binding site was determined using the Zn-
HDAC8 structure deposited in the PDB by Vannini et al. (PDBID 2v5w)[11]. Protonation of the 
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structure and formation of side-chain–metal interactions was performed using the Protein 
Preparation Wizard followed by manual correction in the Schrodinger Drug Discovery Suite 
2013-2.( http://www.schrodinger.com/smdd/) Histidines 142 and 143 were protonated at the 
delta nitrogen and histidine 180, which interacts with zinc at the delta position was protonated at 
the epsilon position. The amido lysine residue of the native peptide ligand (L.ALY5) was used as 
the center for the docking grid. The final cubic docking grid had the dimensions 21x21x21Å3 
constructed using Schrodinger Glide 6.0 with default parameters. Glide XP was used to dock 
PCI-34051 and BRD3811 with options to enhance planarity of aromatic groups and post-docking 
minimization[37]. The pose with the highest Glide XP docking score for each is depicted in 
Figure 4.1 using PyMol. PCI-34051 had a Glide XP score of -6.1 and the methyl analog, 
BRD3811, had a score of only -3.5 with significant decreases in the hydrogen bonding and 
Coulombic score contributions and loss of the metal binding reward. Though even the former 
could be considered low in some virtual screening targets, metal binding is difficult to account 
for accurately. In this system it is handled approximately through limited charge interactions and 
a metal reward added to the score. The favorable interaction energy would likely be improved for 
PCI-34051 if metal interaction were correctly predicted. Conversely, the geometry of BRD3811 
does not permit binding with the metal center and the score should be considered exponentially 
worse than PCI-34051.  
 
Cell Culture and Compound Treatment for Proteomics Experiments 
MCF7 cells were grown and expanded from the same frozen vial stock, followed by 
differentially labeling with non-radioactive stable isotopic amino acids by growing in light, 
medium, and heavy SILAC media (See below for recipe), respectively. MCF7 cells grown in 
SILAC medium were plated (2 million cells/plate, 10 mL per plate) into 10-cm tissue culture 
treated plates and incubated 24 hours prior to treatment. For treatment, 10 l of compounds (10 
mM stocks in DMSO) or DMSO vehicle control were added to the plates, and the cells were 
incubated for 24h. Next, the growth medium was aspirated, and the monolayers of cells were 
rinsed twice with cold-PBS. Cells were detached using a cell scrapper and collected with 1 ml of 
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cold PBS. Cell pellets were harvested by centrifugation at 1,500 rpm for 1 min and flash frozen 
in liquid nitrogen. All pellets were stored in -80 ºC freezer prior to lysis. 
SILAC media 
450 mL DMEM 
50 mL FBS (Sigma, F-0392) 
5 mL 100x Pen/Strep/Glutamine (Gibco 10378) 
3.9 mL 45% Glucose solution (Sigma, G8769) 
500 L Methionine (stock 30g/L, final 30mg/L) 
500 L Proline (stock 20g/L, final 20mg/L) 
500 L Lysine (stock 146g/L, final 146mg/L) 
500 L Arginine (stock 84g/L, final 84mg/L) 
 
Proteomics 
SILAC-labeled MCF-7 cells were lysed in ice-cold 8 M urea, 50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 2 ug/ml aprotinin (Sigma-Aldrich), 10 ug/ml leupeptin (Roche Applied 
Science), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 5 mM sodium butyrate (Sigma-
Aldrich). Lysates were centrifuged at 20,000 x g for 10 min at 4 ºC to remove insoluble material. 
Protein concentrations were measured using a bicincohoninic acid (BCA) protein assay. For each 
replicate, 10 mg of protein per SILAC state was used for acetylation profiling. Proteins were 
reduced with 5 mM dithiothreitol for 45 min at room temperature. After reduction, proteins were 
alkylated using 10 mM iodoacetamide for 30 min at room temperature in the dark. Samples were 
diluted to 2 M urea and digested overnight with sequencing grade trypsin (Promega) using an 
enzyme to substrate ratio of 1:50 (w/w). Trifluoroacetic acid (TFA) was used to quench digests. 
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Peptide samples were desalted on tC18 SepPak SPE cartridges (Waters) exactly as previously 
described[38]. Peptides were fractionated by basic pH reversed-phase (bRP) chromatography 
exactly as previously described[38]. Briefly, a Zorbax 300 Extend-C18 column (9.4 × 250 mm, 
300 Å, 5 µm; Agilent) was used for the separation. Peptides were reconstituted in 5 mM 
ammonium formate (pH 10.0)/2 % (vol/vol) acetonitrile (bRP Buffer A). Using the exact method 
parameters previously described[38], a total of 96 2 ml fractions were collected across the bRP 
separation. For acetylated (Kac) peptide analysis, each fraction was combined in a non-
contiguous manner such that every eighth fraction was combined (final fraction 1 = 
1,9,17,25,33,41,49,57,65; final fraction 2 = 2,10,18,26,34,42,50,58,66; …) to create 8 final 
fractions. Pooled fractions were dried using vacuum centrifugation. An acetyl lysine antibody 
(Immunchem) was used for enrichment of Kac peptides from fractionated samples. Dried 
samples were reconstituted in 1.5 ml of 50 mM MOPS (pH 7.2), 10 mM sodium phosphate and 
50 mM NaCl (IP buffer). Peptides were incubated with 120 ug of anti-Kac antibody beads for 1 
hour at 4 ºC with end-over-end rotation. Antibody beads were washed twice with 1.5 ml of ice-
cold IP buffer followed by three washes with ice-cold PBS. Kac peptides were eluted from the 
antibody with 2 x 50 µL of 0.15 % TFA. Enriched peptides were desalted using StageTips 
exactly as previously described[38]. Samples were analyzed by nanoflow-UPLC-HCD-MS/MS 
using an Easy-nLC 1000 system (Proxeon) coupled online to a Q Exactive mass spectrometer 
(Thermo Fisher Scientific). Samples were reconstituted in 9 µL of 3 % MeCN/0.1 % FA and 4 
µL was injected for analysis. Samples were injected on at a flow rate of 500 nl/min onto a 
PicoFrit column (360 µm (OD) × 75 µm (ID)), 10 µm ID tip, 50 cm length (New Objective) self-
packed with 24 cm of ReproSil-Pur 120 Å, 1.9 µm C18-AQ beads and heated to 50 ºC using a 
column heater (Pheonix S&T). The gradient and flow rate settings used were as previously 
described[38]. The Q Exactive was operated by acquiring an MS1 scan (R = 70,000) followed by 
MS/MS scans on the 12 most abundant ions. For MS acquisition, ion targets of 3 x 106 and 5 x 
104 ions were used for MS1 and MS2 scans, respectively. A maximum ion time of 20 ms and 
120 ms was used for MS1 and MS2 scans, respectively. The HCD collision energy was set to 25. 
The dynamic exclusion time was set to 20 s and the peptide match and isotope exclusion 
functions were enabled. The MaxQuant software package (version 1.3.0.5) was used for 
identification and quantification of MS data. For searching, the enzyme specificity was set to 
trypsin, the maximum number of missed cleavages was set to 2, the precursor mass tolerance 
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was set to 20 ppm for the first search, and the tolerance was set to 6 ppm for the main search. 
Carbamidomethylation of cysteines was searched as a fixed modification and oxidation of 
methionines, N-terminal acetylation of proteins, acetylation of lysines were searched as a 
variable modifications. The minimum peptide length was set to 6, and false discovery rate for 
peptide, protein, and site identification was set to 1%. 
 
Cell Culture and Compound Treatment for Gene Expression Experiments 
MCF7 cells (ATCC, #HTB-22) were cultured in DMEM medium (Gibco, #11995) containing 
10% fetal bovine serum (Sigma, F4135) and 1x Pen Strep Glutamine (Gibco, #10378). Cells 
were plated into 384-well tissue culture treated plates (Corning, #3707) using a Multidrop Combi 
(Thermo, # 5840300) at 2,000 cells per well. Cells were incubated for 24 hours at 37°C in a 
humidified incubator containing 5 % CO2 before treatment. 
Prior to treatment, 10 mM DMSO stock solutions of compounds were diluted to multiple doses 
in DMSO and arrayed into a 384-well plate (Abgene #AB-1056). These 1,000x stock solutions 
were first diluted (100-fold) in culture medium, and then the diluted compounds were transferred 
to the cell culture plates using CyBi-well vario 384-well tips (another 10-fold dilution). 
Ultimately, all compounds were diluted 1,000-fold to their desired serial concentrations with a 
final DMSO concentration of 0.1%. Treated cells were incubated for 24 hours prior to lysis. 
Cells were lysed by partial removal of the culture media (15 l remaining) followed by the 
addition of TCL lysis buffer (Qiagen #1031576) using a liquid handling system. Cell lysate 
plates were sealed using a plate sealer, kept at room temperature for 30 minutes, and then frozen 
at -80°C until L1000 gene expression profiling was performed. Detailed cell culture and 
treatment protocols for L1000 can be found at http://lincscloud.org. 
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Gene Expression 
This study utilized L1000, a high-throughput, bead-based gene expression assay in which mRNA 
is extracted from cultured human cells treated with various chemical or genomic perturbagens 
(small molecules, gene knockdowns, or gene over-expression constructs) as previously 
described[39]. This mRNA is reverse-transcribed into first-strand cDNA. Gene specific probes 
containing barcodes and universal primer sites are annealed to the first strand cDNA. The probes 
are ligated to form a template for PCR. The template is PCR amplified with biotinylated-
universal primers. The end products are biotinylated, fixed length, barcoded amplicons. The 
amplicons can then be mixed with Luminex beads that contain complementary barcodes to those 
encoded in each of the 1000 amplified landmark genes. These 1000 landmark genes were chosen 
as a reduced representation of the transcriptome and account for the majority of expression 
variation across many cellular contexts (Subramanian, et al., manuscript in preparation). These 
beads are then stained with fluorescent streptavidin-phycoerythrin (SAPE) and detected in 384-
well plate format on a Luminex FlexMap flow cytometry-based scanner. The resulting readout is 
a measure of mean fluorescent intensity (MFI) for each landmark gene. The raw expression data 
are log2-scaled, quantile normalized, and z-scored, such that a differential expression value is 
achieved for each gene in each well. In the standard L1000 protocol, each well corresponds to a 
different perturbagen and these differential expression values are collapsed across replicate wells 
to yield a differential expression signature for each perturbagen (Subramanian, et al., manuscript 
in preparation). The signatures of different perturbagens can then be compared to identify those 
that result in similar or dissimilar transcriptional responses as previously described[40, 41]. 
 
CMap Query Integration Analysis.  
A meta-analysis of CMap query results was performed (i.e., lists of perturbations ordered by 
similarity to an input gene expression signature) using a novel algorithm that is currently under 
development (Subramanian, et al., manuscript in preparation). Briefly, we took a set of signature-
level connections and integrated them to yield a set of perturbagen-level connections ranked by 
consistent connectivity across cell lines within a given perturbation type. The summarization 
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algorithm works as follows: A query result is first grouped by cell line and perturbagen type 
(small molecule, consensus gene knockdown, or overexpression). The connectivity scores are 
then normalized by dividing by the signed mean score of each group. The scores are converted to 
percentile ranks within each group. For each unique perturbagen, an integrated score is computed 
as the weighted enrichment score of the best N (by default 4) connected cell types[42]. In 
addition the mean rankpoint for the best N cell types is reported. The output is a table of 
integrated scores and rankpoints for each unique perturbagen id. We currently require 
connections to exist in at least 4 cell lines before integrating. 
 
Western Blotting  
MCF7 cells were treated with compounds for 48 h, at which time, lysates were collected using 
RIPA buffer with added protease (Roche) and phosphatase (Roche) inhibitors. Electrophoresis 
was performed using NuPage 4-12 % Bis-Tris gels (Invitrogen). Proteins were transferred to a 
nitrocellulose membrane and probed using antibodies for p21 (Cell Signaling) and GAPDH (Cell 
Signalling). Chemiluminescence was induced by subsequent incubation with HRP-linked 
secondary antibodies (GE Healthcare UK Ltd.) and treatment of the membrane with the 
appropriate ECL solutions (Thermo Scientific). Visualization was accomplished using a 
ChemiDoc MP System (Bio-Rad), and the raw data files were converted to jpegs using ImageJ 
(NIH). 
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Chapter 5  
Acetylated protein substrates have enhanced reactivity with HDAC8 compared to peptide 
substrates 
 
Introduction 
Histone deacetylases (HDACs) are a group of 18 proteins which catalyze the removal of the 
acetyl moiety from previously modified acetyl lysine residues in proteins[1, 2]. These 
acetylation/deacetylation events alter protein properties[3] and regulate downstream cellular 
events[4, 5]. Regulation of acetylation is important for effective cellular signaling and cellular 
homeostasis. Aberrant acetylation can cause the cell to fail to perform critical tasks resulting in 
diseases ranging from neurological disorders[6, 7] to cancer[8, 9]. As each HDAC is theorized to 
have distinct substrates, identifying the specific substrate set for each HDAC isozyme may lead 
to a better understanding of the role of HDACs in disease prognosis and lead to better treatments 
of these diseases. 
There are many difficulties in determining HDAC-substrate pairs. One complication is that 
multiple HDACs may catalyze deacetylation of the same substrate. As a result, when one 
deacetylase is knocked out or inhibited, another HDAC isozyme may restore deacetylation of a 
target protein. This overlap in specificity has largely prevented genetic knockdowns from 
successfully identifying HDAC substrate sets. Furthermore, interpreting genetic studies have 
been difficult as it is frequently unclear whether phenotypes represent a direct interaction 
between HDAC and a substrate or a downstream effect caused by perturbation of acetylation of 
another HDAC substrate. Another difficulty is the likelihood that HDAC-substrate interactions 
are weak and short lived in contrast with higher affinity protein binding partners that frequently 
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form complexes with HDACs. Therefore is it difficult to differentiate between substrates and 
binding partners in pulldown experiments. Due to challenging and frequently unperformed 
experiments, this lack of differentiation has complicated analysis even after a putative substrate 
is identified. To mitigate these difficulties, the HDAC field has sought to identify sequence 
motifs that define each isozyme’s substrate specificity[10-13]. To date, the vast majority of 
studies have utilized short peptides to determine HDAC recognition motifs. However, the 
validity of mimicking the recognition of proteins using peptides has not yet been established. 
The role of long range interactions and secondary structural elements is still undetermined. 
While a few putative HDAC8 substrates have been identified such as ERRα[14] and SMC3[15], 
the protein substrate set for HDAC8 is currently unclear. Proteomics studies of HDAC8 have 
identified tens of substrates/binding partners[14-21]. Of the putative HDAC8 substrates, many 
are difficult to purify, preventing efforts to assay reactivity of HDAC8 with these proteins in 
vitro. Further adding to these challenges are the difficulties of isolating or preparing singly 
acetylated proteins for kinetic studies. As a result, previous studies of HDAC8 selectivity have 
analyzed reactivity with non-specifically acetylated substrates. Kinetics using these substrates 
provide little information about substrate preference as these protein contain multiple acetylation 
sites which may each be deacetylated with different rates. Furthermore, these analyses are further 
complicated by the fact that acetyl lysines in one position may affect the deacetylation rates of 
another acetyl lysine residues.  
Singly acetylated proteins provide an effective starting place to investigate HDAC8 preferences. 
HDAC8 is located both in the cytosol and the nucleus[20, 22-24] and has been suggested to 
catalyze the deacetylation of histones. In vivo H3 acetylation levels have been shown to differ 
modestly upon the overexpression of HDAC8 in HEK293 cells[25], and may indicate that 
HDAC8 deacetylation of H3 in specific gene regions is masked by the few global acetylation 
changes to histones[26]. Deacetylation of core histones and peptides representing H3 shows that 
HDAC8 can catalyze the deacetylation of H3 in vitro[27, 28]. Histone H3 therefore presents an 
interesting target to study HDAC substrate specificity using full length proteins. Furthermore, 
this substrate presents a framework for future study of HDAC substrate specificity.  
Many HDACs occur in complexes where the protein binding partners may alter substrate 
recognition[29]. HDAC8 has historically been considered to act in the absence of protein 
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cofactors[10-13, 30-33], and thus analyzing the specificity of HDAC8 mitigates the need to 
purify difficult to isolate complexes. If HDAC8 forms larger protein complexes, determination of 
how these complexes affect substrate selectivity is crucial to understanding HDAC substrate 
recognition. Finally, HDAC8 is the best biochemically characterized HDAC with numerous 
crystal[30, 31, 34-38], kinetic[32, 33], and substrate specificity studies[10-13]. These studies 
provide a good platform in which to parse HDAC substrate recognition. 
In this paper, we present the first detailed kinetic study of HDAC-catalyzed deacetylation of 
singly acetylated full length substrates. Singly acetylated lysine side chains are incorporated into 
H3 using unnatural amino acid incorporation[39, 40]. Using these substrates we directly compare 
reactivity of peptide substrates and acetyl sites in single H3 with the same primary sequences. 
Furthermore, we analyze the effects of histone complexes, such as the octamer, on H3 reactivity. 
From these studies we demonstrate that deacetylation of acetylated full length H3 (tetramer and 
octamer complexes) by HDAC8 is significantly faster than acetylated peptides (>10-fold kcat/KM 
over peptides). In H3, HDAC8 recognizes peptide tetramer substrates largely based on the six 
amino acids proximal to the acetyl lysine. Taken together, these results suggest that long range 
contacts enhance substrate recognition while short range contacts determine substrate specificity 
for H3 substrates.  
 
Materials and Methods 
Reagents 
Adenosine triphosphate (ATP), Coenzyme A, Nicotinamide adenine dinucleotide (NAD+), L-
malic acid, citrate synthase, malate dehydrogenase, and propionic anhydride were purchased 
from Sigma. Peptides were purchased from Peptide2.0. Zinc was purchased as an ICP standard 
from GFS Chemicals and the acetic acid standard was purchased from Ricca Chemical 
Company. Chelex 100 resin was purchased from Bio-Rad. Acetyl lysine was purchased from 
Chem-Impex Chemical International Inc. All other materials were purchased from Fisher and 
were of a purity >95 % unless otherwise noted. 
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HDAC8 expression and purification 
2xYT media supplemented with 50 µg/mL ampicillin was inoculated with E. coli cells (BL21 
(DE3)pHD4-HDAC8-TEV-His6x) and grown overnight at 37˚C. 12.5 mL overnight culture/L of 
expression culture was used to induce modified-autoinduction TB medium (12 g/L tryptone, 24 
g/L yeast extract, 8.3g/L Tris-HCl, 4 g/L lactose, 1 g/L glucose, 10 mL/L glycerol, pH 7.4) 
supplemented with 50 µg/mL ampicillin and 200 μM ZnSO4. The cells were grown overnight at 
30°C and harvested 20 - 24 hours post inoculation (9,000 x g, 10 min, 4ºC). Cells were either 
lysed immediately or frozen as a dry cell pellet at -80ºC. The cell pellet was resuspended in low 
salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 50 mM NaCl, 5 mM KCl, 1 
µg/mL tert-Amyl methyl ether (TAME), 10 µg/mL PMSF, pH 7.8) and passed 2 times through a 
microfluidizer (Microfluidics) to lyse. The lysate was then stirred on ice with 0.1% 
polyethylenimine (pH 7.9) for 10 - 15 minutes and pelleted (39,000 x g, 45 min, 4ºC).The 
supernatant from 20 L of cell culture was loaded onto a 100 mL DEAE Sepharose column, and 
the column was washed with 300 mL low salt DEAE buffer. Protein was eluted with 200 mL 
high salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 500 mM NaCl, 5 mM 
KCl, pH 7.8). The eluate was dialyzed against 50 mM HEPES, 50 mM NaCl, 25 mM imidazole, 
pH 7.8 for 1 hour at 4°C to decrease the salt and ZnSO4. 20 mL of chelating sepharose resin 
charged with NiSO4 and equilibrated with imidazole buffer containing 50 mM HEPES, 100 mM 
NaCl, pH 7.8, 25 mM imidazole was incubated for 20 - 30 minutes stirring on ice with the 
dialyzed protein fraction. The slurry was poured into a column and allowed to drain. The column 
was then washed with a stepwise gradient using buffer supplemented with 50 mM, and 250 mM 
imidazole. The presence of HDAC8 was confirmed by SDS-PAGE analysis. There fractions 
were combined and dialyzed overnight in 25 mM imidazole buffer containing 1 mg His-Tagged 
TEV(S219V) protease per 15mg protein at 4˚C overnight. The protein was applied to a chelating 
sepharose resin charged with NiSO4. The column was washed with 50mM imidazole buffer and 
the flow through was collected and concentrated to <3 mL. The protein was run over a GE 
HiPrep 16/60 Sephacryl S200 HR size exclusion column equilibrated with size exclusion buffer 
(30 mM HEPES, 150 mM NaCl, 1 mM TCEP, pH 8). The fractions of >95 % pure HDAC8 
(confirmed by SDS-PAGE) were combined and concentrated to <0.7 mL. HDAC8 was dialyzed 
against 4 L of metal free chelation buffer (30 mM MOPS, 3 mM KCl, 1 mM EDTA, 1 mM 
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TCEP, pH 7.8) overnight at 4˚C to remove metal ions from the proteins. Then, HDAC8 dialyzed 
against metal free dialysis buffer (30 mM MOPS, 3 mM KCl, 1 mM TCEP, pH 7.8) and 
incubated at 4˚C overnight and run over a PD-10 column (GE) in metal free dialysis buffer. The 
fractions containing HDAC8 were concentrated to >500 μM, flash frozen in 10 µL aliquots, and 
stored at -80˚C. HDAC8 activity was confirmed using the Fluor de Lys assay as described 
previously[32, 41].  
 
HDAC assay 
Assays were performed as previously described[42] with a few modifications. Briefly, depending 
on their solubility, peptides were dissolved in water, 50% acetonitrile, or 10% DMSO. The 
dissolved peptide solutions were chelated by incubation with Chelex resin at 4°C for more than 
three hours. Peptide concentrations were measured by fluorescamine assay or OD280 as 
previously described[42, 43]. Peptides (0-100 µM) were incubated in HDAC8 assay buffer (50 
mM HEPES, 137 mM NaCl, 3.7 mM KCl, pH 7.8) for 10 minutes at 30°C before initiating the 
reactions with the addition of 0.5 µM Zn(II)-HDAC8. Assays were performed at 30°C. The 
reactions were worked up as previously described. Initial rates were fit to the linear portion of 
the time versus product curve. 
  
Histone expression and purification 
H3 histones were expressed and purified as previously described[40] with a few modifications. 
Briefly, Quikchange PCR was utilized to modify the codon representing the Lys9, Lys14, and 
Lys56 sites in histone H3 (PCDF PyLT-1 plasmid) to an amber codon sequence. BL21 (DE3) 
cells were transformed with the mutant or wild type PCDF PyLT-1 and pAcKRS-3 plasmids for 
H3 expression (generous gifts from Jason Chin). To express H2A, H2B, and H4, expression 
plasmids of each histone were used (generous gifts from Geeta Narlikar).[44] BL21(DE3) cells 
transformed with the respective plasmids were grown in LB supplemented with the proper 
antibiotic (kanamycin and streptomycin for H3, or ampicillin for H2A, H2B, and H4) and were 
grown overnight at 37°C. Then the cultures were used to inoculate LB medium supplemented 
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with the proper antibiotic and incubated at 37°C until reaching an OD600 of 0.7. For acetylated 
H3, 20 mM nicotinamide and 10 mM acetyl lysine was added, and 30 minutes later protein 
expression was induced by addition of 0.5 mM IPTG. For expression of the other histones, the 
cells were induced with 0.5 mM IPTG after reaching an OD600 of 0.6. The cultures were 
harvested 3 - 4 hours after induction (9,000 x g, 10 min, 4°C). The cell pellets were stored at -
80°C as a dry pellet. 
Cell pellets were resuspended in Phosphate Buffered Saline (PBS) supplemented with 20 mM 
nicotinamide and lysed using the M110L Microfluidizer (Microfluidics). The lysate was 
centrifuged (39,000 x g, 45 min, 4°C) and the supernatant was discarded. The pellets were 
resuspended in PBS supplemented with Triton X-100 and 20 mM nicotinamide and centrifuged 
(39,000 x g, 45 min, 4°C). In total, the cell pellets were resuspended and centrifuged twice in 
PBS with Triton X-100 and nicotinamide, and twice in PBS with nicotinamide. The pellets were 
then macerated in DMSO and incubated at room temperature for 30 minutes to an hour. After the 
incubation, 6 M guanidinium choloride, 20 mM Tris, and 2 mM dithiothreitol (DTT), pH 8 was 
added to the DMSO mix and incubated with shaking at 37°C for 1 hour. The rest of the protocol 
proceeded as previously described for H3 using two a nickel column, followed y cleavage of the 
His-tag with TEV protease and a second nickel column[40]. For H2A, H2B, and H4, the DMSO 
mix was centrifuged as above and dialyzed against 7 M urea, 100 mM sodium acetate (NaOAc), 
20 mM Tris, 100 mM NaCl, pH 7.5 overnight at 4°C. The dialyzed protein extract was applied to 
an SP sepharose column, the column was washed (7 M urea, 100 mM NaOAc, pH 5.2) and 
protein was eluted stepwise with SP buffer (7 M urea, 100 mM NaOAc, pH 7.5) supplemented 
with 300 mM, 500 mM and 1 M NaCl. The fractions containing H2A, H2B, and H4 (confirmed 
by SDS-PAGE) were collected and dialyzed 2 times overnight against MilliQ water and 2 mM 2-
mercaptoethanol (BME). After dialysis, the histones were lyophilized (Labconco Freezone Plus 
6) and stored at -80°C. Tetramer, octamer, and nucleosome were reconstituted as previously 
described [40, 44]. 
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Protein deacetylation assays 
HDAC8 was reconstituted with 1:1 Zn(II) for 1 hour on ice in 1x HDAC8 assay buffer[32]. 
Histone complexes were incubated in HDAC8 assay buffer (above) for 10 minutes at 30°C 
before initiating reactions by addition of 0 - 15 μM Zn(II)-HDAC8. Reactions were performed at 
30°C. Reactions were quenched by addition of 25% trichloroacetic acid at varying times. The 
samples were incubated for 30 minutes on ice and then centrifuged (16,800 x g, 10 min, 4°C). 
The supernatant was removed and the pellet was washed 2 times with acetone and centrifuged 
(as above) after each wash. The pellet was dried in a SPD1010 SpeedVac System 
(ThermoSavant) and frozen at -80°C. The pellets were resuspended in 2 µL propionic anhydride 
and ammonium hydroxide (NH4OH) and incubated at 51°C for 1 hour. 30 µL of 50 mM 
NH4HCO3 was added to each tube, and the pH of each tube was adjusted to 8 using NH4OH as 
indicated by pH paper. Then 0.2 μg sequence grade trypsin (Promega) was added to each tube 
and incubated overnight at 37°C. 3.5 µL of 10% formic acid was added to each tube, and the 
tubes were centrifuged (16,800 x g, 10 min, 4°C). The supernatant was removed and 
deacetylation was quantified by MS/MS mass spectrometry analysis in the lab of Andrew 
Andrews (Fox Chase Cancer Center) as previously described[45]. The kinetic data were 
analyzed using a single exponential decay: . Variations between days was 
less than ~20 %. 
  
Results 
Numerous studies have sought to evaluate HDAC substrate specificity by measuring activity 
with acetylated peptides[10-13]. Utilizing these peptides to determine substrate specificity is 
predicated on the assumption that HDAC8 uses the same interactions to distinguish peptide 
substrates as it does for full length proteins. To test this assumption we probed three 
deacetylation sites on the putative HDAC8 substrate histone H3. Two biologically relevant sites 
(H3K9ac and H3K14ac) were chosen in proximity to each other on N-terminal histone tail as 
they share an unfolded secondary structure (Figure 5.1) but differ in sequence. These sites test 
the role of sequence in determining HDAC8 specificity. A third site (H3K56ac) was chosen 
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because it is contained within an α-helix in the globular structure of H3 (Figure 5.1). This site 
allows probing of the role of secondary structure and long range protein-protein interactions with 
HDAC8 recognition. Varied concentrations of acetylated peptides containing 7 and 13 amino 
acids (7- and 13-mer peptides) representing the sequence of these three H3 acetylation sites were 
incubated with HDAC8 (Figure 5.2). The rate of deacetylation was measured using an assay that 
couples the formation of NADH to acetate[42]. Acetate product increased linearly up to 20 
minutes. The initial rates for these reactions are linearly dependent on the peptide concentration 
yielding values for kcat/KM, as shown in Table 5.1.  
 
Figure 5.1 Schematic of acetylation sites tested 
Shown is the crystal structure[44] of the H3 (blue) and H4 (yellow) histone dimer. The 
residues 1 to 20 are shown in an extended conformation as they have no discrete structure 
within the crystal structure. Three sites on the histone tetramer (a dimer of the H3/H4 dimers) 
were acetylated using non-natural amino acid incorporation into expressed proteins. The K9 
and K14 sites are present in the histone tail while the K56 site is present in an α-helical section 
within the globular section of the protein.  
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Table 5.1 Catalytic efficiencies of substrates 
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Figure 5.2 Example substrate dependence for the 13-mer H3K9ac peptide 
Of the 7-mer peptides, the H3K56ac peptide demonstrated the highest HDAC8 kcat/KM values 
(78 M-1s-1) followed by the H3K9ac (56 M-1s-1) and H3K14ac sites (8 M-1s-1). Few differences in 
kcat/KM values are observed between the 7- and 13-mer peptides (Table 1.1). The differences in 
catalytic efficiency between the 7- and 13-mer peptides for the H3K9ac and H3K56ac peptides is 
<25 % while the larger H3K14ac peptide increases activity <3-fold. A 17-mer peptide 
representing the H3K9ac site also showed less than a three-fold increase in kcat/KM (120 ± 11 M-
1s-1). These data suggest that the three amino acids in flanking both sides of the acetyl lysine 
largely dictate HDAC8 peptide preference at the H3K9ac site.  
  
Deacetylation of acetylated H3/H4 tetramers 
To probe whether HDAC8-substrate interactions distal from the active site play a role in HDAC8 
substrate recognition, we developed a method to assay full length protein substrates. One major 
challenge in identifying HDAC8 substrates is determining the rates of deacetylation for 
individual acetyl lysine sites, as HDAC substrates may have multiple acetyl lysines. To prepare 
proteins with a single acetyl lysine residue, we used the method developed by Jason Chin’s 
group which incorporates non-natural amino acids into recombinantly expressed proteins[39, 
40]. This method has previously been shown to yield large amounts of acetylated proteins 
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substrate through bacterial expression and can be easily scaled. The acetyl lysine is incorporated 
into expressed proteins at an amber codon site (TAG) using a tRNA-cognate tRNA synthetase 
pair. We incorporated amber codons at the K9, K14, and K56 sites of the histone H3 sequence in 
the PCDF PyLT-1 plasmid[39, 40]. Full length histone H3 with a single acetyl lysine residue 
were subsequently expressed and purified. Q-tof mass spectrometry of modified histone H3 
demonstrated that >95% of purified protein contains a single acetyl lysine (Figure 5.3). To 
stabilize H3, stoichiometric H4 was added to form H3/H4 tetramers and the complex was 
purified by size exclusion chromatography. 
 
 
Figure 5.3 H3 Histones are singly acetylated 
Q-Tof mass spectrometry traces showing unacetylated H3 (top) and singly acetylated H3 
(bottom). These peaks are as expected based on the histone sequence and differ 42 m/z as 
would be expected for a singly acetylation. The location of the acetate moiety was confirmed 
using MS/MS (data not shown). 
 
 
Single turnover kinetics 
To measure activity of HDAC8 with singly acetylated H3, we measured the kinetics under single 
turnover conditions ([HDAC8 ] >> [H3]) in which 0.5 µM acetylated H3/H4 tetramer was 
incubated with 3 – 15 μM HDAC8. The reactions were quenched with acid and the tetramer was 
trypsinized. The fraction of the acetylated peptide from H3 trypsinization was measured by 
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MS/MS mass spectrometry as a function of reaction time. These data were best described by an 
exponential equation (Figure 5.4a, b) yielding kobs values. The kobs values are linearly dependent 
on the HDAC8 concentration. Assuming rapid equilibration of the HDAC8-H3/H4 complex, a fit 
of the Michaelis-Menten equation to the data yielded kmax/K1/2 values equal to >45,000 M-1s-1, 
2500 ± 71 M-1s-1, and 4000 ± 570 M-1s-1 for the H3K9ac, H3K14ac, and H3K56ac tetramers, 
respectively. Each of these catalytic efficiencies is 10- to 100-fold faster than the corresponding 
peptide kcat/KM values, which suggests that interactions outside of the 13-mer peptide sequence 
are important for HDAC8 substrate recognition, assuming a comparable rate-limiting step (see 
discussion section). This increase in catalytic efficiency is mainly due to a decrease in K1/2 
relative to KM, suggesting enhanced binding of the protein substrates compared to the peptide. 
Because the deacetylation is likely the rate limiting step, K1/2 and KM are approximately equal to 
KD. While H3 peptides have KM values higher than 100 µM, (data not shown) the H3K9ac/H4 
tetramer has a K1/2 value <0.5 µM and the H3K14ac/H4 tetramer has a K1/2 ~20 µM. These 
differences suggest that longer range interactions enhance reactivity of HDAC8 with full length 
substrate.  
Finally, the 2-10 fold enhanced reactivity of HDAC8 with the H3K56ac peptide compared to the 
H3K9ac peptide is not maintained in the singly acetylated H3K9ac/H4 and H3K56ac/H4 
tetramer, as would be expected if HDAC8 utilized sequence as the primary method of 
recognizing substrates. The ratio of reactivity of HDAC8 catalyzed deacetylation of acetylated 
protein vs acetylated peptide substrates various from >800 for the H3K9ac site to ~300 for the 
H3K14ac site to ~50 for the H3K56ac site. The increased reactivity for histone tail residues is 
consistent with enhanced accessibility of the H3K9ac/H4 compared to the H3K56ac/H4 site 
within the H3/H4 tetramer. In this case, the sequence of the H3K14ac/H4 site could also be s 
poor substrate site for deacetylation by HDAC8. Another explanation of decreased HDC8 
reactivity with the H3K56/H4 site is that the binding surface of an α-helix is better represented 
by the …-3, 0, and +3… residues and therefore a linear peptide may not represent these amino 
acids well.  
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Figure 5.4 Sample single turnover deacetylation data 
A) Sample data from a tetramer deacetylation with 7 µM HDAC8 and 0.5 µM H3K9ac/H4 
tetramer (1 µM acetyl lysine). Data is best described by a single exponential fit. The residuals 
(below) from this single exponential fit show that a single exponential is within agreement of 
the data. B) H3K9ac/H4 kobs vs [HDAC8] curve. Three separate fits are present showing 
different potential K1/2 values: K1/2 = 0.25 (red); K1/2 = 0.5 (black); K1/2 = 1 (blue); K1/2 = 2 
(green). Each fit has the respective kmax/K1/2 value: 86,000 M-1s-1; 45,000 M-1s-1; 24,000 M-1s-1; 
and 13,000 M-1s-1 respectively. The fits below indicate that the K1/2 is less than 0.5 µM. C) 
H3K14ac/H4 kobs vs [HDAC8] curve. The exponential fit indicates that the kmax/K1/2 is 2,500 
M-1s-1. D) H3K56ac/H4 kobs vs [HDAC8] curve. The exponential fit indicates that the kmax/K1/2 
is 4,000 M-1s-1. 
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Deacetylation of histone octamers  
To determine whether the activity of HDAC8 is altered by the formation of larger histone 
complexes, we measured rates of deacetylation with octameric singly acetylated H3K14ac and 
compared this to HDAC8 deacetylation of tetramers. Histone octamers were reconstituted with 
two copies of each core histone (H2A, H2B, H3K14ac, and H4). The deacetylation rate catalyzed 
by HDAC8 was measured under single turnover conditions using mass spectrometry (as 
described above). The time-dependent decrease in the fraction of acetylated H3 was well 
described by a single exponential (Figure 5.4a). The resulting kobs values vary with HDAC8 
concentrations. A fit using the Michaelis-Menten equation yielded a kmax/K1/2 value of 990 ± 200 
M-1s-1 for the H3K14ac octamer. This catalytic efficiency is decreased 3-fold compared to 
H3K14ac/H4 tetramer site and is ~45-fold faster than the deacetylation of H3K14ac peptides. 
These data suggests that the octamer is recognized very similarly to the tetramer for this site; the 
modest decease in the kmax/K1/2 value likely reflects decreased accessibility for the acetylated 
lysine in the larger complex.  
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Figure 5.5 H3K14ac octamer data 
H2a/H2b/H3K14ac/H4 kobs vs [HDAC8] curve. The fit indicates that the kmax/K1/2 is 990 M-1s-
1. This is within two-fold of the H3K14/H4 tetramer data. 
 
 
Multiple turnover of tetramer 
Catalysis of deacetylation of a singly acetylated H3/H4 tetramers under multiple turnover 
conditions yielded unexpected results. Assays were performed with limiting HDAC8 and excess 
acetylated H3/H4 (0 - 2 μM HDAC8 and 4 μM acetyl lysine substrate). Deacetylation was 
assayed using the previously described mass spectrometric method. Unexpectedly, these 
reactions did not proceed to complete deacetylation of the acetylated H3/H4 tetramers as 
expected from the thermodynamics of the reaction. Incubation of 0.5 µM acetylated H3K9ac 
with 4 µM HDAC8 led to an initial decrease in acetylation that plateaued at 0.59 µM 
deacetylation product. Increasing the concentration of HDAC8 in the reaction led to both an 
increase in the initial rate of deacetylation and an increase in the plateau concentration of 
deacetylation product (Figure 5.6). 
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Figure 5.6 HDAC8 turnovers vs enzyme concentration 
A) Raw data of the time versus substrate concentration. Substrate was kept constant while the 
concentration of HDAC8 was varied.  Data was fit to an exponential curve. B) Plateaus from 
data in 4A graphed versus HDAC8 concentration. The slope of this curve indicates that 1.2 ± 
0.069 molecules of acetate are turned over per molecule of HDAC8. Fits were determined by a 
single reaction and errors were calculated based on the differences between the fit and the data. 
 
 
The dependence of the initial rate on HDAC8 concentration is as expected for multiple turnover 
reactions ( ). However the dependence of the apparent end point on 
the HDAC8 concentration is unexpected. A comparison of the end points to the HDCA8 
concentration indicates that ~1 mol product/mol HDAC8 was obtained in these reactions (Figure 
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5.5b; slope = 1.2 ± 0.069) before the reaction rate plateaued. One mechanism consistent with 
these data is that HDAC8 binds to acetylated H3/H4 substrate, catalyzes deacetylation and then 
product dissociation is very slow, leading to the observed biphasic kinetics. Alternatively, 
HDAC8 may dissociate after a deacetylation reaction but revert to a non-catalytically active form 
of the enzyme. Finally, the deacetylated H3/H4 tetramer may bind the HDAC8 with higher 
affinity than the substrate and inhibit further turnover.  
To address the model of product inhibition, 0 – 5 μM non-acetylated tetramer (product) was 
mixed with 2 µM H3K9ac/H4 tetramer and 1 μM HDAC8 was added to initiate the reaction. No 
inhibition of deacetylation was observed (Figure 5.7). Preincubation of HDAC8 and the product 
at 30ºC or on ice for > 1 hour prior to the reaction also did not lead to inhibition of HDAC8 
catalyzed deacetylation (results not shown). These data rule out the possibility that the H3/H4 
product severely inhibits HDAC8. Therefore these data suggest that HDAC8 binds to substrate 
proteins, and catalyzes deacetylation. The reaction then stops at this point because HDAC8 is 
kinetically trapped to the product ceasing further deacetylations (Figure 5.8). Alternatively, 
HDAC8 may dissociate in a non-catalytically active enzyme form.  
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Figure 5.7 No product inhibition measured 
4 µM H3K9ac/H4, 1.5 µM HDAC8, and 0 – 5 µM H3/H4 (unacetylated) were incubated 
together at 30ºC and the concentration of deacetylated tetramer was measured after 10 minutes 
of reaction.  No product inhibition is measured for these reactions. 
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Figure 5.8 Schematic of inhibition mechanism 
There are three potential inhibition mechanisms: 1) Dissociation from the HDAC·tetramer 
complex is slow; 2) Dissociation of the HDAC·tetramer complex is fast but HDAC8 comes off 
in a catalytically inactive form and isomerization into a catalytically active form is slow; 3) the 
deacetylated histone acts as an HDAC8 inhibitor. Data showing that unacetylated tetramer does 
not inhibit HDAC8 suggests that the 3rd mechanism is not correct.  
 
Discussion 
Determining HDAC substrate recognition is important to understanding HDAC’s impact on 
cellular regulation. Thus far HDAC recognition of protein substrates has been largely 
unexplored. For HDACs, the vast majority of studies have utilized small peptide substrates 
which typically span less than a 8 Å x 20 Å section of a ~45 Å x 45 Å binding surface[35]. This 
leaves a large number of potential protein recognition hotspots and negative interactions sites 
unexplored. The potential for many more interactions between HDAC8 and substrates exists 
within this larger binding surface. With a peptide, a single interaction of 0.5 - 2 kcal/mol can 
alter the catalytic efficiency 50-fold[42]. With a larger substrate, there are many more potential 
interaction sites, which can easily overcome the 2 kcal/mol of energy from local interactions. 
There is also precedence in the literature for HDAC8 utilization of interactions distal of the 
active site. A KRHR motif (present in the H4 histone) upstream of the acetyl lysine site, has been 
shown to increase HDAC8 catalyzed deacetylation rates of peptide substrates[12]. We therefore 
probed activity with acetylated protein substrates to determine whether longer range interactions 
form in additional recognition motifs for HDAC8.  
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Optimally, the kcat/KM value of the proteins would be compared directly to the kcat/ KM values of 
the peptides. Due to burst kinetics measured for the multiple turnover of protein substrates, we 
instead measured single turnover kinetics. Comparisons between the single turnover kinetics 
(kmax/K1/2) of the H3/H4 tetramer and the multiple turnover of the peptides is possible due to the 
likelihood that product release is not rate limiting for the peptide substrates. Experimental results 
show that trifluoroacetate peptide substrates are deacetylated with faster chemistry (kcat) 
paralleling the higher chemical reactivity and suggests that product release is not rate 
limiting[28]. kcat/KM values significantly slower than diffusion control (105 M-1s-1 vs 100-105 M-
1s-1) suggest that binding is the rate limiting step, and is further consistent with product release as 
the non-rate limiting step. The kmax/K1/2 value of the protein substrates can be compared to the 
kcat/KM values of the peptides. 
Initial experiments were performed using peptides substrates for comparison with the acetylated 
full length acetylated proteins. Previous studies using peptides have shown that HDAC8 has a 
preference for aromatic amino acids in the position on the C-terminal side of the acetyl lysine 
(+1 position)[10, 11]. Based on this metric alone, the peptides representing the H3 histone are 
not predicted to be efficient HDAC8 substrates. As expected, these peptides were experimentally 
not efficient substrates with catalytic efficiencies ranging from poor (100 M-1s-1) to mediocre (102 
M-1s-1) (Table 2.1). The interactions between 7-mer peptides occur within a ~10Å radius of the 
active site and resulted in ~0.5 kcal/mol (assuming the entropy change is minimal)1. The 
acetylated H3/H4 tetramers, which also lack an aromatic amino acid in the +1 position, were 
deacetylated 2 - 45 times more rapidly than the corresponding peptides. These results suggests 
that interactions present in the tetramer but absent from the peptides enhance HDAC8 
recognition of protein substrates. The catalytic efficiency of the acetylated H3/H4 tetramer was 
increased by 3-6 kcal/mol, lowering the activation energy1 suggesting that more significant and 
longer range interactions are responsible for HDAC8’s recognition of proteins. The surprisingly 
large kmax/K1/2 values for the H3K9ac/H4 tetramer may be due to either a fairly strong interaction 
or an abundance of weak interactions. Additionally, the lowered reactivity of the H3K56ac 
substrates compared to the local and distal sequences as has been previously described[12] or 
may reflect a preference for acetyl lysines close to the C-terminus and/or enhanced accessibility. 
                                                 
1 Δ Δ H ~ Δ Δ G = RT*ln((kcat/kM1)/ (kcat/kM2)) 
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This second hypothesis is bolstered due to the lack of major differences observed for peptide 
substrates as they are all close to the termini of the substrate. Furthermore, histone octamers were 
deacetylated with similar catalytic efficiencies to the tetrameric substrates suggesting that 
interactions with the tetramer are sufficient to explain HDAC8 substrate interactions. 
In many crystal structures, HDAC8 dimerizes at the substrate binding interface as part of the 
fundamental crystal unit. These structures may provide information about HDAC8 substrate 
recognition from the interactions between the two HDAC8 proteins. The HDAC8 substrate 
binding interface is a flexible 45 Å x 45 Å surface that has the potential to foster dozens of 
interactions. Crystal structures show van der Waals and hydrogen bonds between the HDAC8 
dimers. The 3-6 kcal/mol difference measured for the peptides and tetramer associations could be 
due to 10 Wan der Waals interactions or 6 hydrogen bonds, which are present in the diametric 
crystal structures. Also present among the interactions observed in the dimeric HDAC8 structure 
are repulsive interactions such as repulsive charge-charge interactions. As a result, attractive and 
repulsive interactions may work in concert to determine the HDAC8 substrate specificity. These 
additional interaction observed between these two HDAC8 subunits may explain the differences 
observed between the peptide and full length protein catalytic efficiencies.  
Multiple turnover experiments with histone tetramer, showed that HDAC8 activity decreased 
after one cycle of deacetylation. These data best suggest the formation of a slowly reacting 
intermediate after the formation of the E·H3/H4·acetate complex. As HDAC8 is not inhibited by 
unacetylated tetramer, it suggests that HDAC8 is regulated by one of two mechanisms (Figure 
5.8): Either dissociation of the products from the HDAC8 product complex is slow or HDAC8 
forms an alternative inactive confirmation after product formation. Further investigation of this 
phenomenon is necessary to determine whether this single turnover is a regulatory mechanism 
for HDACs in vivo, as this may prove to be a novel regulatory mechanism for HDAC8. 
In this chapter I showed that HDAC8 catalyzes deacetylation of protein substrates at a rate 
constant >10-fold faster than peptide substrates. This difference in catalytic efficiency likely 
represents HDAC8-protein interactions which are absent in HDAC8-peptide binding, and likely 
affects binding. Furthermore, we have shown that slow product release or conformational change 
in HDAC8 may regulate multiple turnover reactions. These phenomena need further 
investigation and set the precedence for establishing initial parameters for investigation of 
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HDAC8 protein substrate specificity. In the future, different substrates and/or other HDAC 
complexes will be necessary to further define HDAC substrate specificity. 
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Chapter 6  
Conclusions 
 
To date, work determining HDAC substrate specificity has been predicated on a number of 
assumptions including: 1) Full length protein substrates are deacetylated with the same 
specificity as peptides sharing the same sequence. 2) The two amino acids flanking the acetyl 
lysine are important to HDAC specificity. 3) Methylcoumarin moieties do not alter peptide 
specificity. These assumptions have allowed researchers to simplify complex HDAC substrate 
specificity studies. Yet, these studies have failed to yield significant insights into biologically 
relevant substrates. As a result, the focus of my thesis has been to evaluate the validity of these 
assumptions. In my final chapter, I theorize how I would continue to move forward addressing 
the protein substrates and biological function of HDACs. 
 
Differentiating substrates from binding partners and downstream effectors 
One major issue plaguing the HDAC field is determining whether a protein associated with 
HDAC or affected by perturbation of HDAC activity is a substrate, binding partner, or 
downstream target. Assays for parsing HDAC interactions have utilized a series of techniques 
such as association studies (2-hybrid[1] and pull downs[1-3]), functional assays (knockdowns 
and overexpression[4-6]), and motif identification studies[7-9].  While these methods have 
produced an array of proteins (Chapter 1) they have yet to identify (on a large scale) the 
relationship between HDAC and these proteins.  As a result, there are likely many misidentified 
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substrates and binding partners of HDAC8.  In my research, (Chapter 4) it is unclear whether the 
acetylated proteins identified by mass spectrometry after inhibition of HDAC8 are direct 
substrates of HDAC8 or downstream targets affected by HDAC8 inhibition.  As a result, these 
proteins cannot be positively identified as substrates.   
In another example from my thesis, I have described data demonstrating that HDAC8 catalyzes 
deacetylation of H3 histones which suggests that H3 may be an in vivo substrate of HDAC8 
(Chapter 5). This result needs to be validated by in vivo.  Experiments show that H3 acetylation 
levels differ modestly upon HDAC8 overexpression (add ref). These results can be juxtaposed to 
results showing that H4 acetylation levels are significantly perturbed upon overexpression of 
HDAC8[5]. These data suggest that HDAC8 reacts with H4 more efficiently than H3 in vivo. 
However there are no data directly confirming this hypothesis. An alternative explanation, 
proposed in Chapter 5, is that HDAC8 may deacetylate both H4 and H3 but that HDAC8 
deacetylates H3 only in specific gene regions, which mutes the observation of acetylation 
changes upon varying the HDAC8 concentration. Another alternative is that acetylation levels of 
both proteins are regulated by other HDAC8 substrates. One way to begin to answer this 
question is to prepare singly acetylated H4 histones and measure the reactivity of HDAC8 with 
the aceylated H3/H4 tetramer using the methods described in Chapter 5. We predict that HDAC8 
would deacetylate H4 at least an order of magnitude faster than H3, if it is a better in vivo 
substrate. Caveats with this methodology are that the in vitro deacetylation rate may not be the 
only factor affecting HDAC8 activity in vivo and that deacetylation activity is affected by 
multiple post-translational modifications on the histone tails (see Chapter 1).  
There are a large number of proposals as to how HDAC8 selects its substrates, which include 
cofactors that alter molecular recognition and regulation of multiple turnover activity by cellular 
release factors (Chapter 5).  These hypotheses suggest that HDAC8 interacts with and/or affects 
a number of non-substrate proteins. In all, many careful experiments will ultimately be needed to 
identify the HDAC8 biological substrates.  These experiments likely include those performed in 
my thesis.  Other experiments such as the bump-and-hole [10] method or crosslinking 
methods[11-13] may also be helpful in identifying HDAC8 substrates and differentiating them 
from binding partners and proteins affected downstream by HDAC perturbation. In the 
169 
 
meantime, we must be cautious when interpreting our results as changes in phenotypes due to 
HDAC8 alterations may occur as a result of indirect HDAC effects on those proteins.  
 
Identifying the local HDAC-substrate contacts using peptides 
Another issue affecting the HDAC field has been the use of peptide substrates containing a 
variety of N- and C- terminal moieties. These peptides have been used to make conclusions 
about substrate specificity, though it is unclear how accurately these peptides report on the 
recognition of full length proteins[7-9, 14, 15].  To date, these studies have been largely 
ineffective in determining the substrate sets of HDACs. 
The Fluor de Lys assay[16] is one of the main activity assays used by the HDAC field, yet its 
ability to accurately profile substrate selectivity remains unclear. This assay utilizes a peptide 
conjugated to a methylcoumarin moiety on the C-terminal side of the acetyl lysine residue 
(Figure 1.2a). Upon deacetylation, this peptide becomes a trypsin substrate which allows the 
methylcoumarin to be cleaved from the peptide. The cleaved and uncleaved methylcoumarin 
moieties fluoresce at different wavelengths which allows deacetylation to be quantified. 
Kinetic and substrate specificity studies on peptides containing a methylcoumarin have been 
largely predicated on the assumption that the methylcoumarin moiety does not alter substrate 
selectivity. Studies by the Mrksich lab suggest that this is not the case[8]. These studies show 
that HDAC8 deacetylates a methylcoumarin-conjugated peptide >10-fold faster than the same 
peptide lacking the methylcoumarin[8], and it is unclear whether this alters selectivity. As the 
SAMDI mass spectrometry method used to measure HDAC8 reactivity is semi-quantitative, I 
developed a coupled assay to measure HDAC8 catalyzed deacetylation of unlabeled peptides 
(Chapter 2). Using the coupled assay, I was able to show that the observations made by the 
Mrksich group were correct, though the quantitative changes were previously overestimated. 
Only a ~2-fold change was observed in catalytic efficiencies between peptides with a 
methylcoumarin and amide C-terminus, although larger differences were observed between other 
moieties (Chapter 2). For instance, substitution of a carboxylate moiety for the methylcoumarin 
at the C-terminus decreases the value of kcat/KM by >40-fold. This >40-fold change corresponds 
170 
 
to ~2.2 kcal/mol and shows that a few interactions between HDAC8 and a peptide substrate can 
drastically alter substrate specificity.  While these results could be peptide specific, they suggest 
that HDAC8 is very sensitive to changes in substrate sequence. However, these C-terminal 
elements do not exist in a full length protein and likely do not play an important role in HDAC8 
selectivity in vivo. Therefore standardization of the peptide termini is important for using 
peptides to dissect HDAC substrate specificity. Interestingly, peptide length (7 to 15 amino 
acids) barely altered substrate selectivity (Chapter 5). Taken together these results suggest that 
HDAC8 recognizes specific positions in the peptide sequence, particularly the 2 amino acids 
flanking both sides of the acetyl-lysine moiety. This phenomenon has been previously alluded to 
but has not yet swayed the field to standardize substrate length and termini[8, 15].  
Finally, data performed in collaboration with Ed Holson’s lab (Chapter 4) suggests that HDAC8 
protein substrates may yield sequences that are good peptide substrates. The Holson lab utilized 
a unique mass spectrometry approach to identify possible in vivo HDAC8 protein substrates. 
Peptides representing the protein substrates identified by the mass spectrometry method were 
assayed. Two of the peptides identified by this method (ARAD1A and CSRP2BP) represent two 
of the fastest known HDAC8 peptide substrates. Further studies using computational methods to 
identify efficient peptide substrates in collaboration with Ora Schueler Furman’s lab (Chapter 3), 
will be useful in determining whether the converse is true: that peptides can be used to predict 
HDAC in vivo substrates. Currently, we are in the process of using the algorithm from the 
Schueler-Furman lab, in conjunction with Ed Holson’s mass spectrometry approach, to identify 
in vivo HDAC8 substrates. Validation that efficient peptide substrates identify in vivo substrates 
would be an important step forward for the HDAC field, indicating that these will be an effective 
means to determine HDAC substrate sets. Mass spectrometric experiments performed by Ed 
Holson’s group (Chapter 4) are not sufficiently sensitive to detect the acetylated proteins that the 
Schueler-Furman  algorithm predicts as HDAC8 substrates (Chapter 3). We are therefore 
developing techniques to isolate and test targets identified by the computational approach such as 
protein specific pull downs. 
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Utilizing proteins to identify long range HDAC-substrate interactions 
The putative substrate binding surface of HDAC8 extends tens of angstroms beyond the peptide 
binding site and thus it is reasonable to propose that longer range interactions are involved in 
substrate binding/specificity.  To date there are no studies which have determined detailed 
kinetics on the deacetylation of full length proteins. In my thesis I present the first detailed 
kinetic study of HDAC8-catalyzed deacetylation of protein substrates (Chapter 5) which is an 
important step in determining in vivo HDAC8 substrate preferences. The deacetylation rate 
constants (kcat/KM) catalyzed by HDAC8 for a protein substrate is 1,000-fold larger than the 
corresponding peptide substrate. As a result, these studies strongly suggest that HDAC8 utilizes 
distal interactions to enhance substrate affinity. These data suggests that a new set of long range 
interactions will need to be discovered to completely understand HDAC8 substrate specificity. 
Within a single protein (the H3 histone) kinetic measurements show that location in addition to 
sequence can significantly alter substrate recognition. In the H3 histone for instance, 
deacetylation of the H3K9ac/H4 site as opposed to the H3K14ac/H4 site (only 5 amino acids C-
terminal of the H3K9ac/H4 site) shows a 10-fold change in catalytic efficiency. This is in 
contrast to peptides which show that longer sequences (7- vs 17-mer) do not significantly alter 
substrate specificity. Further experiments using other HDAC substrates (e.g., SMC3, CREB, and 
ARID1A) will be necessary to determine whether the selectivity rates identified for the H3 
histone extend to other protein substrates.  Also understanding how sequence and position play a 
role will be important in understanding how HDACs recognize their substrates.  As a result 
switching replacing the sequences in the histone tails with the best computationally determined 
peptides will further reveal how short range and long range interactions dictate HDAC 
specificity. 
Work within my thesis suggests that for the H3/H4 histone tetramer, HDAC8 binds to the 
globular surface of H3 and then utilizes short range interactions to define whether a specific 
acetylated lysine is a substrate (Chapter 5).  It is interesting to consider that in the case of the 
mass spectrometry approach only a limited number of the identified acetylated proteins 
correspond to good peptide substrates (Chapter 4).  One explanation for these data may simply 
be that acetylation of these proteins may be regulated by downstream effects of HDAC8 activity. 
Alternatively, long range interactions and/or protein cofactors may define substrate specificity 
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for these substrates making the peptides poor substrates. In this case a full length substrate would 
need to be assayed to show that these are in vivo substrates.  In the future, assaying the full 
length proteins identified in Chapter 4 may reveal whether this is the case. 
The results presented in Chapter 5 suggest that evaluation of contacts distal to the peptide 
binding site will be key to determining the in vivo substrate specificity of HDAC8. It is currently 
unclear whether these results obtained for the reactivity of HDAC8 with protein substrates will 
extend to other HDAC isozymes, and it will be interesting to discover whether each HDAC 
utilizes a similar or a unique set of interactions to recognize their substrates. Further analysis of 
HDAC8 with defined acetylated proteins is essential for delineating the molecular recognition of 
these proteins. 
Finally, full length proteins have been integral in revealing a potential novel regulatory 
mechanism for HDAC8. Upon deacetylation of a full length histone, HDAC8 only performed 
one cycle of deacetylation before stopping. Further experiments on other protein substrates will 
be necessary to determine whether this mechanism is utilized in vivo. Should it be used, HDAC8 
regulation may depend on small molecules or complexes as another means of regulation. 
 
Does HDAC8 function in protein complexes 
While HDAC8 has been traditionally considered to act in the absence of other protein 
cofactors[6-9, 14, 16-23], a growing body of work suggests that this is incorrect[2, 3, 24-27]. 
Complexes are important in determining the specificity of other HDACs (e.g. HDAC1, 2, 3), and 
may be important in regulating HDAC8. While there are a number of putative HDAC8 
complexes (Chapter 1) to date, it is unclear whether they are biologically relevant and how they 
alter biological activity. Furthermore, it is not clear whether there is one large HDAC8-protein 
complex or many smaller complexes. These complexes may alter HDAC8 localization (i.e. 
CREB and DEC1), be involved in substrate specificity (like the Sin3b complex is for 
HDAC1[28]), or be involved in another process such as product release (Chapter 5). The analysis 
of the substrate binding partners is an important future research topic. 
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Appendix A 
Kinetics of peptide substrates tested 
Corresponding Protein N-terminus Sequence C-terminus kcat/KM (M-1s-1)
kcat (s-
1) KM 
p53 Ac RHKacKac Methylcoumarin 800 0.9 1100 
H3 Ac TARKacSTG NH2 55 
H3 Ac TKQTARKacSTGGKA NH2 54 
H3 Ac ARTKQTARKacSTGGKAPR NH2 120 
H3 Ac TGGKacAPR NH2 5 
H3 Ac RYQKacSTE NH2 100 
SWI/SNF complex subunit 
SMARCC1 Ac SGKacKGQ COO- 0.66 
Apoptosis-inducing factor 1 Ac IIKacDGE COO- 1.5 
NADH-cytochrome b5 reductase 3 Ac DIKacYPL COO- 7.9 
Transcription factor E2F1 Ac PGKacGVK COO- 3.7 
Signal peptidase complex subunit 2 Ac DDKacYTL COO- 0.67 
Nucleoprotein TPR Ac TQKacQEQ COO- 1.5 
Histone H1.5 Ac VSKacGTL COO- 8.5 
E3 ubiquitin-protein ligase TRIM33 Ac SFKacSDQ COO- 12 
Histone acetyltransferase KAT6A Ac VSKacGPF COO- 61 
Alpha-enolase Ac SGKacYDL COO- 6.6 
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CREB Binding Protein Ac DSKacNAK COO- 5.2 
CREB Binding Protein Ac KKKacNNK COO- 1.7 
Corresponding Protein N-terminus Sequence C-terminus kcat/KM (M-1s-1)
kcat (s-
1) KM 
Histone acetyltransferase KAT6A Ac VGKacSVS COO- <0.6 
Histone acetyltransferase KAT6A Ac DHKacTLY COO- 7.5 
E3 ubiquitin-protein ligase TRIM33 Ac FTKacDHL COO- 3.2 
E3 ubiquitin-protein ligase TRIM33 Ac KGKacTAQ COO- 3.1 
Histone H1.5 Ac GVKacKVA COO- 1 
Histone H1.5 Ac KPKacAAK COO- 4.1 
Histone H1.5 Ac SFKacLNK COO- 0.61 
Nucleoprotein TPR Ac NQKacLTA COO- <0.6 
CAD protein Ac SLKacEFY NH2 78 
DNA mismatch repair protein Msh6 Ac LSKacFLR NH2 880 
Cellular tumor antigen p53 Ac ISKacYDR NH2 85 
60S ribosomal protein L7 Ac RKKacGEP NH2 13 
La-related protein 1 Ac KIKacRLR NH2 7.7 
SMC1A Ac LGKacFRR NH2 50 
AMP deaminase 2 Ac RLKacYSQ NH2 83 
Interferon regulatory factor 2 Ac SGKacYFA NH2 20 
Hematological and neurological 
expressed 1 protein Ac TWKacANF NH2 77 
Allograft inflammatory factor 1 Ac TFKacGVD NH2 14 
Succinate-semialdehyde Ac GGKacAFG NH2 21 
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dehydrogenase, mitochondrial 
Actin-binding protein anillin Ac FVKacAFA NH2 2.8 
 
Corresponding Protein N-terminus Sequence C-terminus kcat/KM (M-1s-1) kcat (s
-1) KM 
Zinc finger protein 318 Ac GIKacPFL NH2 <2
Elongation factor 1-alpha 1 Ac FGKacFSW NH2 4400
E3 SUMO-protein ligase CBX4 Ac SFKacYAW NH2 1200
DNA-dependent protein kinase 
catalytic subunit Ac SGKacYYY NH2 21
Nuclear receptor corepressor 2 Ac SEKacPEK NH2 2.6
SWI/SNF complex subunit 
SMARCC1 Ac KGKacDAE NH2 5.7
RAI1 Ac KLGGKacQRAA NH2 11 ± 1.4 > 0.03 > 3000 
MLL2 Ac SKIQKacQLDQ NH2 32 ± 5.7 > 0.015 > 400 
ZRANB2 Ac TEIGKacTLAEK NH2 4.1 ± 0.30 > 0.018 > 4500 
SRSF5 Ac KLSGKacEING NH2 9.8 ± 1.9 0.018 ± 0.0060
1800 ± 
900
THRAP2 Ac LGDGKacMKS NH2 4.6 ± 0.10 > 0.015 > 3000 
CSRP2BP Ac STPVKacFISR NH2 160 ± 27 0.16 ± 0.040
970 ± 
430
ARAD1A Ac KLISKacFDKL NH2 740 ± 36 1.0 ± 0.07
1400 ± 
150
NCOA3 Ac KRILHKacLLQN NH2 50 ± 5.0 > 0.1 > 1600 
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Appendix B 
Protocols: 
 
Coupled acetate assay stopped 
5x assay buffer 
3 g HEPES (Sigma# H3375) 
2 g NaCl  (Sigma# 71376) 
0.05 g KCl (Sigma# 60128) 
pH 8 using metal free NaOH (Sigma# 306576) 
Final volume 50 mL add ~2 mL of Chelex resin 
  
Solution 1 
0.48 g HEPES (Fisher# BP310) 
0.034 g L-malic acid (Sigma# M1000) 
0.21 g NaCl (Sigma# S7653) 
0.01 g KCl (Sigma# 60128) 
0.4f MgCl (Fisher# BP214) 
pH 8 using NaOH 
Volume adjust to 32 mL 
Steriflip to filter 
 
Solution 2 
36.8 mg ATP (Sigma# A7699) 
4 mg CoA (Sigma# C4282) 
10 mg NAD+ (Sigma# 8285) 
312 µL 5x buffer 
1248 µL H20   
 
Zn(II)-HDAC8 reconstitution (Co2+ and Fe2+ can be substituted in for Zn2+): 
Making 100 µM Zn: 
6.5 µL Zn (1,000 ppm = 15.4 µM) (zinc: GFS Chemicals# 1837; cobalt: GFS Chemicals# 1726) 
200 µL 5x Buffer 
793.5uL H20 
 
Reconstitution of Zn(II)-HDAC8: (HDAC8 is reconstituted at 1:1 metal:HDAC8 at 10 µM) 
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10 μL HDAC8 (657uM in this case) 
131.4 μL 5x buffer 
449.9 μL H20 
65.7 μL Zn (100uM) 
 
 
Acetate Standard Curve: 
Make 100 µM acetate: 
 µL acetate (Ricca Chemical Company# R0091100) 
 µL 5x Buffer 
 µL H20 
 
Making standard curve: 
 
acetate (μM) 
  0 1 2 5 10 20 
5x buffer 200 200 200 200 200 200 
Acetate 
(100uM) 0 10 20 50 100 200 
H20 800 790 780 750 700 600 
Add 60 µL of each standard to a tube containing 2.5 µL 10 % HCl and freeze in liquid nitrogen 
 
Assay: 
Label tubes: 1 for each time point plus one for the reaction tube 
Into each tube (except for the reaction tube) put 2.5 µL 10 % HCl (diluted in water) 
 
Reaction: 
X µL of peptide  
Y µL of 5x buffer (diluted to 1x final in reaction) 
Z µL of H20 (Total-peptide-buffer-HDAC) 
A µL HDAC8 (10 µM) 
(Each assay will use 60 µL per time point plus 30 µL on top of that as a buffer so that you don’t 
run out of solution) 
 
Preincubate tubes at 30ºC before starting reaction (~10 minutes) 
Initiate with metal-HDAC8 
 
To take time points remove ~60uL of reaction and quench into the 10% HCl 
Freeze time points in liquid nitrogen within 20 minutes. 
 
  
Coupled reaction: (calculate how much is necessary: ~10 µL/time point + extra) 
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600uL    Solution 1  
180uL    Solution 2  
12uL    MDH (Sigma# M2634) 
18uL    CS (Sigma# C3260) 
10uL    ACS 
Mix, spin down and incubate at room temperature for at least 25 minutes before use 
 
1) Unthaw all tubes containing 62.5 µL and add 7.5uL of the 6% NaHCO3 (Mallinckrodt# 7412) 
to each tube separately.  (I’ve found that this step is not as well done with a multichannel) 
MAKE SURE TO WEAR EYE PROTECTION DURING THIS STEP. 
 
2) Votrex and centrifuge each tube 
 
3) transfer 60 µL assay and acetate standards from each tube into a 96 well plate that has been 
cleaned using pressurized air 
 
4) Add 10 µL of the coupled reaction mixture to each well using a multichannel pipette 
 
5) Cover the plate (preferably with a lid and foil to protect from light) 
 
6) Incubate plate at room temperature for 45 minutes before reading 
 
7) Read the plate on plate reader at ex = 340nm; em = 460nm 
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Histone deacetylation mass spectrometry assay (short protocol) 
 
5x assay buffer 
3 g HEPES (Sigma# H3375) 
2 g NaCl  (Sigma# 71376) 
0.05 g KCl (Sigma# 60128) 
pH 8 using metal free NaOH (Sigma# 306576) 
Final volume 50 mL add ~2 mL of Chelex resin 
 
Assay: (STO experiment) 
Set up quenches: 
Into each quench tube add 1/3 volume of each single time point tricholoroacetic acid (e.g. 50 µL 
TCA for a 150 µL reaction) 
Reaction 
X µL HDAC8 (HDAC is varied in this reaction) 
Y µL H3/H4 tetramer substrate (~1 x 10-10 mols/reaction needed) 
Z uL 5x Buffer (1x buffer final) 
A uL H20 (volume needed to make ~1 x 10-10 mols the proper concentration) 
For the 0 time point (before adding the HDAC8): Remove 1 time point  
Initiate the reaction with the remaining HDAC8  
Take time points by pipetting them into the quench tubes.  
Workup: 
1) Incubate protein solution on ice for 30 minutes 
2) Centrifuge the samples for 10 minutes at 4ºC.  
3) Remove the supernatant 
4) Rinse the precipitate with 150 µL of -20ºC, spin again, and remove the supernatant 
5) Repeat #4 
6) Speedvac the pellet until dry. 
7) Store the pellets at -80ºC 
 
Propioylation 
8) Add 2uL propionic anhydride and 6uL NH4OH separately to each tube 
9) Incubate tubes at 51ºC for 1 hour 
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Trypsin Digest 
10) Add 30 µL NH4HCO3 and 2 µL NH4OH to each tube 
11) pH each tube to (pH 8) using with 2 µL allocations NH4OH 
12) Once pHed, add 2 µL of .1 mg/mL trypsin to each tube 
13) Incubate tubes at 37ºC overnight 
 
Mass spec analysis 
14) Add 3 µL of 10% formic acid to each tube 
15) Spin tubes for 10 minutes 
16) Transfer supernatant from tubes into autosampler vials 
17) Store vials at 4ºC until read for use 
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Histone deacetylation mass spectrometry assay (long protocol) 
 
 
Workup: 
1) On the day of the assay (after finishing the assay) incubate precipitated protein solution 
on ice for 30 minutes 
2) Centrifuge the samples down 10,000-14,000 rpm (benchtop centrifuge) for 10 minutes at 
4ºC.  
a. Make sure that the tops of the Eppendorf tubes are pointed the same direction 
during centrifugation so that you can keep track of the pellet 
b. After centrifugation the pellets are not always clearly visible 
3) Remove and discard the supernatant from the tubes 
a. 100% does not need to be removed, I usually leave 5-20 µL at the bottom of each 
tube 
b. Be careful not to disturb the pellet 
c. If you do disturb the pellet just be careful in subsequent spins not to remove the 
pellet with the supernatant 
4) Add 150 µL of -20ºC acetone to each tube  
5) Centrifuge the samples down 10,000-14,000 rpm (benchtop centrifuge) for 10 minutes at 
4ºC.  
6) Remove and discard the supernatant from the tubes 
7) Add 150 µL of -20ºC acetone to each tube  
8) Centrifuge the samples down 10,000-14,000 rpm (benchtop centrifuge) for 10 minutes at 
4ºC.  
9) Remove and discard the supernatant from the tubes 
10) Speedvac the pellet ~10 minutes till dry 
11) Store pellet at -80ºC or proceed immediately 
 
Propionylation 
12) Add 2 µL propionic anhydride (Aldrich# 240311) to each tube 
a. Perform this step in the hood! 
b. Do not mix in large quantities with NH4OH! 
c. Use the propionic anhydride to wet the pellet 
13) Add 6 µL NH4OH (Aldrich# 33,881-8) to each tube 
14) Incubate mixture at 51ºC for at least 1 hour 
 
Trypsin Digest 
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15) Add 30uL of 50 mM NH4HCO3 (Sigma# A6141) and 2 µL of NH4OH to each tube then 
vortex and spin down each tube (just a few seconds) 
16) pH each tube to pH ~ 8: 
a. Dip the tip of a P2 pipette into each tube  
i. There is no need to suck up any liquid, just use capillary action to get a 
little 
b. Place the liquid onto pH paper (pHydralk paper 7-11) 
c. If the paper turns green or blue (pH =<8) the tube is the correct pH, set aside 
d. If the paper does not turn green or blue add 2 µL of NH4OH then vortex and spin 
down each tube (just a few seconds).  Repeat as necessary 
17) Once all tubes are the correct add 2 µL of 0.1 mg/mL trypsin (Promega# V5113) to each 
tube  
a. Trypsin should be resuspended in the buffer that comes with the kit 
18) Incubate the tubes at 37ºC overnight 
 
Mass spec analysis  
19) Add 3 µL of 10 % formic acid (Sigma F2004 resuspended in water) into each tube 
20) Spin tubes for 10 minutes at 10,000-14,000 in the bench top centrifuge 
21) Transfer the supernatant into a new tube (vial: Thermoscientific National# C014-1. top: 
Thermoscientific National# C4013-60A. insert: Thermoscientific National# C4012-530) 
a. Make sure not to get much/any of the precipitate 
22) Flick vials until the air bubble at the bottom goes away 
23) Store vials at 4ºC until ready to mass spec 
187 
 
 
Measuring peptide concentration with Fluorescamine 
Create your samples: 
 
1) Dilute of peptide 29 (Ac-KGGAKacW-NH2) (~5 µM initial concentration) in water: 
peptide/water 1 µL/50 µL, 1 µL /100 µL, 1 µL /150 µL, 1 µL /200 µL  
 
2) Dilute desired peptide 1 µL /50 µL, and 1 µL /100 µL 
 
3) Measure the OD280 of the peptide 29 dilutions using the Nanodrop (~2 µL per sample) 
 
4) Measure all peptide concentrations and a water sample using the Fluorescamine assay: 
Into a well of a 96 well plate: 
75uL Buffer (1M borate pH 9) (Sigma# 7901) 
25uL peptide dilution or water sample 
15uL of fluorescamine (Acros# 38183-12-9) (15mM in acetone)  
Mix (~10x up and down) incubate for >10 minutes at room temperature 
Measure fluorescence ex. 340; em. 460 
 
5) Make a standard curve using the ε = 5690 M-1cm-1 for the peptide 29.  This can be directly 
compared to any peptide with one non-acetylated lysine  
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HDAC8 purification 
Expression: 
(expect ~1.5 mg/L protein final) 
Autoinduction TB: (make as much as you need, I typically do a >20 L expression) 
Per 2 liter: 
24g Tryptone 
48g Yeast Extract 
Add 1800mL of H20 and autoclave 
  
Sugar Mix 
13.8g KH2PO4 
62g K2HPO4 
5mL Glycerol 
0.5g Glucose 
2g Lactose 
Adjust to 600uL H20 and sterile filter using a Steritop and Stericup (500mL all will fit) 
  
 
1) Transform HDAC8 Bl21-DE3 cells and plated onto an LB/AMP plate and incubated at 37C 
overnight. (Transform HDAC8 fresh each time!) 
 
2) In the morning inoculate 5mL 2xYT/AMP using 1 colony and shake at ~200rpm at 37C until 
the solution is cloudy (~3-5 hours) 
 
3) Add the 5mL of 2xYT to 100mL of 2xYT/AMP and shake at 37C until cloudy (~2 hrs) 
 
4) Use the culture to inoculate the autoinduction TB 
Into 2L of autoinduction TB the following was added: 
100 µg/mL AMP 
200 µM ZnSO4 
25mL of Culture 
200mL Sugar mix 
  
5) Incubated culture at 30ºC overnight shaking ~170rpm 
 
6) In the morning pellet the culture using the 6 L centrifuge (5,000 rpm, 10 minutes, 4ºC) and 
stored dry at -80ºC or begin the protocol below immediately. 
  
  
Purification: 
Buffers: (filter all buffers except for MF and PD-10 buffers using a .45uM filters HAWP 
filter) 
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DEAE low salt buffer (2 L): 
30mM HEPES 
200uM ZnSO4 
1mM TCEP 
100mM NaCl 
10ug/mL PMSF 
1ug/mL TAME 
pH 7.8  
 
DEAE high salt buffer (1 L): 
30 mM HEPES 
200 µM ZnSO4 
1 mM TCEP 
500 mM NaCl 
10 µg/mL PMSF 
1 µg/mL TAME 
pH 7.8  
 
Low imidazole buffer (1 L): 
30 mM HEPES 
100 mM NaCl 
25 mM Imidazole 
1 mM TCEP 
pH 7.8  
 
High imidazole buffer (1 L): 
30 mM HEPES 
100 mM NaCl 
250 mM Imidazole 
1 mM TCEP 
pH 7.8  
 
Dialysis buffer 1 (4L): 
25 mM HEPES 
1 mM TCEP 
pH 7.8  
  
O/N dialysis buffer 1: 
25 mM HEPES 
100 mM NaCl 
1 mM TCEP 
pH 7.8  
  
Size Exclusion buffer: 
30 mM HEPES 
100 mM NaCl 
190 
 
1 mM TCEP 
pH 7.8  
 
MF dialysis buffer (w/ EDTA) 
30 mM MOPs (Acros Orgnics# 327665000) 
2 mM KCl (Sigma# 603128) 
1 mM TCEP (Goldbio# TCEP25) 
1 mM EDTA (Sigma# E4884) 
pH 7.8 using MF NaOH 
 
MF dialysis buffer w/o EDTA 
30 mM MOPs (Acros Orgnics# 327665000) 
2 mM KCl (Sigma# 60128) 
1 mM TCEP (Goldbio# TCEP25) 
pH = 7.8 using MF NaOH 
 
PD-10 buffer 
25mM HEPES (Sigma# H3375) 
2mM KCl (Sigma# 60128) 
pH = 7.8 using MF NaOH (Sigma# 306576) 
 
 
1) Resuspended cells in ~200mL of DEAE low salt buffer and lysed 2x passes in the 
microfludizer 
 
2) Put cells into a 200mL beaker with a stir bar on ice and stir 
 
3) Add 1% PEI [final] (pH 7.9) relatively slowly (just faster than drop wise) and stirred for 10-15 
minutes 
 
4) Spin the cell lysate at 18,000rpm for 45 minutes in the big floor centrifuge 
  
5) Add the cleared lysate to a 150mL DEAE column equilibrated with 3x volumes of low salt 
buffer 
 
6) Allow the lysate to flow through as fast as it can  
 
7) Add 2x column volumes of Low salt buffer and allowed the buffer to flow through as fast as it 
can by gravity 
 
8) Add 200mL of high salt buffer to the column and allowed to flow through as fast can by 
gravity. (Make sure to collect the elusion!) (There is no need to run a gel in between these steps) 
 
9) Put the elusion into dialysis tubing (Spectra/Por MWCO 6-8,00) and incubate in Dialysis 
buffer 1 for an hour at 4ºC 
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10) Mix the dialyzed elusion with Imidazole ([final] = 25mM) and 20mL Ni resin 
 
11) Allow this to stir on ice for 1 hour 
 
12) Add the slurry to an empty column and allowed to flow through as fast as it can by gravity 
 
13) Wash the resin with 50mL of 25mM imidazole buffer (50mL low imidazole buffer) and 
50mL of 50mM (44 mL Low imidazole buffer 6 mL High imidazole buffer)  
 
14) Elute HDAC8 with 50mL of high imidazole buffer   
 
15) Run a gel on the purification to confirm the location of the protein 
 
16) Add 3 tubes of TEV per 10 L culture to the elution  
 
17) Put the TEV/elusion in dialysis tubing and dialyze O/N dialysis buffer 1 at 4ºC 
 
18) In the morning, applied the dialyzed HDAC8 to clean Ni column and collect the FT 
 
19) Wash the column with 50mL of 50mM imidazole buffer and collect this wash 
 
20) Combine the wash and FT and concentrate in 30mwco filters 3200rpm until the final volume 
< 3mL.   
 
21) Run the protein on the Large Size Hiprep 26/60 Sephacryl S200 column  
 
22) Run a gel on the fractions and pool the fractions with pure HDAC8 
 
23) Concentrate the fractions to ~0.5mL in 30mwco filters at 3200rpm and put the protein into a 
<0.5 mL dialysis cassette and dialyze O/N in MF buffer with EDTA at 4ºC  
 
24) The next day move the cassette to the MF buffer w/o EDTA and inucbate O/N at 4ºC 
 
25) A PD-10 column was run on the HDAC8 using PD-10 buffer and all the fractions containing 
HDAC8 (check with NanoDrop) were concentrated >500uM and flash frozen in 10uL aliquots 
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ACS purification 
Expression: 
(expect ~1.5 mg/L protein final) 
Autoinduction TB: (make as much as you need, I typically do a >20 L expression) 
Per 2 liter: 
24g Tryptone 
48g Yeast Extract 
Add 1800mL of H20 and autoclave 
  
Sugar Mix 
13.8g KH2PO4 
62g K2HPO4 
5mL Glycerol 
0.5g Glucose 
2g Lactose 
Adjust to 600uL H20 and sterile filter using a Steritop and Stericup (500mL all will fit) 
 
1) Transform ACS plasmid into Bl21-DE3 cells and plated onto an LB/AMP plate and incubated 
at 37C overnight. (Transform HDAC8 fresh each time!) 
 
2) In the morning inoculate 5mL 2xYT/AMP using 1 colony and shake at ~200rpm at 37C until 
the solution is cloudy (~3-5 hours) 
 
3) Add the 5mL of 2xYT to 100mL of 2xYT/AMP and shake at 37C until cloudy (~2 hrs) 
 
4) Use the culture to inoculate the autoinduction TB 
Into 2L of autoinduction TB the following was added: 
100 µg/mL AMP 
200 µM ZnSO4 
25mL of Culture 
200mL Sugar mix 
  
5) Incubated culture at 30ºC overnight shaking ~170rpm 
 
Buffers: (filter all buffers using a .45uM filters HAWP filter) 
Low Imidazole Buffer (1 L): 
8.7 g NaCl 
7.14 g HEPES  
1.36 g Imidazole  
0.286 g TCEP   
pH 8 using NaOH 
Filter solution using a .45uM filters HAWP filter 
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Store at 4C 
  
High Imidazole Buffer: 
8.7 g NaCl 
7.14 g HEPES  
13.6 g Imidazole  
0.286 g TCEP   
pH 8 using NaOH 
Store at 4C 
 
Size exclusion buffer (1 L):  
8.7 g NaCl 
11.9 g HEPES 
0.238 g TCEP 
pH 8 using NaOH 
Store at 4C 
 
Dialysis Buffer (4L): 
Add a stir bar to the beaker 
34.8 g NaCl  
28.5 g HEPES 
5.44 g Imidazole  
1.14 g TCEP 
pH 8 using NaOH 
Store at 4C 
 
6) Spin the cell lysate at 18,000rpm for 45 minutes in the big floor centrifuge 
7) Load the cleared lysate onto a 10mL Ni-column (either FPLC or gravity) 
 
8) Run ~50 mL of low imidazole buffer followed by a ~100 mL gradient of low to high 
imidazole buffer 
 
9) Run a gel to confirm location and purity of ACS 
 
10) Pool fractions containing ACS and concentrated in a 30mwco filter to <1mL   
  
11) Run the protein on the Large Size Hiprep 26/60 Sephacryl S200 column  
 
12) Dialyze with 2 tubes of TEV in against Dialysis buffer 
 
13) In the morning run dialyzed ACS on a Ni-tallon column 
 
14) Run a gel to confirm the location of ACS and pool ACS 
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15) (Optional) Assay ACS: 
Mix: 
100uL solution 1 (see Appendix A: coupled acetate assay) 
20uL Solution 2 (see Appendix A: coupled acetate assay) 
1uL MDH 
.3uL CS 
3uL ACS 
  
In a 96 well plate: 
Into well 1: 1x buffer 
Into well 2: 20uM acetate 
  
Read fluorescence 340nm; em = 460nm 
No creep should be observed in well 1 and well 2 should show activity. 
16) Concentrate ACS to >750 mM using a 10,000 mwco filter 
17) Flash freeze ACS in 10 µL fractions and store at -80ºC 
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Acetylated tetramer purification and assembly 
 
Day 1: 
Transform H4 and H3 
Make 12L of LB (60g/2L of LB tablets) 
 
 
Day 2: 
O/N growth H3 and H4 (100mL LB each) 
Make 10x PBS  
80g NaCl 
2g KCl 
14.4g Na2HPO4 
2.4g KH2PO4 
pH 7.4 
Adjust to 1L H20 
 
 
Make 1x PBS w/20mM nicotinamide  
Make 1x PBS w/20mM nicotinamide and 1% (v/v) triton x-100  
 
 
Day 3: 
H3 and H4 expressions 
Start cultures 25mL culture /2L LB 
For H3: 
Grow at 37C 
Grow til OD600= .5-.7 
Add with 1g/L acetyl-lysine and 2.4g/L nicotinamide 
After 1/2 hour induce with .119g/L IPTG 
Grow 3 hours and harvest 
Resuspend in 1xPBS w/ 20mM Nicotinamide and spin for 10 minutes at 4000rpm 
Freeze at -80C 
 
 
For H4: 
Grow at 37C 
Grow til OD600= .6 
Add hour induce with .119g/L IPTG 
Grow 4 hours and harvest 
Freeze at -80C 
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Buffers: (No need to filter unless specified) 
(make buffers containing UREA or Guanidinium chloride day of) 
Guanidinium chloride Buffer 
114g guanidinium chloride 
.5g Tris base 
Add a dash of TCEP 
pH = 8 - usually no pHing needed 
adjust 200mL H20 
 
 
His low buffer 
84g Urea 
2.4g NaH2PO4 
A dash of TCEP 
pH = 6.2 
adjust 200mL H20 
 
 
His high buffer 
84g Urea 
.3g Sodium Acetate 
2.3g NaCl 
A dash of TCEP 
pH = 4.5 
adjust 200mL H20 
 
 
Q low buffer 
84g Urea 
.3g Sodium Acetate 
1.1g NaCl 
A dash of TCEP 
pH = 5.5 
adjust 200mL H20 
 
 
Q high buffer 
84g Urea 
.3g Sodium Acetate 
2.2g NaCl 
A dash of TCEP 
pH = 5.5 
adjust 200mL H20 
 
 
SP low buffer 
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84g Urea 
3g Sodium Acetate 
3.3g NaCl 
A dash of TCEP 
pH = 5.2 
adjust 200mL H20 
 
 
SP high buffer 
84g Urea 
11.5g NaCl 
1.6g Sodium acetate 
.5g Tris 
A dash of TCEP 
pH = 7.5 
adjust 200mL H20 
 
 
Urea dialysis buffer 
840g Urea 
3g Sodium Acetate 
pH = 7.5 
Adjust to 2L of H20 
 
 
H3 TEV buffer: 
24g Tris base 
pH = 7.4 
Adjust to 4L H20 
 
 
Day 4 begin purification: 
Thaw pellets and resuspend in 1x PBS w/ 20mM nicotinamide with 1 protease inhibitor tablet 
Lyse using 2 passes of the microfluidizer 
Spin at 18,000 ss34 roter for 15 minutes and decant supernatent 
Resuspend cells in PBS + nicotinamide + triton 
Spin at 18,000 ss34 roter for 15 minutes and decant supernatent 
Resuspend cells in PBS + nicotinamide + triton 
Spin at 18,000 ss34 roter for 15 minutes and decant supernatent 
Resuspend cells in PBS + nicotinamide 
Spin at 18,000 ss34 roter for 15 minutes and decant supernatent 
Resuspend cells in PBS + nicotinamide 
Spin at 18,000 ss34 roter for 15 minutes and decant supernatent 
Macerate pellet in 2mL DMSO for 30 minutes at room temperature 
Add 100mL of Guanidinium chloride Buffer and shake at 37C for 1 hr 
Spin at 18,000 ss34 roter for 15 minutes and collect the supernatent 
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For the H4: 
Add to 3500mwco dialysis tubing and dialyze in 1L of the Urea dialysis buffer at 4C for the rest 
of the day 
 
 
For the H3: 
Purify over a 5mL Ni column: 
Filter supernatant with a .45uM filter 
Put onto AKTA pure and run H3 ni program using the His low buffer and His high buffer 
The peak during the gradient is the H3 - collect and put into 3500mwco dialysis tubing into 4L of 
H20 + 1.4mL BME store at 4C overnight 
 
 
H4: 
Move into a new liter of Urea dialysis buffer at 4C overnight 
 
 
Day 5: 
Place H3 into H3 TEV buffer 
 
 
Purify H4: 
Filter supernatant 
Run on the Q column using the Q program in the AKTA pure (remember to set the loop size) 
run a gel on the product 
Run an SP column using the SP program in the AKTA pure (remember to set the loop size) 
the peak during the gradient is where the H4 will be found 
Put the H4 into 3500mwco dialysis tubing place that in 4L of H20 + 1.5mL BME and incubate at 
4C overnight 
 
 
The H3: 
Place 4 tubes of TEV into the H3 and incubate at 4C overnight 
 
 
Day 6: 
Move the H4 and H3 into 4L of H20 + 1.5mL BME in the morning.   
Move the H4 and H3 into 4L of H20 + 1.5mL BME around 1. 
 
 
Make buffers: 
1M HEPES pH = 7.5 
119g HEPES metal free 
pH = 7.5 using metal free NaOH 
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Adjust to 500mL 
 
 
If making tetramer: 
Unfolding buffer 
14.3g Guanidinium HCl 
.5mL 1M HEPES pH = 7.5 metal free (Sigma# H3375) 
.019g DTT 
pH = 7.5 
Adjust to 25mL H20 
 
 
Refolding buffer with EDTA (make 2x): 
233g NaCl metal free (Sigma# 71376) 
20mL 1M HEPES pH = 7.5 metal free (Sigma# H3375) 
0.6g EDTA metal free (Sigma# E4884) 
1g TCEP (Goldbio# TCEP25) 
Adjust to 2L 
 
 
Refolding buffer without EDTA and lower NaCl: 
34g NaCl metal free (Sigma# 71376) 
20mL 1M HEPES pH = 7.5 metal free 
1g TCEP (Goldbio# TCEP25) 
Adjust to 2L 
Put aside 50mL of the buffer in a metal free falcon tube 
 
 
At the end of the day ~6pm put the H3 and H4 into tubes and spin  
Move the H3 and H4 into new 50mL tubes put ~15mL into each tube and surface freeze in liquid 
nitrogen 
Lyophilize histones 
 
 
Day 7: 
If making tetramer: 
Once lyophilized resuspend the H3 and H4 separately in .5mL unfolding buffer and determine 
the concentration using the nanodrop: 
H4:  
mw = 15,256 
ε276 = 5,400 
 
 
H3: 
mw = 11,236 
ε276 = 4040 
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Mix the H3 and H4 in a 1:1 molar ratio and dilute to 1mg/mL using the Unfolding buffer. 
Place this mix in 6000-8000 mwco cutoff 23mm flat width tubing 
Place in the Refolding buffer w/ EDTA spinning fast incubate overnight at 4ºC 
 
 
 
Day 8: 
Concentrate the sample to <1 mL using a 10,000mwco cutoff filter 
Run the tetramer on the small Size Hiprep 26/60 Sephacryl S200 column using size exclusion 
buffer 
 
Size exclusion buffer (1 L): 
116g NaCl  
11.9 g HEPES  
pH 7.5 
 
Run an 4-18% SDS page gel to confirm location of the tetramer 
 
Concentrate the sample to <1 mL using a 10,000mwco cutoff filter 
 
Add the sample into the dialysis tubing or a dialysis cassette 30,000mwco and out in refolding 
buffer w/ EDTA overnight at 4ºC 
 
Day 9: 
Move the tetramer into refolding buffer w/o EDTA and lower NaCl overnight at 4ºC 
 
Day 10: 
Run a PD-10 column on the tetramer using some fresh refolding buffer w/o EDTA and lower 
NaCl 
Use A276 to determine the fractions which contain tetramer concentrate the fractions to the 
desired concentration using a 10,000 or 30,000 mwco spin column 
Store protein at 4ºC in an ice bucket 
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Purifying 601 DNA for nucleosome 
Reference: Dyer et al. Reconstitution of Nucleosome core Particle, Methods in Enzymology Vol 
375, 2004 
 
General notes: 
 plasmid is Amp resistant 
 Plasmid has 23 copies of 601 sequence, these are separated by EcoRV sites; there are also 
2 EcoRV sites on either side of the insert (25 total EcoRV sites) 
 601 is 147 bp long (total insert is 3.4kbp) 
 Best to amplify plasmid in mg quantities and purify using Qiagen Mega or Giga Prep kit 
(1 Gigaprep is preferred for the amounts of nucleosome we desire) 
 
General procedure: 
1. Digest 
2. Precipitate vector 
3. check purity of sequence 
 
Day 1: Digestion 
 1mL reactions digest plasmid at a concentration of 1mg/ml 
 Add 30 units EcoRV per nanomole of EcoRV site in 1x buffer #3 from NEB+1x BSA 
(10U/reaction) 
 Incubate at 37 for 16hr.  
 Check completion on 1% agarose gel (1x TBE) 
 If not complete, add 50% more enzyme and incubate another 15 hrs. 
 
Day2: Precipitate vector 
***it might be best to test purification with a small amount of your digested product so you see if 
this protocol works for you or if you have to adjust spin time, % PEG etc.) 
 Add 0.192 volume 4M NaCl and 0.346 volume 40% PEG 6000 to digestion (THESE 
RATIOS ARE CRITICAL SO THAT YOU ONLY PRECIPITATE THE PLASMID 
BUT NOT THE LOW MW INSERT) 
 Incubate on ice for 1hr 
 Spin down 27,000g/4 degrees/20min. (or 14000rpm/4degrees/40 min) 
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 Transfer supernatant to a new tube (601 fragment is here)- run on gel to make sure there 
is no contamination from vector... if there is contamination titrate in more PEG and 
repeat spin to get full separation of vector and insert 
 Add 2.5 volumes 100% cold ethanol 
 Keep at -30 overnight or at -80 for 1hr. 
 Spin down 14500rpm/4 degrees/20min 
 Carefully remove supernatant; pellet = target DNA 
 Air dry DNA by leaving open to air ~10min. (drying completely reduces solubility) 
 Dissolve in 2.5mL TE 10/0.1 (or desired volume to get desired concentration) [10mM 
Tris, 0.1 mM EDTA, pH 8.5] 
 probably best to also dialyze into TE to get rid of any residual PEG 
 
If looks good, no need to further purify, store in aliquots of known concentration at -20. 
 
 
 
 
 
